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Stephen Muench 
Ph.D. Thesis 
Enoyl acyl carrier protein reductase enzyme (ENR) catalyses one of the two reductive 
steps in fatty acid elongation within the fatty acid synthesis type II cycle that is 
common to plants and prokaryotes. Since enzymes of this pathway are absent in 
humans they have become the target for several potent antibacterial compounds 
including triclosan which inhibits ENR in the picomolar range. 
As part of this thesis the gene for a type II ENR was located in the genomes of the 
apicomplexan parasites Plasmodium falciparum and Toxoplasma gondii. Analysis of 
the derived protein sequences suggested that these enzyme reside in the apicoplast. X-
ray crystallographic techniques have been used to solve the structure for Plasmodium 
falciparum (Pf) and Toxoplasma gondii (Tg) ENR in complex with the NAD+ cofactor 
and triclosan by molecular replacement to 2.2A and 2.6A, respectively. Both enzymes. 
are tetrameric with the approximate dimensions of 90A x 90A x 50A. Each subunit is 
formed by a 7 stranded parallel p-sheet flanked by 9a helices, reminiscent of a 
Rossmann nucleotide binding fold common to several NAD+ binding enzymes. 
Analysis of the ENR family reveals that a characteristic of apicomplexan ENRs is an 
insert which varies in size from 42 residues in the P jalciparum enzyme to 6 residues in 
T.gondii ENR and which flanks the inhibitor/substrate binding site. In PfENR this loop 
is disordered but in the structure of TgENR the loop can be clearly seen and the 
structure shows that the loop lies close to the bound inhibitor but makes no direct 
contacts. 
Comparisons of the binding sites of a range of different ENR inhibitor complexes has 
led to a better understanding of the plasticity of the enzyme in response to inhibitor 
(and possibly substrate) binding. Moreover analysis of the substrate/inhibitor binding 
pocket in P jalciparum and T.gondii ENR shows that whilst they are similar to the 
bacterial enzymes there are distinct differences which could be exploited for the 
development of novel antiparasitic agents. A major hurdle in the delivery of inhibitors 
targeted towards the apicoplast organelle is the need to cross several barriers including 
the parasite membranes and host cell walls. However the addition of a releasable eight 
arginine linker to the phenolic OH group of triclosan significantly improved the speed 
of delivery and enabled triclosan to enter both the extracellular and intracellular 
T.gondii tachyzoites and bradyzoites. The identification of both a novel inhibitor for 
the apicomplexan family and a possible general delivery mechanism may provide a 
foundation for the development of ENR inhibitors that will efficiently treat several key 
parasitic diseases. 
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CHAPTER! 
General Introduction 
1.1 Fatty acid biosynthesis 
1.1.1 Introduction 
The use of fatty acids for membrane growth, maintenance and for the storage of energy in 
the form of triacyglcerols, makes fatty acid production essential to all cellular life. Fatty 
acid biosynthesis is catalysed by the Fatty Acid Synthase Complex (F AS), which exists in 
two forms. The type I F AS is found within yeast and most eukaryotic cells and has all of 
its catalytic domains on one or two polypeptides (Smith, 2003). In contrast the type II 
F AS is found in bacteria and plants and has each catalytic step on a separate polypeptide 
(Magnuson et al., 1993). Although there is a clear difference in the two types of pathway 
they both carry out fatty acid synthesis through the same set of reactions and require an 
acyl-carrier protein (ACP) to carry the fatty acid substrate through each stage of the cycle. 
The overall reaction involves a growing fatty acid chain being elongated by the sequential 
addition of two carbon units derived from malonyl-CoA in each reaction cycle. The 
difference between the type I F AS pathway and the type II F AS pathway has led to it 
becoming a prime target for drug design where the toxicity to humans could be potentially 
low. 
1.1.2 Fatty acid synthesis type I pathway 
The type I F AS has all of the catalytic domains on one or two multifunctional polypeptide 
chains, with the yeast type 1 F AS pathway being encoded by two multifunctional 
domains, whereas the vertebrate and some bacterial type I F AS are encoded by just one 
multifunctional protein (Smith, 1994). The type I F AS is composed of eight distinct 
domains, seven of which have a discrete catalytic function. It has been proposed that the 
genes encoding the type I F AS pathway have "fused" over time, producing the large 
multidomain complex (Wakil et al., 1989). One proposed advantage of this multidomain 
system is the ability to move the substrate from one active site to another, removing the 
limitation of random diffusion of the reactants through the cytosol to successive enzymes 
in the pathway (McCarthy & Hardy, 1984). 
1.1.3 Fatty acid synthesis type II pathway 
The type II F AS pathway is composed of seven separate enzymes all encoded on different 
polypeptides and is responsible for carrying out fatty acid synthesis in Prokaryotes and 
plants (Figure 1.1). Each of these enzymes can be purified and catalyse their respective 
stage of the fatty acid synthesis pathway independently (Magnuson et ai. , 1993). In plants 
and bacteria, the use of the type II F AS pathway may be advantageous to the host in that 
each stage can be independently regulated and the consequences of misincorporation of 
residues during the synthesis of the components may be reduced. The ability to over-
express, purify and characterise each of the separate enzymes of the type II F AS 
independently has led to a detailed picture of each stage of the cycle to be developed 
(Rock & Cronan. 1996). 
1.1.4 Enzymes of the type II F AS pathway 
1.1.4.1 Acyl Carrier protein 
The Acyl Carrier protein (ACP) is a small, charged, highly soluble protein and is one of 
the most abundant proteins within the E.coli cell (Magnuson et aI. , 1993). The role of 
ACP is to covalently bind the acyl intermediates of fatty acid biosynthesis via a 
phosphopantetheine arm which is covalently linked to a fully conserved serine residue 
(Worsham et ai. , 2003). The flexibility and 20A length of the prosthetic group is 
essential in allowing the substrate into close contact with each enzyme active site without 
any unwanted protein-protein interactions. To date the structure of ACP has been solved 
2 
Fatty acid products 
.... 
. s 
H02Cn 'ACP -R~S'ACP 
o o noyl Reductase 
s _, 
NAD(Pt H3C~ 'ACP ... _ 
II 1 st cycle only o ~ NAD(P)H 
C02+ACP 
RyyS The type II FAS pathway. 
'ACP 
o 0 
NAD(P)H 
R~S""'ACP 
o 
J3-ketoacyl reductase 
H20~ 
....... RyyS ..... ACP 
OH 0 
dehydratase 
Figure 1.1. The type II Fatty Acid Synthase cycle. 
in several species including E.coli, B.subtilis and Mtuberculosis and it is based on a 4 
helix bundle (Figure 1.2a), packed through hydrophobic interactions (Roujeinikova et al., 
2002, Xu et aI., 2001 & Wong et al., 2002). 
1.1.4.2 Acetyl-CoA carboxylase 
Acetyl-CoA carboxylase is responsible for carrymg out two distinct half reactions 
catalysed by two different protein sub complexes, commonly consisting of the biotin 
carboxyl carrier protein, biotin carboxylase and transcarboxylase (Elborough et al., 1996). 
The first of the half reactions is the formation of carboxybiotin, by the A TP-dependent 
carboxylation of biotin with bicarbonate. The second reaction involves the transfer of the 
carboxybiotin carboxyl group to the acetyl Co-A forming malonyl-CoA. This is the rate 
controlling and first committed step of the fatty acid synthesis cycle. The structures for 
the carboxy-terminal fragment of the biotin carboxyl carrier subunit (Yao et al., 1997) 
and biotin carboxylase (Athappilly et al., 1995 & Waldrop et al., 1994) have been solved 
and can be seen in Figure 1.2b and 1.2c. 
1.1.4.3 Malonyl-CoA:ACP transacylase 
Malonyl-CoA:ACP transacylase (FabD) is a monomeric protein responsible for the 
transfer of malonyl-Co A onto the SH group of the phosphopantetheine arm on ACP. This 
conversion is carried out by a His-Ser catalytic diad, with the His residue being a proton 
donor and the serine attacking the thioester carbonyl of the malonyl-CoA forming a stable 
malonyl-serine intermediate (Keatinge-Clay et al., 2003). This subsequently undergoes 
nucleophilic attack on the ester bond by the sulfhydryl of ACP, yielding malonyl-ACP, 
the major building block of fatty acids. Analysis of E.coli and Streptomyces coelicolor 
FabD revealed it t~ be a monomer composed of two sub domains ((Keatinge-Clay et aI., 
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2003 and Serre et al., 1995)(Figure 1.2d)). The small domain is composed of a four 
stranded anti-parallel j3-sheet surrounded by two a-helices in a ferredoxin like fold and 
the larger sub domain has a core structure that is similar to the alj3 hydro lases composed 
of a central parallel j3-sheet surrounded by 12 a-helices. 
1.1.4.4 j3-Ketoacyl ACP synthase 
The condensing enzyme j3-Ketoacyl ACP synthase can be found as three different 
isoforms, I, II and III (FabB, FabF and FabH) and is responsible for the addition of a CH2 
group and subsequent chain elongation in F AS. Although FabB and FabF share 38% 
sequence identity within E.coli there is no apparent homology to FabH (Qiu et al., 2001) .. 
However studies of the structure of FabB and FabH have revealed a similar active site 
architecture and dimeric structure. Furthermore, the antibiotic cerulenin inhibits both 
FabB and FabF but not FabH, with thiolactomycin inhibiting all three (Pricea et al., 
2001). 
The FabH enzyme (Figure 1.2e) catalyses the first condensation of acetyl-CoA and 
malonyl-ACP yielding acetoacetyl-ACP, releasing CO2. Structural studies have 
suggested that the catalytic triad Cysll2, Asn274 and His244 is responsible for catalysis 
within E.coli FabH with strong sequence identity for these residues being found in all 
bacterial species (Qiub et al., 1999 & Qui et al., 2001). Inhibitor modeling and high 
throughput screening of both E.coli and s.pneumoniae FabH have led to the development 
of dichlorobenzyloxy-indole-carboxylic acid, which has an ICso of 0:04).lM and 0.83).lM 
for S.pneumoniae and E.coli FabH, respectively (Daines et al., 2003). A second study on 
s'aureus FabH produced two inhibitors, 5-chloro-4-phenyl-[1,2]-dithiol-3-one, and 4-
4 
phenyl-5-phenylimino-[l,2,4]di-thiazolidin-3-one, which have an ICso for FabH of 
1.87!JM and 0.775IlM, respectively (He et al. , 2002). 
The FabB and FabF enzymes differ from FabH in that an acyl-ACP primer is used rather 
than acyl-CoA. Furthermore, the FabB and FabF active sites have a conserved His-His-
Cys triad in contrast to the FabH His-Asn-Cys triad (Pricea et ai., 2001). The FabB 
enzyme (Figure 1.2t) is critical for the condensation of fatty acids within the type IT F AS 
pathway and gene knockout mutants require fatty acid supplements for growth. The FabF 
enzyme controls the temperature dependent regulation of fatty acid conditions allowing 
the elongation of palmitoleate to cis-vaccenate (Magnuson et ai., 1993), with mutants 
lacking this gene growing under normal standard growth conditions. The overall reaction 
can be written as: 
R-CO-S-ACP + HOOC-CH2-CO-S-ACP <=> R-CO-CH2-CO-S-ACP + C02 + ACP-SH 
1.1.4.5 f3-Keto ACP reductase 
The first reductive step in the fatty acid synthesis cycle is the formation of 13-
hydroxybutyryl-ACP, catalysed by f3-Keto ACP reductase (FabG). The structure ofFabG 
from B.napus has been solved to 2.3A and revealed each subunit to be comprised of a 
central parallel seven stranded f3-sheet flanked by eight a-helices in a manner similar to 
the enoyl reductase enzyme ((Figure 1.2g)(Fisher et aI., 2000)). The FabG active site has 
been shown within E.coli to contain a Ser, Tyr and Lys catalytic triad which through a 
Lys residue is linked to four water molecules (Price et aI., 2004). These water molecules 
are predicted to be responsible for replenishing the proton donated to the substrate during 
catalysis by the catalytic Tyr residue. Furthermore the binding of the NAD(P)H cofactor 
has been shown to cause a substantial structural change, positioning the catalytic triad 
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(Ser138, Tyr151 and Lys155) into the active conformation (priceb et a/., 2001). FabG shows 
negative cooperativity with the binding of ACP in one active site of the tetramer 
decreasing the affinity of the other sites to ACP allowing the active site to be cleared of 
product and promote NAD(P)H binding. Sequence alignments have shown a highly 
conserved YX3K motif within the FabG family, common to the short-chain 
dehydrogenase/reductase (SDR) family (Filling et at., 2002). The overall reaction can be 
shown as: 
R-CO-CH2-CO-S-ACP + NAD(P)H ¢:> R-CH(OH)-CH2-CO-S-ACP + NAD(Pt 
1.1.4.6 f3-Hydroxy ACP dehydratase 
f3-Hydroxy ACP dehydratase is responsible for catalysing the reversible dehydration of 
the hydroxyl group at C3 to produce trans-2-enoyl-ACP. Within E.coti two genes have 
been shown to encode a f3-Hydroxy ACP dehydratase, FabA and FabZ, with FabA being 
more efficient at catalysing medium length substrates and FabZ efficiently catalysing 
short and long chain substrates (Heath & Rock. 1996). The FabA structure revealed a 
homodimer with each subunit containing a seven stranded antiparallel f3-sheet wrapped 
around a five-turn a helix, reminiscent of a "hot dog fold" ((Figure 1.2h)(Leesong et a/. , 
1996» . The overall reaction can be shown as: 
R-CH(OH)-CH2-CO-S-ACP ¢:> RHC=CH(CO)-S-ACP + H20 
1.1.4.7 EnoyJ ACP reductase 
Enoyl ACP reductase (FabI) is responsible for the last stage of the F AS pathway and 
involves the reduction of the trans-2-enoyl-ACP by the reduction of the double bond 
between positions C2 and C3 by the following reaction: 
RHC=CH(CO)-S-ACP + NAD(P)H + W ¢:> R-CH2-CH2-CO-S-ACP + NAD(Pt 
6 
The structure of this enzyme has previously been solved for B.napus, E.coli, Hpylori 
and Mtuberculosis (Baldock et al., 1996, Rafferty et al., 1995, Moon et al., 2001 and 
Dessen et al., 1995) and will be dealt with in detail in section 1.2. 
1.1.4.8 Successive Cycles 
F or every cycle of the type II F AS pathway two carbon atoms are added through the 
addition of a malonyl-ACP molecule (Magnuson et al., 1993). The lipid chain is 
transferred from ACP to the cysteine side chain of the condensing enzyme (Wakil, 1989), 
after which a malonyl group is added to the ACP by the malonyl CoA:ACP transacylase. 
The lipid chain is then transferred back to the malonyl-ACP with the reactions catalysed 
by FabG, FabZ and FabI being repeated, resulting in the addition of two carbon units. 
Termination of this cycle occurs once the chain has reached the required length, typically 
16 carbons (palmitoyl-ACP or C:16-ACP). 
1.1.4.9 Chain termination 
Palmitoyl thioesterase catalyses the hydrolysis of palmitoyl-ACP to yield one unit of 
palmitate and ACP resulting in chain termination (Vance et al., 1973). It is essential that 
chain termination is carried out with long chain acyl-ACP's inhibiting the continuation of 
the cycle at the condensation stage, affecting the j3-ketoacyl ACP synthase by feedback 
inhibition (Heath & Rock, 1996). 
1.2 Enoyl ACP Reductase 
1.2.1 Structural studies of enoyl reductase (ENR) 
At the outset of work described in this thesis the structures of E.coli, B.napus, Hpylori 
and Mtuberculosis ENR had been determined (Baldock et al., 1996, Rafferty et al., 
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1995., Moon et al., 2001 & Dessen et al., 1995) The family shares both a common fold 
similar to the Rossmann dinucleotide binding fold (Rossmann et aI., 1974) and sequence 
similarities (Figure 1.3), especially for those residues situated close to the active site. 
1.2.1.1 B.napus ENR 
The crystal structure for B.napus (oil seed rape) ENR (BnENR), a 30 KDa protein 
organized into a homotetramer with four independent active sites, was determined to 
1.9A by X-ray crystallography (Rafferty et al., 1995, Figure 1.4). The overall fold is 
reminiscent of a Rossmann nucleotide binding fold (Rossmann et al., 1974) consisting of 
a central parallel p-sheet flanked on either side by a-helices which together form a 
hydrophobic core. The plant ENR enzymes contain two large inserted loops, which are 
distant to both the active and NAD+ binding sites and appear to play no role in enzyme 
catalysis. 
A striking similarity was noted between the BnENR structure and members of the short-
chain alcohol dehydrogenase family as exemplified by the similarity to 3a, 20p-
hydroxysteroid dehydrogenase (HSD)(Rafferty et al., 1995). Both enzymes utilize 
NADH as a cofactor and have a. conserved active site motif consisting of a catalytic 
tyrosine and lysine residue. 
1.2.1.2 M. tuberculosis ENR 
Mycobacterium tuberculosis ENR, (MtENR), is the target of the maj()r anti tuberculosis 
drug isoniazid, the front line chemotherapeutic treatment for tuberculosis (BaneIjee et 
al., 1994) and differs from the ENR family as it prefers longer chain fatty acyl substrates 
for the purpose of synthesizing mycolic acids (Rozwarski et al., 1998). In order to 
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Figure 1.3. A structure based sequence alignment of the ENR enzymes from E.coli, 
Mtuberculosis, s'aureus, Hpylori, B.subtilis and B.napus. The structural elements 
and sequence numbering for the E.coli and B.napus enzymes are shown above and 
below the alignment, respectively. The blue cylinders represent a-helices and red 
arrows f3-strands. Those residues fully conserved between all sequences are in black 
boxes and those residues with strong sequence similarity or sequence identity within 
the bacterial sequences are highlighted in red. The sequences were aligned using 
ClustalW (Higgins & Thompson 1994) and the figure was produced using the 
program Alscript (Barton, G.1. 1993). 
Figure 1.4. B.napus ENR complexed with NAD+ and triclosan, with the 4-chloro 
phenoxy ring of the triclosan stacking on top of the NAD+ cofactor in a face to face 
manner allowing x-x stacking interactions. The triclosan and NAD+ are coloured in 
atom colour and the a.-helic~s and p-strands are coloured blue and magenta, 
respectively. The picture was created using the Pymol graphics program (Delano, 
2002). 
accommodate a larger substrate a predominantly hydrophobic, glycine rich 10 amino acid 
insert, not present within other sequenced bacterial or plant ENR enzymes, increases the 
size of the substrate binding pocket. The structure of MtENR bound to its NAD+ cofactor 
and also in complex with a Cl6 fatty acid substrate has been solved to 2.7A and 2.8A, 
respectively (Dessen et al., 1995, Rozwarski et al., 1999). The study of the 
MtENRlNAD+/CI6 fatty acyl substrate complex revealed the substrate bound in a "U-
shaped" conformation, allowing the trans double bond to be positioned adjacent to the 
nicotinamide ring of NAD+ ((Figure 1.5) Rozwarski et al., 1999). The emergence of 
isoniazid resistant strains of Mtuberculosis is through a mutation of Ser94 to Ala which 
disrupts the hydrogen bonding network that stabilises NADH binding in the ENR enzyme 
(Des sen et al., 1995). The increase in resistance of MtubercuZosis to isoniazid has led to 
an increased difficulty in tuberculosis treatment (Raviglione et aZ., 1995). 
1.2.1.3 H.py/or; ENR 
The structure of HpyZori ENR in complex with NAD+ and diclosan has been deposited 
within the rscb PDB (IJW7) and has a fold similar to that described for other members of 
the ENR family with a parallel j3-sheet central core flanked by several a-helices (Figure 
1.6 a). The binding of the diclosan inhibitor is in a manner similar to triclosan with the 4-
chloro phenoxy ring of diclosan stacking on top of the NAD+ inhibitor making extensive 
1t-1t stacking interactions (Figure 1.6 b). There are currently no publications which 
describe the structure of HpyZori ENR. 
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Figure 1.5. Mtuberculosis ENR with bound NADH and C16 fatty acyl 
substrate. which can be seen in a "V-shaped" conformation, with the trans 
double bond placed above the NADH unit. The a-helices are in blue and 
the B-strands are in green. The figure was created using the graphics 
program Pymol (Delano, 2002). 
(b) 
Figure 1.6. (a) H.pylori ENR complexed with NAD+ and diclosan. (b) A close up 
view of the diclosan binding site showing the stacking interactions formed between 
the diclosan inhibitor and NAD+ cofactor. All figures are coloured with yellow for 
carbon, blue for nitrogen, red for oxygen, green for chlorine and purple for 
phosphorous. Figures were produced using the graphics program Pymol (Delano, 
2002). 
1.2.1.4 E.coli ENR 
The crystal structure of E.coli ENR (EcENR) has been solved in complex with a variety 
of inhibitors revealing the mechanism of inhibitor binding for a range of drugs. The first 
complex solved was the EcENRlNAD+/diazaborine complex (Baldock et ai., 1996) 
revealing the formation of a tight covalent bond between the diazaborine and NAD+. 
Comparisons between the E.coli and B.napus ENR active sites showed that a sequence 
change of a glycine to alanine within BnENR blocked diazaborine binding by producing 
steric hindrance within the inhibitor binding pocket ((Figure 1.7)(Roujeinikovab et ai., 
1999)). Studies of EcENRlNAD+ bound to triclosan or thieno-diazaborine revealed that a 
proposed substrate binding loop, residues 192-198, is seen as disordered when no 
inhibitor is bound, in an ordered loop in the diazaborine ternary complex and forms a 
helix upon triclosan binding (Roujeinikovab et ai., 1999 & Qiua et ai., 1999). The 
ordered helix formed over the inhibitor binding site upon triclosan binding, makes 
extensive van der Waals interactions increasing the hydrophobic character of the binding 
pocket (Roujeinokovaa et ai., 1999). In particular the Ala 196 residue that is fully 
conserved across the family makes extensive van der Waals interactions and a conserved 
Ser194 or Thr194 residue makes a hydrogen bond from its side chain hydroxyl atom to the 
pyrophosphate moiety (Stewart et ai., 1999). 
1.2.2 Inhibitors of the Enoyl reductase enzyme 
1.2.2.1 Triclosan 
ENR is the target for the broad spectrum anti microbial agent triclosan (McMurry et ai., 
1998). Triclosan has been demonstrated to be a very potent inhibitor of ENR and is 
found in many household formulations including toothpastes, mouthwashes and chopping 
boards ((Table 1.1)(Bhargava & Leonard 1996)). Its success arises from its ability to 
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Figure 1.7. The active site of E.coU ENR with NAD+ and thienodiazaborine 
bound. The boron atom of the inhibitor (orange) is approximately 1.5 A away from 
the NAD+ cofactor allowing for the formation of a covalent bond. The two fully 
conserved catalytic residues, Tyr and Lys are labelled and are in close proximity to 
the inhibitor. The residue Gly93 is within 3.5 A of the inhibitor, however if 
replaced by an alanine residue, a feature common to the plant ENR enzymes this 
distance is reduced to 2.3 A, causing steric hindrance and subsequently inhibiting 
drug binding. The figure is coloured in atom colour with yellow for carbon, red for 
oxygen, green for sulphur, blue for nitrogen, purple for phosphorous and orange for 
the boron atom in the diazaborine inhibitor. The figure was produced using the 
graphics program Pymol (Delano, 2002). 
o ;r CI 
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Figure 1.8 The structural formulae of nine ENR enzyme inhibitors, produced 
using the program Isis draw. 
FabI IC50 (~M) MIC (~g/mLJ 
Compound S.aureus H.infllJenzae E.coli S.aureus H.influenzae E.coli 
Triclosan 0.07±0.OS" 
-
0.43±0.036< :0:;0.06" :0:;0.06" 
Compound 4 0.047b 0.13" 
-
0.06b 2.0b 8.0" 
Compound 29 0.13±0.03< 0.39±0.06< 0.07< 0.06< 16.0< 8.0< 
Acrylamide 2.4±1.2" 4.2±1.I" 
- OS >64" -
Benzamide 6.7±0.Sa 4.7±0.3a 
-
16" >64" -
Imidazole SO.7±16.9" 
-
>\00· 
- - -
Thieno-
- - - - -
1.6" 
diazaborine 
Benzodiazaborine 
- - - - -
12.5" 
Isoniazid 
- - - - - -
Table 1.1 The inhibitory properties of several inhibitors of the ENR enzyme 
from s'aureus, Hinjluenza and E.eali. 8values taken from Millerb et al., 2002, b 
values taken Payne et al., 2002, C values taken from Seefeld et ai., 2003, d values 
taken from Heerding et ai., 2001, e values taken from Grassberger et ai., 1984. 
inhibit the ENR enzyme at sub j.lm concentrations with inhibitor binding being shown 
within EcENR to be stoichiometric (Ward et al., 1999). Furthermore, it has been shown 
within EcENR that triclosan binding is reversible with neither the NAD+ or triclosan 
being modified during inhibition. Triclosan is however highly insoluble and must be 
dissolved in a solvent such as DMSO, limiting its use as a microbial inhibitor. Its mode 
of binding is through the mimicking of the fatty acid substrate with the 4-chloro phenoxy 
ring of triclosan and in particular the alcohol group mimicking the enolate anion 
intermediate «Figure 1.8)(Levy et al., 1999». The 4-chloro phenoxy ring of triclosan is 
responsible for stacking on top of the NAD+ nicotinamide unit forming 7t-7t stacking 
interactions and extensive van der Waals interactions. Furthermore a hydrogen bond is 
formed between the triclosan alcohol group and the catalytic tyrosine of ENR (Baldock et 
al., 1996). The formation of the ENRlNAD+ complex has been shown to be critical for 
triclosan binding (Heath et al., 2000). This tight binding of the triclosan blocks fatty acid 
binding, subsequently inhibiting the enzyme. 
1.2.2.2 Isoniazid 
Isoniazid (Figure 1.8), is currently a first line drug for tuberculosis and works through the 
inhibition of MtENR. Isoniazid is a prodrug and requires a mycobacterial catalase 
peroxidase (KatG) to convert it into the active form of the drug that covalently binds to 
the NAD+ cofactor causing inhibition (Rozwarski et al., 1998). It has been shown that 
isoniazid binding is a two step enzyme inhibition mechanism, with an initial weak 
binding complex followed by a slow conversion to the tight binding final complex (Rawat 
et al., 2003). The inhibitory effects of isoniazid are limited to the Tuberculosis family 
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due to the requirement of drug conversion and as such have a limited use as a broad 
spectrum antibmicrobial. 
1.2.2.3 Diazaborines 
Inhibition of the ENR enzyme by members of the diazaborine family involves the 
formation of a covalent bond from the diazaborine boron atom to the 2'-hydroxyl group 
of the nicotinamide ribose moiety of the NAD+ cofactor ((Baldock et al., 1996)(Figure 
1.7)). Although effective inhibitors, the diazaborine family are potentially toxic due to 
the structural element of arenoboronic acid amide ((Figure 1.8)(Grassberger et al., 
1984)). Furthermore a point mutation of Gll3 to a bulkier Ala residue, which is common 
in plant enzymes, leads to diazaborine resistance through steric hindrance of the inhibitor 
(Roujeinikovab et al., 1999). 
1.2.2.4 New and Developing drugs 
Initial studies carried out by GlaxoSmithKline Pharmaceuticals revealed that the 1,4-
disubstituted imidazoles (Figure 1.8) target EcENR with modest success ((Table 1.1) 
(Heerding et al., 2001)) with the thiophene ring of the inhibitor forming 1t-stacking 
interactions with the nicotinamide ring of the NAD+ cofactor (Figure 1.9). A second 
class of inhibitors reported by GlaxoSmithKline Pharmaceuticals is based on 
aminopyridine derivatives ((Millerb et al., 2002)(Figure 1.8)) whose inhibitory properties 
were better than those previously reported for the imidazole based drugs (Table 1.1). The 
structure of EcENR in complex with NAD+ and the aminopyridine based inhibitors 
((1LX6 benzamide, lLXC acrylamide) has shown that these inhibitors interact with the 
fully conserved Tyrl46 and Tyrl56 residues and also Phe203, with the linking amide 1t-
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Imidazole based inhibitor 
Benzamide based inhibitor 
Figure 1.9. A diagrammatic representation of several inhibitors bound 
within the active site of EcENR. For all figures the atoms are coloured with 
yellow for carbon, blue for nitrogen, red for oxygen, purple for phosphorous 
and orange for sulphur. The figure was produced in the graphics program 
Pymol (Delano, 2002). 
stacking over the nicotinamide ring of the NAD+ cofactor (Figure 1.9). However the 
aminopyridine subunit of the acrylamide based inhibitor binds in a different mode to the 
benzamide based inhibitor by producing two hydrogen bonds to the Ala95 (Millerb et al., 
2002). 
Further screening of compounds based on the aminopyridine inhibitors led to the 
development of "compound 4", whose inhibitory properties are similar to those of 
triclosan ((Figure 1.8 & Table 1.1)(Payne et al., 2002)). The structure of 
EcENRlNAD+/compound 4 complex has not yet been published or released into the 
public domain, however the structure of compound 29, which differs from compound 4 
in the positioning of the methyl group on the indole unit has been solved and published 
((Figure 1.9)(lMFP, Seefeld et al., 2003)). The structure of the compound 29 complex 
showed the central cis-amide fragment participating in a 7t-stacking interaction with the 
nicotinamide ring of the NAD+ cofactor. The indole portion of the inhibitor is involved 
in tight hydrophobic packing with the residues Met206, Phe20\ Tyr156 and Tyr146, with 
Ala95 forming two hydrogen bonds to the naphthyridinone group (Seefeld et al., 2003). 
1.2.3. Enzyme mechanism 
The proposed ENR catalytic mechanism, involves the hydride transfer from the C4 
position ofNADH to the C3 position at the double bond of the enoyl substrate ((Rafferty 
et al., 1995)(Figure 1.10a and b)). This leads to the formation of an enolate anion 
intermediate, which can be protonated on the oxygen atom to form an enol, which 
subsequently goes through tautomerization forming the reduced acyl product. There are 
two residues which are fully conserved between all ENR sequences implicated in this 
mechanism: a Tyr residue is the proton donor to the enolate anion and a Lys residue 
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Figure 1.10a. The proposed catalytic mechanism for the ENR enzyme, numbered 
with respect to the E.coli structure. Figure adapted from Bladock et aI., 1998. 
Figure 1.10b. The active site of Mtuberculosis ENR, with bound NAD+ and fatty 
acid substrate. The ENR secondary structure is shown with a-helices coloured in 
red, j3-strands in blue and loop regions in green. The substrates and residues are 
coloured with yellow for carbon, red for oxygen, blue for nitrogen, purple for 
phosphorous and orange for sulphur. The residues are numbered with respect to 
Mtuberculosis ENR. The figure was produced using the graphics program Pymol 
(Delano, 2002). 
stabilises the negative charge of the transition state and lowers the pKa of the Tyr-OH to 
promote proton transfer. This mechanism is similar to that for the short chain 
dehydrogenase reductase (SDR) family that also have a conserved catalytic lysine and 
tyrosine residue within the active site. The SDR enzymes contain a YX3K motif 
conserved within the active site (Filling et al., 2001), whereas the ENR family contain a 
YX7K or YX6K motif which would accommodate the increase in spacing between the 
point of hydride transfer and proton donation (Baldock et al., 1998). Furthermore two or 
three water molecules are present within the active site of the SDR enzYmes, (Filling et 
al., 2002, Benach et al., 1998) the role of which is predicted to be in stabilising the 
positive charge of the catalytic Lys residue and in forming a proton relay mechanism. 
1.3 The apicomplexan family 
The apicomplexan family is a group of protozoan parasites, which all contain a unique 
plastid known as the apicoplast and includes Plasmodium, Toxoplasma and Eimeria. The 
following sections will explain the importance of the apicoplast as a drug target and detail 
two of the most important apicomplexan parasites, Plasmodium Jalciparum 
(P.falciparum), the causative parasite of malaria and Toxoplasma gondii (T.gondii), 
which is responsible for toxoplasmosis. 
1.3.1 The apicoplast 
All apicomplexan parasites contain an apicoplast, a large plastid organelle, the origins of 
which arose through the endosymbiosis of a cyanobacterial like prokaryotic cell 
(McFadden et al., 1999). The presence of four membranes surrounding the apicoplast 
demonstrates secondary symbiosis in which a plastid containing the primary 
endosymbiont has been engulfed and retained by the apicomplexan parasites (Waller et 
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aI., 1998). The initial algae origins of this organelle are unclear due to the lack of any 
photosynthetic pigment, although phylogenic trees based on elongation factor Tu, have 
suggested a green-algal ancestry (Kohler et al., 1997). This has resulted in a eukaryotic 
parasite family containing several prokaryotic enzymatic pathways, which may prove 
important in the design of inhibitors with potentially low toxicity in man. 
1.3.2 The apicoplast as a drug target 
The apicoplast genome is the smallest plastid genome currently reported at 35 Kb and is 
composed of a supercoiled circular architecture (Gleeson et aI., 2000). It is thought that 
the majority of genes, which were once encoded for by the apicoplast genome have, over 
time been incorporated into the apicomplexan parasites genome and are subsequently, 
targeted back. Importantly ciproflaxin and other flouroquinolones, which have been 
shown to have an inhibitory effect on prokaryotic DNA gyrases, inhibited the replication 
of the apicoplast and resulted in cell death (Fichera & Roos, 1997). Furthermore it is 
completely devoid of any internal membranes and contains little or no photosynthetic 
pigment. Hence its maintenance was hypothesised to be based on other essential 
. metabolic pathways or functions which it carries out and not through any photosynthetic 
role (McFadden & Roos 1999). One such pathway is the shikimate pathway common to 
plant plastids, which is inhibited by the herbicide glyphosate (Keeling et al., 1999 & 
Roberts et al., 1998). The apicomplexan parasite T.gondii was shown to be sensitive to 
glyphosate, with the genes encoding the shikamate pathway being encoded on the 
T.gondii genome but targeted towards the apicoplast. The P jalciparum genome project 
has revealed both a non-mevalonate pathway that leads to isopentenyl diphosphate 
subunit synthesis (Jomaa et al., 1999) but also several key enzymes in the fatty acid 
synthesis type II pathway, (FabH, FabZ and ACP), (Waller et al., 1998), which has been 
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shown to be the target of several antimicrobial drugs. It is hoped that the localization and 
characterization of a possible ENR enzyme, which may also be targeted towards the 
apicoplast, could lead to the development of novel inhibitors against the apicomplexan 
family. 
1.3.3 Targeting to the Apicoplast 
The apicoplast is predicted to be targeted by approximately 500 proteins (Foth et ai., 
2003), all of which must be able to target and cross the 4 membrane bound plastid 
organelle. The minimum time for targeting proteins to the apicoplast was shown to be 
less than 45 minutes (Dooren et ai., 2002) and is achieved by using a bipartite N-terminal 
signal sequence. The signal sequence which targets the proteins to the secretary pathway 
has been shown to contain a von Heijne-type cleavage motif which is composed of a 
positively charged region followed by a short hydrophobic region which precedes the 
neutral but polar end region (Nielson et ai., 1997). The second part of the signal 
sequence, the transit peptide, has a net positive charge which is required to transport the 
proteins across the multiple membranes and divert the protein into the apicoplast (Waller 
et ai., 2000). Although the sequence homology for the transit sequence is very low with 
no known secondary structure, there are a set of commonalities. The transit peptides are 
low in acidic residues but highly enriched in lysine and asparagine residues, the former 
resulting in an overall positive charge. Furthermore >90% of apicoplast transit peptides 
contain an Hsp70 binding site, suggesting an importance in apicoplast targeting (Foth et 
ai., 2003). 
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1.4 Plasmodium (alciparum 
The Plasmodium species is a large family of intracellular parasites responsible for the 
development of malaria within specific mammalian hosts. There are four species 
responsible for infecting Homo sapians, they are P. vivax, P.malariae, P.ovale and 
P.falciparum, the most important of which is P.falciparum, which is responsible for over 
95% of severe cases of malaria. The global impact of malaria is extensive with over 500 
million people infected a year of whom an estimated 2 to 3 miIlion die (Breman et al., 
2001). Recently the genome sequence was completed for P .falciparum, with work 
continuing for several other Plasmodium species. 
1.4.1 Pathology of the Plasmodiumfalciparum parasite 
The factors affecting the onset of disease after a malarial infection are complex and 
involve a variety of organs and tissues within the body, with the parasite invading two 
cell types within the body, the red blood cells (RBC) and liver hepatocytes. The infection 
and subsequent destruction of a large proportion of RBC results in various degrees of 
anaemia. This can be compounded by the P .falciparum parasite, which causes rosseting 
of red blood cells, which in tum attach to blood vessel walls causing an obstruction in 
blood flow (Dondorp et al., 2000). Importantly the lack of a fully functional tricarboxylic 
acid cycle within the parasite results in the majority of its energy being produced through 
anaerobic respiration, resulting in the mass production of lactic acid, which can build up 
in the host's blood. Furthermore damage caused to the liver through hepatocyte invasion, 
results in a decrease in efficiency of lactic acid removal (English et al., 1997). The 
increase in metabolic stress caused in the main by severe anaemia, liver damage and 
blood acidosis results in a decrease in the oxygen delivery to tissues, including the brain 
and may result in a coma (Englisha et al., 1996). There is a need for significant amounts 
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of clean water to re-hydrate the body during infection, where clean water is unavailable 
severe dehydration can occur and add to the stresses already placed on the body (Englishb 
et al., 1996). 
1.4.2 Life cycle of the Plasmodiumfalciparum parasite within a human host 
The initiation of the P jalciparum lifecycle within the human host (Figure 1.11) is 
through the introduction of sporozoites into the body either directly into the blood stream 
or into the subcutaneous tissue by a mosquito bite. Once inside the blood stream the 
sporozoites quickly migrate over 30-60 minutes to the liver passing through several 
different hepatocyte cells before going through invasion and the subsequent parasite 
development within the selected hepatocyte cell (Mota et al., 2001). Within the 
hepatocytes the sporozoites develop into tens of thousands of merozoites, each merozoite 
capable of invading a RBC upon release from the liver and it is this invasion of the RBC, 
which causes the onset of the clinical symptoms of malaria (Millera et al., 2002). After 
the red blood cells are invaded by merozoites they continue to mature and divide 
asexually, rupturing 48 hours later. It is at this point that a small proportion of the 
merozoites develop into gametocytes, essential for the transmission to others through the 
mosquito vector. These gametocytes are taken up by the mosquito when it takes a blood 
meal allowing for parasite development within the mosquito. The complexity of the 
Plasmodium lifecycle and the intracellular nature of all but the short lived merozoite stage 
makes it difficult for a host to mount an efficient immune response and leads to 
difficulties in the production of an effective vaccine against the Plasmodium parasite. 
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Figure 1.11. A diagrammatic representation of the Plasmodium lifecycle within 
both a human host and the defmitive Anophelles mosquito host. The figure is taken 
from the Sanger Centre (www.sanger.ac.uk). 
1.4.3 Currently available antimalarial drugs 
1.4.3.1 Quinine 
The first antimalarial drug to be used on a global scale was Quinine (Figure 1.12), a 
relatively inexpensive compound (Table 1.2), which is extracted from the bark of the 
Cinchoma tree. It was used as a first line drug in the U.K, but this practice is unusual 
within the tropics as compliance is a major problem caused by the need to take Quinine 
three times a day for seven days, its bitter taste and unpleasant side effects at a normal 
therapeutic dose (Winstanley, 2003). It is however an effective replacement for 
chloroquine and its cure rates can be improved further if combined with tetracycline or 
clidamycin, with a recent study showing that a three day regime of quinine combined with 
clindamycin was well tolerated (Parola et al., 2002). 
1.4.3.2 Chloroquine and amodiaquine 
Chloroquine (CQ), a derivative of quinine is both cheap and safe making it the treatment 
of choice for uncomplicatedfalciparum malaria (Figure 1.12). The mode of action for 
CQ and its related analogues is thought to be through inhibiting the removal of the toxic 
product of hemoglobin degradation, ferriproporphyrin IX (FP) (Ginsburg et al., 1999 & 
Sanchez et al., 2000). It is suggested that CQ forms a complex with FP, in so doing the 
parasite is unable to polymerize FP into harmless hemozoin. This subsequently leads to 
an increase in cellular FP and an increase in membrane permeability resulting in parasite 
cell lysis. In addition to this chloroquine has been shown to bind within the cofactor 
binding site of the P jalciparum lactate dehydrogenase, acting as a competitive inhibitor 
in blocking NADH binding by occupying a position similar to that of the adenine ring of 
the NADH and forming interactions with several amino acids unique to the malarial form 
of the enzyme (Read et al., 1999). The more expensive amodiaquine is thought to 
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Quinine and its analogues. 
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Figure 1.12. The structural formulae for the main antimalarial drugs currently 
in use. The figures for artimisinin and its derivatives were taken from 
All other figures were cre.ated in the 
program IDraw32. 
Drug Cost of adult Cost of adult dose Introduced 
dose USS 1990 USS2003 
Chloroquine 0.12 0.1 1945 
Sulphadoxine- 0.2 0.13 1967 
pyrimethamine 
Amodiaquine 
-
0.3 1945 
Quinine 1.8 1.5 1632 
Mefloquine 2.4 2.0 1977 
Artemisinin 6.0 1.0-3.0 1984 
LapDap 
-
5.0· TBRb 
Halofantrine 7.0 5.0 1977 
Atovaquone 
-
30.00 1996 
proguanil 
Table 1.2. The relative cost of antimalarial treatments over a 12 year period, 
values from 1990 are taken from Molyneux et al., 1999, data for 2003 is taken from 
Pharmacopeia 2003. (a) recent publications have suggested that LapDap may 
become available at non profit prices within Africa, costing approximately $0.29 
for a three day adult treatment. (Pincock et al., 2003). (b) The general release date 
is yet to be established for LapDap 
produce growth inhibition in a manner similar to that of chloroquine but with a higher 
efficacy and as such is a common second line drug in many areas of Africa. 
1.4.3.3 Mefloquine (Larium) 
Mefloquine is a more expensive member of the quinolone family and (Figure 1.12) 
although too expensive for general use throughout tropical Africa is used in wealthier 
countries with multi drug resistance such as Thailand (Winstanley, 2003). An increase in 
drug resistance has led to its combination with artimisinin derivatives, increasing the 
overall effectiveness of the drug. 
1.4.3.4 Artemisinins 
Acting against the sexual stage gametocytes within the blood, artemisinins are potent and 
fast acting but expensive in comparison to the quinoline drug family (Table 1.2). Several 
semi-synthetic derivatives of artemisinin are in use and include artemether, artesunate and 
arteether, all of which are metabolised to the main active agent dihydroartemisinin 
«Figure 1.12)(Meshnick et al., 2002». The mechanism of action of the artimisinin based 
drugs is yet to be established with evidence supporting two different modes of action 
being published (Ridley, 2003). It has been hypothesized that the endoperoxide bridge, 
necessary for antimalarial activity, breaks open in the presence of intra parasitic heme and 
iron in tum releasing toxic free radicals, which inhibit several parasitic pathways (Olliaro 
et al., 2001). More recently it has been suggested that these drugs target and irreversibly 
inhibit the malarial calcium-dependant ATPase (Eckstein-Ludwig et aI., 2003). 
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1.4.3.5 Atovaquone/proguanil (Malarone) 
The antimalarial atovaquone (Figure 1.12) targets the cytochrome c reductase, which is 
part of the mitochondrial electron transport system (Fry et at., 1992), however a point 
mutation has lead to the onset of drug resistance (Srivastava et aI., 1999). The rapid 
development of resistance after only several months of general release has led to the drug 
being used in conjunction with proguanil in a synergistic manner. Proguanil is 
metabolized to the active reagent cyc10guaunil that primarily exerts its effects by 
inhibiting the dihydrofolate reductase-thymidylate synthase (DHFR-TS) and disrupting 
deoxythymidylate synthesis (Winstanley et at., 2001). The difficulty in synthesising 
atovaquone has led to a relatively high cost treatment and it is consequently rarely used in 
developing countries. 
1.4.3.6 Sulphadoxine-Pyrimethamine antifolates (Fansidar) 
The most commonly used anti folate drugs are sulphadoxine and pyrimethamine, which 
are given together as a cheap combination therapy (Table 1.2, Figure 1.12). The 2,4-
diaminopyrimidine pyrimethamine, targets the dihydrofolate reductase enzyme (DHFR-
TS), in a manner similar to that of proguanil (Ridley et at., 2002 & Yuvaniyama et at., 
2003). Sulphadoxine inhibits the dihydroopteroate synthase (DHPS), a member of the 
folate pathway, in an as yet undetermined manner. Both of these are used together in a 
synergistic manner enhancing their activity and reducing the onset of resistance (Newton 
& White, 1999). 
1.4.3.7 Antibiotics 
Used in combination with antimalarials, antibiotics have been shown to help both inhibit 
parasite growth and slow down the onset of resistance. It is thought that their mode of 
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action is through inhibiting prokaryotic like pathways within the apicoplast, in particular 
self replication and protein synthesis (Ralph et al., 200 I). The combinations of quinine 
with tetracycline or doxycycline are commonly found in parts of south east Asia (Ridley, 
2002). 
1.4.3.8 Drug resistance 
There are several factors which can influence the development of resistance including the 
drugs half life, patient compliance, administration, non-target drug pressure and cross 
resistance. This is coupled with the ability of both the P jalciparum and the Anophelles 
mosquito to undergo positive genetic mutations within drug pressure environments. 
Resistance to CQ is through selective mutations of two genes pfcrt, a membrane 
transporter and pfmdrl a P-glycoprotein homologue (Wongsrichanalai et al., 2002). 
Furthermore recent publications may suggest that CQ resistance is achieved or 
compounded through the acquisition of a CQ drug efflux pump (Sanchez et al., 2003). 
Point mutations of the DHFR have been shown to confer resistance to pyrimethamine, 
however the crystal structure of DHFR may offer insights into the development of new 
inhibitor analogues capable of overcoming these mutations (Yuvaniyama et al., 2003). 
The time period between drug introduction and the first reported resistance can be very 
short (Table 1.3), emphasizing the need for drug combination therapies to lengthen the 
lifespan of new antimalarials. Although drug resistance can be found world wide (Figure 
1.13), an area of great concern is Africa which has resistance to CQ and a loss of 
sulphadoxine-pyrimethamine sensitivity. This is compounded by a lack of economic 
wealth to afford the more expensive antimalarials (Wongsrichanalai et al., 2002). 
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Antimalarial Introduced 1 st reported Difference 
drug resistance (years) 
Quinine 1632 1910 278 
Chloroquine 1945 1957 12 
Proguanil 1948 1949 1 
Sulphadoxine- 1967 1967 0 
Pyrimethamine 
Mefloquine 1977 1982 5 
Atovaquone 1996 1996 0 
Table 1.3. The time taken for resistance to occur for each of the main 
antimalarial drugs produced. The figure is based on data from Wongsrichanalai 
etaL,2002. 
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Figure 1.13. The global distribution of malaria in 2002 is represented through the red shading of the map, 
with red and yellow circles showing areas of parasite resistance to chloroquine and sulphadoxine-
pyrimethamine, respectively. Figure is taken from Ridley et al. , 2002. 
1.4.3.9 New and Developing drugs 
Although new antimalarial drugs have been developed over the last two decades both the 
price of these drugs and the level of drug resistance have rapidly increased ((Table 1.2) 
(Molyneux et al., 1999)). A promising solution may be in the development of 
Chlorproguanil-dapsone (LapDap) (Lang et al., 2003) which may have an overall cost 
over a 3-day period of US$ 0.3 makes it an affordable option for many countries (Pincock 
et al., 2003). Initial studies have shown LapDap to be well tolerated and effective against 
non complicated malarial infections. The use of two combined drugs may slow down the 
onset of drug resistance, with a new chloroproguanil-dapsone-artesunate combination 
drug being under development that may slow resistance further. 
The discovery of several prokaryotic pathways residing in the apicoplast has led to the 
development of fosmidomycin, an inhibitor of I-deoxy-D-xylulose 5-phosphate (DOXP) 
reductoisomerase, part of the essential mevalonate-independent, isoprenoid biosynthesis 
pathway (Wiesner et al., 2003). Initially isolated as a natural antibiotic from 
Streptomyces lavendulae in the 1970's, it was not unti11998 that its molecular target was 
discovered. Although still in development it shows low toxicity, a short plasma half life 
and activity against multidrug resistant parasite strains. 
The lack of a functional citric acid cycle within the malarial parasite makes anaerobic 
glycolosis an attractive drug target, in particular the lactate dehydrogenase, which is 
responsible for the generation ofNAD+ by the reduction of pyruvate to lactate. The high 
resolution structure for Pfalciparum lactate dehydrogenase has been solved (Dunn et al., 
1996), revealing significant structural differences to human lactate dehydrogenase, which 
may be targeted as part of a rationally based drug design program. Currently the only 
promising lead inhibitor of lactate dehydrogenase is gossypol, which is isolated from 
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cotton seeds and displays a modest in vitro anti malarial activity (ICso= 15-29 J.LM) 
(Razakantoanina et al., 2000). 
1.5 Toxoplasma gondii pathology 
Toxoplasma gondii is one of the most widespread infections of man and warm blooded 
animals, infecting an estimated 25% of the worlds human population (Sibley, 2003). The 
prevalence of the infection varies greatly on a geographic scale with an estimated 16-40% 
of the UK and US infected, whereas in continental Europe and Central and South 
America up to 80% may be infected. The main transmission route into humans is through 
the consumption of under cooked contaminated meat and is the third most common cause 
of food-borne deaths in the United States (Mead et al., 1999). Although infections in 
humans are predominantly asymptomatic, the parasite can produce severe complications 
.. and may be fatal. There are two main risk groups for infection by T.gondii. Firstly, 
patients suffering from immune suppression, with approximately 30% of European and 
10% of American patients suffering from Acquired Immunodeficency Syndrome (AIDS) 
dying from toxoplasmosis (Hill & Dubey, 2002). Furthermore patients undergoing 
transplantation surgery can also suffer from toxoplasmosis infections due to the immuno-
suppressive drugs administered to reduce the risk of transplantation rejection (De 
Medeiros et al., 2001). The second major risk area for a T.gondii infection is when it is 
passed from mother to neonate and is the leading cause of congenital neurological birth 
defects (Boyer & McLeod, 2002) with the health care burden within the USA, reportedly 
estimated to cost $5.2 billion per year (Roberts et al., 1994). 
Consideration must also be given to the bio-terrorism possibilities of this organism. Its 
genetics are relatively simple, as there are only two stages to its life cycle in which only 
the initial infection that is caused by rapidly multiplying tachyzoites can be targeted by 
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drugs. These turn into slower growing bradyzoites which reside in tissue cysts and can 
not be targeted by any current drug treatment, due to difficulties in crossing the bradyzoite 
cyst wall. By a theoretically simple process of genetic engineering it would be possible to 
place a more virulent toxin such as cholera or shigella under the control of a bradyzoite 
promoter. This might create a pathogen, which may target most mammalian cells and go 
unnoticed until established as a bradyzoite by which point no drugs would be available to 
inhibit parasite growth once it starts producing its more virulent toxins. 
1.5.1 Toxoplasma gondii lifecycle 
The T.gondii parasite can infect almost all warm blooded animals, however the definitive 
host is the Felidae family. In the intermediate host such as humans or livestock, the 
T.gondii undergoes two phases of asexual development in which tachyzoites develop into 
.. bradyzoites (Figure 1.14). Infection by the T.gondii parasite is commonly initiated 
through an oral route by the ingestion of undercooked contaminated meat containing 
tissue cysts or highly infectious oocysts from cat faeces (Carruthers, 2002). These 
oocysts once within the small intestine liberate sporozoites which quickly differentiate 
into trachyzoites and rapidly disseminate throughout the body. Ingestion of contaminated 
meat may result in the release of bradyzoites which like the oocysts quickly differentiate 
into trachyzoites which then migrate throughout the body. The tachyzoites, over the next 
8-12 days multiply rapidly through repeated endodgeny in many different host cell types 
after which the tacyzoites develop into slower growing bradyzoites (Dubey et al., 1998). 
The differentiation of these bradyzoite, which is thought to be triggered by the host 
immune system, marks the start of the chronic phase in which parasite replication is 
significantly slowed down and the parasite forms a cyst wall protecting itself from the 
host immune response (Bohne et al., 1994). These tissue cysts have a preference for the 
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Figure 1.14. A schematic diagram of the Toxoplasma gondii life cycle, taken from 
Dubey et aI., 1998. Within this cycle, cats, the definitive hosts of Tgondti; can become 
infected by ingesting sporulated oocysts or (most often) infected animals. The oocysts 
are infectious to most mammals and birds. Toxoplasma can be transmitted to 
intermediate hosts through oocysts, by the ingestion of undercooked contaminated meat, 
or transpiacentally. 
central nervous system, the eye and skeletal muscle and may last for the life of the host 
(Tenter et al., 2000). It is thought that these cysts may break down periodically, releasing 
tachyzoites which can re-infect tissue creating more tissue cysts (Dubey et al., 1998). 
If ingested by the definitive host, the Felidae family, another stage of asexual 
proliferation is carried out by the bradyzoite, consisting of initial multiplication followed 
by repeated endopolygeny in the small intestine epithelial cells (Tenter et al., 2000). A 
sexual phase of replication then occurs in which gamogony and oocysts are formed within 
the epithelial cells. The faeces is then used to pass unsporulated oocysts into the 
environment, sporogony is then carried out outside the host, leading to the production of 
infectious oocysts, containing two sporocysts, each containing four sporozoites. 
1.5.2 Currently available drugs 
. To date there are no drugs available which will totally eliminate a T.gondii infection 
especially with respect to the slower growing bradyzoite cysts which are composed partly 
of host and parasite constituents which can cause chronic lifelong illness (Boyer & 
McLeod, 2002). The current treatment of choice for a T.gondii infection is a combination 
of sulphadiazine and pyrimathamine which is only effective against the rapidly 
multiplying tachyzoite stage of growth. Furthermore these drugs are limited by their 
toxicity and allergy (Boyer & Mcleod, 2002). In difficult cases atovaquone, spiramycin, 
diaminodiphenylsulphone and clindamycin have been used to varying degrees of success. 
1.6 Aims and Objectives 
Recent studies have suggested that the apicoplast within apicomplexan parasites carries 
out fatty acid synthesis via the type II F AS system and subsequently could be targeted by 
key inhibitors of this pathway as described previously. The aim of this project is to 
26 
determine through crystallographic techniques the structure of the P jalciparum and 
T.gondiii ENR enzymes in complex with NAD+ and tric10san in the hope of further 
understanding the ENR family. 
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CHAPTER 2 
X-ray diffraction theory 
This chapter describes the techniques used to prepare protein crystals and the principals 
of protein crystallography used in the structural analysis of the enoyl reductase from 
P.falciparum and T.gondii. The mathematical formulae for diffraction theory were 
obtained from Drenth, 1999 and Blow 2002. 
2.1 Macromolecular crystallization 
The crystallisation of protein molecules is carried out in a manner similar to that of small 
molecule crystallisation, with the aim being to remove the solvent molecules from around 
the protein inducing a low degree of supersaturation in solution. This forces the protein 
molecules together and encourages intermolecular contacts to form. Unlike small 
molecule crystals however, protein crystals typically contain large volumes of solvent 
(30-90%), which reduces the size of protein surface interactions. The majority of 
intermolecular bonds holding the crystal together tend to be multiple weak forces 
involving hydrophobic interactions, ion pairs and H-bonds, with the occasional small 
molecule salt, ligand or metal interaction. There are two stages to the growth of the 
protein crystal, the first being the initial nucleation stage in which a small number of 
protein molecules aggregate to form a nucleus whose intermolecular contacts resemble 
those of the final crystal. This occurs at higher supersaturation levels, whereas at lower 
supersaturation levels, the second stage, the growth of the crystal is supported with 
additional molecules joining the stable nuclei. In general slower supersaturation 
minimises the growth of large numbers of crystal nuclei and as such helps to encourage 
the growth of fewer larger and better quality crystals (Figure 2.1). The growth of protein 
crystals is halted when either the concentration of the remaining protein in solution is too 
low or when the surface of the protein crystals become badly formed and no longer 
allows for the formation of a regular crystal lattice. 
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Figure 2.1. The theoretical solubility curve for a protein, as a function of salt 
concentration, adapted from Drenth, 1994. 
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Figure 2.2 The hanging drop method of vapour diffusion crystallisation. 
2.1.1 Crystallization experiments 
In order to achieve the conditions required for crystallisation many parameters must be 
taken into account. These include protein purity, solubility, concentration, temperature, 
pH, precipitant type and concentration and the presence of both 
cofactors/substrates/inhibitors of the protein, which may change its surface character. 
The temperature for most crystallisation conditions is often standardised at around 17°C 
but can be varied if necessary. With the integrity of a protein crystal being dependant on 
the virtually faultless repetition of the unit cell, impurities or heterogeneity within the 
protein sample can, and does, affect crystal quality and for this reason the purity of the 
protein should generally be above 95%. The concentration of the protein generally 
ranges from 5-20mg/ml with the solubility and stability of a protein affecting the useable 
concentration range. The number of conditions that may be altered allows for limitless 
combinations. However by setting up a relatively small number of initial conditions 
ranging over all the parameters, initial conditions can be found and later optimised. In 
order to carry out the initial screen of the protein several sparse matrix screens can be 
used, the more popular being those of the Hampton Research Screens 
(www.nvxtal.comlscreens.html) including Crystal Screen I, II and the PegIon screen. 
2.1.2 The vapour diffusion method of crystallization 
The most popular of the crystallisation techniques is that of vapour diffusion. In this 
method a small amount of purified and concentrated protein solution, typically between 2 
and 5 III is placed either on a siliconised cover slip (hanging drop method) or on a micro 
bridge (sitting drop) in a closed environment with the crystallisation solution (Figure 
2.2). The protein sample is commonly mixed, usually in a I: 1 volume ratio with the 
reservoir solution prior to sealing. The precipitant and protein concentration increases 
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gradually over time, through the dehydration driven reduction in droplet volume by 
equilibration of water vapour with the reservoir or well solution. 
2.2 Crystal mounting 
Due to the high levels of solvent within a protein crystal lattice any removal of the 
solvent through evaporation will destabilise the crystal. To overcome this the crystal 
must be kept within a stable environment either within the mother liquor or in the 
saturated vapour of the mother liquor. This requires the crystal to be either cryo cooled to 
lOOK in a micro-fibre loop or placed within a sealed glass capillary tube containing 
mother liquor. This stabilised crystal is then placed within the X-ray beam and aligned 
using a goniometer head. The goniometer has two perpendicular arcs allowing the crystal 
rotation about two perpendicular axis permitting the alignment of the crystal within the 
X-ray beam. 
2.2.1 Tube mounting 
For tube mounted crystals the crystal is mounted within a glass capillary tube whose 
diameter is slightly larger than that of the crystal. Once within the tube a small amount of 
mother liquor is placed either side of the crystal forming a saturated vapour around the 
crystal, stabilising it. The tube is then sealed using wax. The walls of the capillary are 
very thin to reduce the amount of background X-ray scattering produced by the glass 
tube. Once positioned within the tube the protein crystal is stable and can be kept for 
short periods of time, (weeks) before crystal degradation (Figure 2.3). 
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Figure 2.3. A schematic representation of a crystal mounted within a glass 
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Figure 2.4. (a) A schematic representation of a loop mounted crystal. (b) 
A photograph of a loop mounted crystal taken from Mac Sweeney et a!. , 
2003. 
2.2.2 Cryo cooling 
As the protein crystal is exposed to increasing levels of X-ray radiation large amounts of 
damage can occur to the crystal. This damage can be caused largely by the 'primary' 
interactions of the beam with the crystal in a dose dependant manner, producing both 
heat, through thermal vibration of the molecules and the breakage of bonds between 
atoms in the molecules. Reactive radicals are subsequently produced through damage to 
the polypeptide and to the solvent. These radicals diffuse through the crystal using 
thermal energy and cause 'secondary' damage. This X-ray damage is both time and 
temperature dependent and at cryo-temperatures of around lOOK immobilisation of these 
reactive products occurs. At room temperature however this 'secondary' damage diffuses 
through the crystal and can destroy the crystal. For this reason freezing the crystals at 
lOOK in liquid nitrogen is the preferred method for crystal mounting. The most 
convenient way of cryo-cooling crystals is the loop mounting method (Teng, 1990). 
2.2.3 Loop mounting 
In order to obtain data from a frozen crystal it is critical that the crystal cools so fast that 
the water is vitrified and does not form crystalline ice, which would produce a strong 
diffraction ring upon the image. In order to do this 'antifreeze' or cryo protecting agents 
such as glycerol, mineral oil, paratone N or PEG are added that act by slowing down the 
speed of ice formation within the solution. The crystal is firstly soaked within a mixture 
of its stabilising solution and the cryo-protecting agent for a variable length of time. This 
crystal is then quickly 'scooped' out of the solution using a loop made up of a thin fibre 
(l 0-30~m in diameter), with the surface tension of the solvent holding it in place (Figure 
2.4 a, b) and is then immediately plunged into liquid nitrogen. The speed at which this 
process occurs allows for a vitrified glass to form around the crystal holding it in place 
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without disrupting the crystal lattice, limiting the disruption to the diffraction properties 
of the crystal. Several cryo protecting agents are often tested until the optimum 
conditions can be found. Once frozen the crystals maybe stored in a liquid nitrogen 
Dewar for long periods of time (month). However frozen crystals can gain an increase in 
mosaicity due to small changes in the lattice upon freezing. Factors affecting this are, the 
speed of cooling and transfer to the cryogen and size of the crystal. It is important to 
limit this through a good technique and choice of cryo protecting agent so as to collect 
the best set of data possible from your crystal. 
2.3 X-ray generation 
X-rays are high frequency electromagnetic radiation having wavelengths ranging from 
10-7 m (1000A), (soft X-rays), to 10-11 m (IA ), (hard penetrating X-rays). For 
macromolecular crystallography the shorter wavelength X-rays, which are of a similar 
scale to the distance between atoms are used. X-ray radiation is produced when 
electrons, from a cathode of high negative potential are accelerated in a vacuum towards 
a positive anode. The electrons subsequently hit the anode at high speed and are lifted to 
a higher energy level and as they fall back down to a lower energy level they release 
energy. This energy is dissipated in the main as heat, however some takes the form of X-
rays emitted in two ways, as a sharp peaks of specific wavelengths and as a broad band of 
wavelengths (Figure 2.5). It is the sharp peaks that are used within X-ray studies and are 
generated by the electron transitions within the metal anode. The usual source of a metal 
anode is copper and the corresponding CuKa and CuK(3 X-ray wavelengths produced are 
generated by the transition of electrons from the Land M-shell, respectively to the K-
shell. 
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Figure 2.5 The characteristic X-ray emission spectra produced by a copper 
target, adapted from Drenth, 1994. 
2.3.1 The rotating anode source 
The most common source of X-rays within protein crystallography is through a rotating 
anode source where a heated tungsten filament bombards an anode usually constructed 
from a copper cylinder rotating at high speed with a beam of focussed electrons. The 
highly negative potential of the filament with respect to the anode and the presence of a 
vacuum allows the electrons to hit the anode at high speeds and produce X-rays in the 
manner described above. To select the desired wavelength of X-rays (the CuKa rays), a 
series of slits and a graphite crystal coated monochromator or nickel or platinum coated 
focussing mirrors combined with a nickel filter can be used. The anode source must be 
kept rotating at high speeds as one of the largest constraints upon an X-ray tube is its 
ability to dissipate heat and if the anode were stationary then the constant bombardment 
of electrons would concentrate large amounts of heat energy upon a small area of the 
anode causing it to melt. 
2.3.2 Synchrotron radiation 
The use of synchrotron radiation is now commonplace within protein crystallography and 
the ability to both change the wavelength and use a more intense X-ray beam makes it a 
powerful tool. Synchrotron radiation is produced by a particle accelerator, which has a 
large storage ring circulating electrons at velocities near to the speed of light. The 
electrons are circulated using a series of focussing magnets and any loss of energy is 
compensated by a radio frequency input, the constant change in direction by the electrons 
causes the emission of energy in the form of electromagnetic radiation. The intensity or 
flux of the beam on a synchrotron source containing bending magnets is two orders of 
magnitude greater than that of a conventional X-ray generator and furthermore, the use of 
a wiggler undulator is another two orders as intense again. This increase in beam 
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intensity allows for data collection on weakly diffracting or small crystals. For crystals 
with a large unit cell and subsequently small spacing within the diffraction pattern the 
low divergence of the synchrotron X-ray beam allows for high resolution data to be 
collected. The tunability of the wavelength allows mUltiple wavelength dispersion 
(MAD) phasing experiments to be carried out by tuning the wavelength to the absorption 
edge of an anomalous scattering heavy atom such as selenium. The increase in beam 
intensity also allows for much shorter exposure times on the crystal (seconds rather than 
minutes) and subsequently can reduce some of the secondary radiation damage and also 
shorten the time of the experiment. 
2.4 Diffraction of X-rays 
X-ray beams may be regarded as electromagnetic waves with an oscillating electric field. 
The interaction between an X-ray photon and an electron may set the electron oscillating 
about its nuclei with the same frequency as the X-ray. This produces a secondary 
scattered wave of the same frequency as the incident X-ray. Coherency is achieved 
because all the scattered waves from a source electron will have the same phase 
relationship to the incident X-ray beam, known as Rayleigh (elastic) scattering. However 
there is an incoherent or Compton (inelastic), scattering component, where the 
wavelength has changed due to exchange of energy and momentum when the X-ray hits 
the atom. As the coherent scattering component from many atoms in a crystal is 
significantly greater Compton scattering is generally ignored. Scattering of X-ray 
radiation by different electrons leads to interference as the relative phases add up, either 
in phase, resulting in an amplitude equal to the sum of the individual amplitudes or out of 
phase in which the amplitude is equal to the difference of the two amplitudes, or any 
amplitude between. 
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2.4.1 Bragg's law 
The simple equation for Bragg's law 
nA= 2d sin9 
was derived in 1913 (Bragg, 1913) and can be used to explain why crystals appear to 
reflect X-ray beams at certain angles of incidence (9). The wavelength of the incident X-
ray beam is given as A, d is the distance between the atomic layers in a crystal and n is an 
integer. The equation gives the conditions for which two scattered waves are in phase 
/ 
and interfere constructively, producing diffraction. The two incident beams are always in 
phase and parallel until the top beam strikes the top layer at atom z (Figure 2.6a) whereas 
the second beam is scattered by atom B in the second layer. In order for the two beams to 
continue to travel in phase the extra distance traveled (AB + BC) must be an integral (n) 
multiple of the wavelength (A) such that 
nA=AB+BC 
By taking d as the hypotenuse of the right angled triangle ABz (Figure 2.6b), simple 
trigonometry can be used to relate d and 9 to the distance (AB + BC). The distance AB is 
opposite 9 so, 
AB = d sin9 
The equation nA = AB + BC can be rewritten as nA = 2AB as AB = BC. Combining this 
equation to the equation above gives us Bragg's law: nA = 2d sin9. 
2.4.2 Structure factor for a single electron 
The structure factor is a complex number which represents the amplitude and phase of the 
resulting diffracted wave. An absolute scale is used for defining the structure factor by 
defining the diffraction from a single electron as having an amplitude of Ie: 
F(S) = Ie e(21tirS) 
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Figure 2.6. (a), (b) Schematic description of diffraction from planes obeying 
Bragg's law. 
where S is the vector perpendicular to the reflecting plane and r is the vector representing 
the position of the electron relative to the origin. As such the diffracted wave has a phase 
of 27tir·S, relative to the origin. 
2.4.3 Scattering by an atom 
As it is the electron cloud of an atom which scatters X-rays, the scattering is dependent 
on the nature of the atoms. The atomic scattering factor f is the sum of the entire 
scattering over the volume of the atom: 
f= J per) e [21tir, Sldr 
r 
where integration is over the whole space r, the electron density at position r is per), r is 
the position of the electron from the centre of an atom (origin) and S is the scattering 
vector. 
2.4.4 Scattering by a unit cell 
The unit cell has n atoms at positions rj (j = 1, 2, 3, 4, ...... , n) with respect to the unit 
cell origin all of which will make a contribution to the total unit cell scattering. 
Therefore, the diffraction from the unit cell is the total sum of the scatter from the 
individual atoms and is defined as: 
n 
F(S) = L jj exp[21tirj . S] 
j=1 
The structure factor F(S), so called because it depends on the arrangement of atoms in the 
unit cell and describes the distribution of electron density within the unit cell. 
2.4.5 Scattering by a Crystal 
As a crystal is comprised of many unit cells, the scattering from a crystal can be 
described as the sum of all the unit cells with respect to a single origin. 
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m n2 n3 
K(S) = F(S) x L e [21tita. S] x L e [21tiub. S] x L e [21tivc. S] 
t=O u=O v=O 
The crystal contains translation vectors in the direction a, b and c, where nJ, n2 and n3 are 
the number of unit cells in the direction a, b and c, respectively. The indices t, u and v 
are the translatory steps which relate each of the unit cells along each vector. As there 
are many unit cells in the crystal, the values of nl, n2 and n3 are very high which means 
nl 
that the summation L e [21tita. S] and the other two summations over u and v are almost 
t=O 
equal to zero unless a. S = h, b • S = k and c • S = I, the Laue conditions. Therefore, the 
total diffraction from a crystal will consist of small well orientated maxima and each 
maxima is indexed with the hkl indices. 
2.4.6 The reciprocal lattice and the Ewald sphere 
Protein crystals are comprised of rows of ordered molecules arranged in a lattice with its 
subsequent diffraction pattern also being seen as a lattice. However the diffraction lattice 
is the reciprocal of the real lattice and as such has axis dimensions a*, b* and c*, which 
are inversely proportional to the real crystal lattice dimensions a, b and c. In order for a 
diffracted beam to be at a maxima it must fulfill the specific conditions defined by the 
Ewald sphere (Ewald, 1979). The Ewald sphere has a radius of 1/1." and in order for a 
reflection to occur the reciprocal lattice point must lie on the surface of the sphere 
(Figure 2.7). By rotating the crystal in the X-ray beam, all lattice points will pass 
through the surface of the sphere and as such be measured. Some reflections will not be 
measured due to the occurrence of blind regions, in which, due to the alignment of the 
crystal, some reflections will lie on the rotation axis and never lie on the Ewald sphere. 
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Figure 2.7 The Ewald sphere. With radius 1/A, the lattice centre is at O. So 
indicates the direction of the incident beam; s indicates the direction of the scattered 
beam. The figure is taken from Drenth, 1999. 
2.5 Calculation of electron density 
If x, y and z are fractional coordinates in the unit cell where h, k and I are the indices for a 
reflection in the reciprocal lattice and V is the volume of the cell, then the structure factor 
F (8) can be rewritten as F(hkl). 
1 1 1 
F(hkl) = V f f f p(xyz) exp [2n i(hx + ky + lz)] dx dy dz 
x=o y=o z=o 
The electron density for every position x, y, z, in the unit cell p(xyz), is given by the 
Fourier transform ofF(hkl) and can be written as: 
p(xyz) = J.-L L L F(hkl) exp [-2n i(hx + ky + lz)] 
V h k I 
F(hkl) is a wave that has an amplitude component I F(hkl) I and a phase component a(hkl) 
such that: 
F(hkl) = I F(hkl) I eiU(hkl) 
The I F(hkl) I component of this equation can derived experimentally as the intensity of 
the reflections within the diffraction pattern is proportional to the square of its structure 
factor amplitude. However as well as the measured amplitudes the phase information 
must also be calculated and this cannot be gained directly from the experimental data set 
collected. This is commonly referred to as the phase problem within protein 
crystallography and can be overcome by a variety of techniques such as isomorphous 
replacement, anomalous scattering, MAD, direct methods and molecular replacement. 
2.6 Data collection 
The most widely used devices within protein crystallography for measuring diffraction 
data are image plate detectors and CCO cameras. 
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2.6.1 Image plate detectors 
A typical image plate is constructed using a thin layer of barium halide phosphor of 
BaFBr doped with europium, which is excited into a meta-stable electron state by 
incident X-rays (Figure 2.8). The image is subsequently read by a fine He-Ne laser beam 
.. 
(A,=633nm) scanning plate, which through stimulation of the meta-stable europium atoms 
can read the violet luminescence (A,=390nm) emitted. Importantly the intensity of violet 
luminescence is proportional to the number of absorbed X-rays, giving a system which 
offers a uniform sensitivity across the detector face with well characterised spatial 
distortion and a high signal to noise ratio. The image plate is subsequently erased by the 
exposure to intense light (optimally yellow), which returns the BaFBr back to its 
unexposed state. 
2.6.2 CCD cameras 
A CCO camera (charged coupled device) which utilises a phosphor screen to convert the 
X-rays into visible light photons is an alternative to an image plate and has the advantage 
of having a faster readout time. In a CCO the light image is de-magnified down to the 
size of a CCD chip using a fibre-optic taper converting the light image to an electric 
charge image which can then be digitised (Figure 2.9). 
2.7 Data processing with DENZO and SCALEPACK 
Having collected diffraction data each image must be correctly indexed, scale and merged 
which can be done using DENZO and SCALEPACK (Otwinowski et al., 1997). The 
reduction and analysis of a single crystal diffraction data set can be broken down into the 
seven major steps laid out in the HKL manual version five (Gewirth, 1999). These are: 
1. Visualisation and preliminary analysis of the original, unprocessed diffraction pattern 
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Figure 2.8 Diagrammatic representation to show the principle of a MAR 
image plate on an X-ray detector. The figure is adapted from Drenth, 1999. 
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Figure 2.9 A diagrammatic representation of a CCDQ4 camera. Figure is taken from 
the ADSC home page (www.adsc-x-ray.comlproducts.html). 
2. Indexing of the diffraction pattern. 
3. Refinement of the crystal and detector parameters. 
4. Integration of the diffraction maxima. 
5. Finding the relative scale factors between measurements. 
6. Precise refinement of the crystal parameters using the whole data set. 
7. Merging and statistical analysis of the measurements related by space group 
symmetry. 
The first four steps are carried out using DENZO and the last three by SCALEPACK. 
2.7.1 Auto indexing of an image 
For auto indexing in DENZO a single oscillation diffraction image is used to calculate the 
lattice type, crystal orientation and crystal unit cell parameters. The first step is to carry 
out a peak search in which reflections above a minimum intensity are located, the default 
being IOcr. These peaks are then used to carry out a complete search of all possible 
indices which subsequently allows a set of real space vectors to be calculated. The 
minimum triclinic unit cell that will index all, or almost all of the observed peaks is then 
worked out using the observed peaks. All of the 14 possible Bravais lattices are then 
worked out by applying transformations to the initial primitive triclinic cell and these are 
then output by the program along with a 'distortion index', representing the amount of 
distortion needed to apply the unit cell parameters to the respective lattice. The most 
appropriate lattice is then taken from the list by selecting the highes~ symmetry lattice 
that fits the data with minimal distortion. It is also important' prior to processing to 
manually inspect the raw data to look for any abnormalities within the diffraction pattern 
which would be too complex to be analysed numerically by a computer. These may 
include the presence of two lattices within the diffraction pattern brought about by the 
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presence of a satellite crystal. Also spot smearing may result in the incorrect indexing of 
the image and lead to the incorrect positioning of reflections. Furthermore it is important 
when carrying out experiment on crystals frozen at lOOK, to check that no ice rings are 
present on the image. 
2.7.2 Image refinement and prediction of the diffraction maxima 
The precise position and index of each reflection must be known before integration in 
DENZO, with information obtained from the strong reflections being used to predict the 
position of weak reflections. High accuracy prediction of the weak reflections depends 
on the precise knowledge of detector and crystal orientation parameters. A more accurate 
estimate of these parameters is calculated using a least squares method combined with 
partiality refinement (the intensity of partially recorded reflections is compared to the 
predicted partiality multiplied by an average intensity in the same resolution range). 
Once an accurate index has been established the intensity of the diffraction maximum is 
integrated by profile fitting. In profile fitting a curve, derived by averaging over the most 
intense reflections, is fitted to the data and the volume under the curve is taken to be the 
intensity. For each image a .x file is output that contains a header containing the initial 
parameters, a list of reflections and finally a list of the final DENZO parameters as 
refined from the image. 
2.8 Data scaling, merging and post refinement 
The program SCALEP ACK is used to complement DENZO and carries out the scaling 
and merging of different data sets and also the global refinement of crystal parameters 
(post refinement). The unit cell parameters refined from a single image may at this stage 
still be imprecise owing to the correlation between the crystal ~d detector parameters. 
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More accurate estimations of unit cell lengths and angles, the orientation of each image 
and crystal mosaicity may be obtained from global refinement by making use of the 
information within the whole data set, resulting in a scaled and merged data set. The 
output statistics from SCALEP ACK can be used to evaluate the quality of the resulting 
data. These statistics include the ratio of the intensity over the standard deviation in 
intensity (IIaI) and on the agreement between symmetry related reflections (Rmerge), 
which can both be used to estimate the resolution to which the crystal diffracts and the X2 
(likelihood) which gives a goodness-of-fit of the data to the error model. The resulting 
output from SCALEP ACK is in the form of a .sca file which contains the reflections hkl 
position and their accompanying I and 0'1 values. 
2.9 The Patterson function 
In the absence of any phase information it is still possible to obtain some information on 
the structure using the intensity information alone. The Patterson function is a Fourier 
summation with intensities as coefficients and with all phase angles equal to zero 
(Patterson, 1934). It can be expressed by the equation: 
1 
P(u v w) = - L 1 F(hkl) 12 cos[2n:(hu + kv + lw)] 
V hkl 
which can alternatively be written in a more physically interpretable definition in terms of 
electron density at real space co-ordinates (x, y, z) as:-
$(u v w) = J >(x y z) >(x + u, y + v, z + w) dv 
where u, v and w are co-ordinates in the unit cell and are so called to avoid confusion 
with x, y and z in the real cells. A Patterson function thus represents a density map of the 
vectors between scattering objects in the cell. The vector between the origin and any 
non-origin peak in the Patterson map represents the vector between two atoms in the real 
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cell. The Patterson map for a protein is impossible to solve given that for any N atoms 
within a real unit cell there will be N2 peaks, because N vectors can be drawn from each 
atom. Of the N2 peaks N will be situated at the origin because they represent vectors 
between an atom and itself. Therefore the actual number of non-origin peaks is N(N-1). 
Important points within a Patterson map are that: 
1. A peak is produced within the Patterson map for each pair of atoms. 
2. Patterson maps are centro-symmetric. 
3. The height of a peak within the Patterson map is directly proportional to the product of 
the atomic numbers of the two atoms represented by the peak. 
2.10 Molecular replacement 
One common way to solve the phase problem is to carry out molecular replacement in 
which a known 3D structure, which is predicted to be similar to the experimental model 
can be used to give an estimate of the phases. The known structure, or search model must 
have a reasonable sequence identity of around 25% or greater to the target molecule. It is 
assumed that a high sequence identity will result in a similar fold and as such a better 
estimation of the initial phases. In order to obtain the initial phases the search model 
must be reoriented such that it is in the same position as the target molecule within the 
unit cell. To do this the search model must be rotated and then translated. Molecular 
replacement is thus carried out in two steps, first the rotation, then the translation to 
minimise the computing power required. 
2.10.1 The cross rotation function 
The cross rotation function allows for the orientation of the search model that produces 
the maximal overlap onto that of the target structure. To achieve this a Patterson function 
43 
of the search model is calculated and compared to that calculated from data collected on 
crystals of the target molecule. This exploits the fact that the Patterson function is 
dependent on only the orientation and not its position within a unit cell. It is desirable 
that when calculating a rotation function, a radius of integration is carefully chosen so 
that cross-vectors, (intermolecular vectors), arising from neighboring molecules in the 
Patterson are excluded as the rotation function should be dominated by self vectors 
(intramolecular vectors). For this reason a sphere of integration of approximately 75% of 
the radius of the search molecule is commonly used. The resolution limits used can also 
have a large influence on the quality of the rotation function. As the resolution increases 
the model similarity will decrease, such that resolution ranges of 6A to 3A are commonly 
used. The presence of more than one subunit in the asymmetric unit will result in a 
corresponding number of solutions, such that a tetramer will reveal four solutions relating 
in symmetry to each of the four subunits. Problems may arise if more than one molecule 
is present within the asymmetric unit as the solution to one of the molecules will only 
account for a portion of the scattering matter of the crystal and as such would give a 
lower signal to noise ratio than a solution accounting for almost all of the crystal 
scattering matter. The rotation of a molecule with respect to another in a rotation 
function is often expressed by the angles K, cp and ro which represent the polar angles 
(Figure 2.10) with rotation K being about an axis whose direction is defined by the 
spherical polar angles cp and roo 
2.10.2 The translation function 
Once a solution to the rotation function has been found it is possible to carry out the 
translation function. In contrast to the rotation function the translation function as 
described by Crowther and Blow (Crowther & Blow, 1967) is ~ependent on the cross-
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Figure 2.10. A diagrammatic view of the spherical polar angles 0), ~ and 
K used for the rotation function in molecular replacement www-
strutted. corm. cam. ac. auk/ course.html 
vectors (intennolecular) from the Patterson, which are between atoms In adjacent 
asymmetric units. The intermolecular vectors are calculated by removing the 
intramolecular vectors calculated from the Patterson. The full symmetry translation 
function, TO is two dimensional and is calculated for every pair of symmetry related 
molecules. 
TO(t) = fpo (u) . Pc (u,t) du 
v 
where Po(u) is the observed Patterson function, u is the vector in Patterson space and t is 
the translation for the identity asymmetric unit. The function T(t) reaches a maximum 
when t is equal to the true translation vector to because the computed search model 
Patterson Pc(u,t), fits the observed Patterson function Po(u) correctly. 
An improved translation function, the T2 function, has been derived by Crowther and 
Blow (Crowther and Blow, 1967), which is a three-dimensional function which utilises 
all the symmetry operators simultaneously. The T2 function can be expressed by 
subtracting the intramolecular vectors. 
T2(t) = f(Po(u) - L Pu (u» (Pe(U, t) - L Pu (u» du 
v I I 
Where Pn is the calculated intramolecular vector for each subunit of the search model. 
A possible solution to the translation function can be checked by examining the steric 
clashes between molecules in the cell. This is done during the translation search by the 
program Molrep (Vagin & Teplyakov 2000), whereas the progra~ Amore (Navaza, 
1994) only calculates this once a solution has been obtained. 
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2.11 Phase improvement 
The initial phases obtained for the protein through molecular replacement often contain 
large errors, resulting in a poor electron density map. In order to improve the map quality 
and remove errors a number of procedures may be used. 
2.11.1 Solvent flattening 
Within a protein crystal the protein is surrounded by both ordered and disordered solvent 
molecules. The ordered solvent molecules are hydrogen bonded to the protein and as 
such their electron density forms discrete features in the map. The disordered solvent 
however forms a flat featureless continuum beyond this. In addition the phase errors 
associated with initial phase sets can often contribute false peaks into the disordered 
solvent. To reduce the map noise caused by this, solvent flattening aims to change the 
phases so as to flatten out the electron density of the disordered solvent to a constant 
correct value. This results in improved phases for the electron density in the protein 
region (Wang, 1985). A molecular boundary is defined by dividing the unit cell into a 
grid with the density at each grid point being replaced by a new value, being proportional 
to the weighted sum of the density of a sphere of radius, R, from the grid point j. The 
"flattened" map can then be used to calculate new structure factor amplitudes and phases 
which are combined with the initial phases to produce a new map, which is modified and 
back transformed. This method has proved successful for phase refinement especially for 
crystals with a high solvent content however it is poor for phase extension (Wang, 1985). 
2.11.2 Molecular NCS averaging 
This technique utilises the presence of non-crystallographic symmetry (NCS) common to 
many protein crystals to improve the phases. It is assumed that differences between 
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molecules within the asymmetric unit are negligible and therefore that the density for the 
various subunits can be mapped onto each other and averaged. This process also involves 
flattening the solvent. The asymmetric unit is then reformed and phase angles for the 
new model can be calculated by back transforming the new map. The obtained phase 
information is then combined with the previous phases, with the 'best' phases being used 
to calculate the next electron density map. 
2.11.3 Histogram matching 
Although not as powerful a technique as solvent flattening or molecular averaging an 
important technique in phase improvement is histogram matching (Zhang & Main, 1990). 
F or this the electron density distribution of the map is plotted against frequency and 
compared with that of a standard map at the same resolution. These two graphs are 
subsequently divided into bins containing an equal number of density points. Deviations 
from the predicted histogram result in incorrect phasing and tend to give a broader 
histogram than the true one. By reassigning the electron density to the predicted 
distribution of density, a modified map is produced which should be a truer 
representation of the structure. 
2.12 Structure refinement 
The aim of refinement is to increase the agreement between the calculated structure factor 
amplitudes and the observed structure factor amplitudes. The map used for the initial 
model building will contain errors due to inaccurate measurements and poor estimates of 
the phases. Refinement is improve the estimated phases and subsequently improve the 
quality of the electron density map. The main drawback in refinement is the low 
observation to parameter ratio because for each atom in the pro~ein 4 parameters (x, y, z, 
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and the B-factor) are commonly refined. In order to decrease the number of parameters 
or increase the number of 'observations' certain restraints can be placed upon the model. 
These include restraints on bond lengths and angles, van der Waals contact distances, 
planarity of groups and maintenance of the chirality of chiral groups. Further restraints 
can be placed on the model based on the non-crystallographic symmetry which may exist 
between molecules within the asymmetric unit cell, allowing the application of symmetry 
constraints. Parameters may further be reduced by describing the structure as a set of 
rigid bodies 
Crystallographic refinement can be described as the search for a global minimum of a 
target: 
E = Echem + ffix-rayEx-ray 
where E is a function of the parameters of the atomic model, Echem contains the 
empirical information about chemical interactions, describing covalent (bond lengths, 
bond angles, torsion angles, chiral centres and planarity of aromatic rings) and non-
bonded interactions. A measure of the differences between the observed and calculated 
data is given as Ex-ray and ffix-ray is a weighting term. 
2.12.1 Maximum likelihood refinement 
The method of maximum likelihood refinement as implemented in the program 
REFMAC5 (Murshdov et al., 1997) is based on the likelihood of a model given estimates 
of the errors in the measured intensities as well as the model (Bricogne, 1997). 
Improvements to the model to make the observations more probable will increase the 
likelihood of the model being correct. Errors in the model are provided by the 0' A 
distribution, which is the square root of the correlation coefficient between the 
normalised observed and calculated structure factors from the model. As improvements 
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to the model are made the (j A distribution changes and new estimations are made. 
Refinement that improves the model structure factors, will decrease the error estimates 
and this will improve the next round of refinement. In the work described in this thesis 
refinement was carried out by the program REFMAC (Murshudov et al., 1997). 
2.12.2 Rigid body refinement 
The first stage of refinement is rigid body refinement in which segments of the protein 
are treated as a rigid unit in a manner specified by the user. Rigid body refinement 
typically uses low resolution data and allows for a more accurate placement of a model 
obtained by molecular replacement into the electron density. 
2.12.3 Monitoring the progress of refinement 
In order to monitor "improvement" within a crystal structure the agreement between the 
structure factor amplitudes calculated from the model with the observed structure factor 
amplitudes, the R-factor is calculated. In order to calculate the R-factor the following 
equation is used; 
when the Fobs and Fcalcs are in very good agreement then the R-factor will be low and 
the model is a good likeness to the protein structure. A desirable R-factor is 
approximately 10% of the model resolution such that for a 2A model you would expect 
an R-factor of between 0.15 and 0.2. To eliminate bias and over fitting of a model the 
free R-factor (Rfree) was introduced (Brunger, 1997), in which a randomly selected 
section of data usually 5-10%, is removed from the refinement to form a test data set, T. 
R-factors are produced for the test set using the following equation. 
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The value obtained for the R-free should not be higher than more than 5% of the R-factor. 
The Rfree is a good indicator as to whether changes made to the model to lower the R-
factor such as the addition of waters or NCS restraints are doing so through over-fitting of 
the data. As another check of model quality, the program PRO CHECK (Laskowski et 
a/., 1993) is used to calculate a Ramachandran plot (Ramachandran, 1963) for the model 
and to check model stereochemistry to reveal areas for possible model improvement. 
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3.1 Introduction 
This chapter describes the identification, cloning, overexpreSSlOn, purification, 
crystallisation and structure determination by molecular replacement of Pfalciparum 
enoyl reductase (PfENR) complexed with NAD+ and triclosan. 
3.2 Identification of the P.(alciparum ENR gene 
The identification of the PfENR sequence was carried out by conducting a BLAST 
search on the amino acid sequence data within the P falciparum genome database, 
PlasmoDB, (www.PlasmoDB.org) against the E.coli and B.napus ENR sequences. 
Comparison of the PfENR sequence revealed approximately 44% and 18% sequence 
identity to the ENRs of B.napus and E.coli, respectively, consistent with the 
apicoplast being of an algal not bacterial origin (Figure 3.1). The gene for PfENR 
was found to be located on chromosome "BLOB", which was later assigned to 
chromosome 6 (Asn no. AF338731). Analysis of the pattern of sequence 
. conservation within the region of the triclosan binding site showed that of the 11 
residues shown to be within 4A of the triclosan inhibitor within the E.coli and 
B.napus ENR structures 8 and 10 residues, respectively are conserved in the 
Pfalciparum sequence (Figure 3.2). Consistent with PfENR being of an apicoplast 
origin, a large bipartite N-terminal signal sequence was identified, using the program 
PlasmoAP (Foth et al., 2003) preceding the mature PfENR gene. A striking feature of 
the sequence alignment is the presence of a large, polar, low complexity insert of 42 
amino acids within the PfENR sequence that is not mirrored in any other of the 
reported ENR sequences. The only possible exception to this is in MtENR, where a 
small 10 residue glycine-rich hydrophobic insert can be identified at the equivalent 
position. Within the MtENR structure this insert has been implicated in allowing the 
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Figure 3.1. A multiple structure-based sequence alignment of the ENR enzyme from 
Ecoli, H.pylori, B.subtilis, Mtuberculosis, P jalciparum and B.napus. The secondary 
structure elements of Ecoli (top) and B.napus (bottom) ENR are shown with red 
arrows for l3-strands and blue cylinders for a-helices_ Sequence numbers for Ecoli 
and B.napus ENR are given on top and below the alignment, respectively_ Those 
residues completely conserved are in reverse type and those involved in triclosan 
binding within the E,coli structure have a black circle above_ Residues conserved 
between B.napus and P jalciparum ENR are in red. The predicted start of the mature 
PfENR enzyme is shown by a black arrow and the start of the cloned PfENR sequence 
is indicated by a purple arrow_ The sequences were aligned using ClustalW (Higgins 
& Thompson, 1994) and the figure was produced using th~ program Alscript (Barton, 
G-1_, 1993)_ 
Figure 3.2. A stereo view of the three dimensional arrangement of the atoms that 
form the binding pocket for triclosan in BnENR, with those residues conserved 
between the B.napus and P falciparum ENR enzymes and within 4A of the inhibitor 
labelled in red. The diagram was produced using the graphics program TURBO-
FRODO (Roussel et al. , 1990). 
enzyme to accommodate larger substrates such as mycolic fatty acids by increasing 
the size of the substrate binding pocket (Rozwarski et al., 1999). However the 
contrast between the small, predominantly hydrophobic, glycine rich sequence and the 
large bulky polar hydrophilic sequence may suggest an additional or novel function of 
this insert in the PfENR enzyme. 
3.2.1 Other P .jaiciparum type II F AS genes 
In order to establish whether a complete type II F AS pathway exists within the 
Pfalciparum parasite a Blast search was carried out using search sequences of the 
enzymes from the pathway from the plants A.thaliana and B.napus and the bacteria 
E.coli and B.subtilis. Searches for the FabB, FabD, FabG and FabH genes revealed 
approximately 30% sequence identity to the homologues from A. thaliana (Figure 
3.3). The FabZ sequence was found to share approximately 30% sequence identity to 
the B.subtilis homologue enzyme (Figure 3.3). These data together with the presence 
of the gene for the acyl carrier protein, (Waller et al. , 1998) indicated the presence of 
a fully functional type II F AS pathway within the Pfalciparum parasite. Analysis of 
the genes showed that they all contain a bipartite N-terminalleader sequence to allow 
for targeting to the apicoplast but only the ENR gene contains any significant insert 
within the coding sequence. The location of these genes within the Pfalciparum 
genome does not indicate the presence of any kind of operon system with the FabD 
and FabZ genes being present on chromosome 13, the FabB and Fabl genes being 
present on chromosome 6 and the FabH and FabG being present on chromosomes 2 
and 9, respectively. A Blast search was also carried out to try to detect a type I FAS 
pathway, using the sequences from Homo sapiens, Candida albicans, Saccharomyces 
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Figure 3.3. Sequence alignments of the F AS type II pathway enzymes of Pfalciparum, against 
the A.thialana enzymes, except for the FabZ sequence which is aligned against the B.subtilis 
homologue sequence. Those residues which share sequence identity are in a blue box with 
reverse type. Those residues which are similar are in a red box with reverse type. The 
sequences for the P falciparum F AS genes were obtained from the PlasmoDB 
(www.PlasmoDB.org).TheA.thialana and Hsubtilis sequences are from the swissprot 
database (Boeckmann et al. , 2003). The sequences were aligned using ClustalW (Higgins & 
Thompson, 1994) and the figure was produced using the program Alscript (Barton, G.J., 1993). 
cerevisiae and Rattus norvegicus. However no hits were detected suggesting the lack 
of a type I F AS pathway within the Pfalciparum parasite. 
3.3 Overexpression and purification of PfENR 
Difficulties in the over expression of the PfENR enzyme, caused in the main by a high 
genetic A + T ratio and the use of several rare codons not commonly found in the 
expression hosts led to the establishment of a collaboration with Prof Sean Prigge at 
the Johns Hopkins Bloomberg School of Public Health who developed a novel over-
expression system for this enzyme. The mature PfENR sequence corresponding to 
residues 85-432 minus the large signal sequence was cloned into modified version of 
the pMALc2x vector (PMALcHT) as a fusion protein with maltose binding protein 
(MBP), a TEV protease recognition site and a hexa His tag (Figure 3.4a). The 
pMALcHT vector was cotransformed in E. coli along with a plasmid encoding the 
TEV protease (PKM586) and a pRIL plasmid which codes for the rare tRNAs. 
During a long low temperature induction period substantial quantities of the soluble 
fusion protein were synthesised which was then cleaved in vivo by the TEV protease 
which was over-expressed at the same time on the pKM586 vector. Purification could 
then be carried out on both a Nickel column to obtain PfENR through its His6 tag and 
an amylose column to separate protein tetramers in which all the subunits have been 
cleaved from any uncleaved PfENRlMBP protein, which may be present (Figure 
3.4b). Analysis of the purified protein (Figure 3.4c) showed the sample to be 
approximately 95% pure. The PfENR enzyme was then concentrated to 12mg mr} in 
a buffer of 20mM Na/K phosphate pH 8.0, 150mM NaCI for crystallization trials. 
The overexpressed PfENR is numbered such that the first residue, which formed the 
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20kDa-+ 
14kDa-+ 
(C) 
-MBP-ENR 
_MBP 
-ENR 
}-Overdigestion 
Figure 3.4. (a) A schematic representation of the pMALcHT vector. A single letter 
abbreviation is used to describe the sequence of the linker between the MBP fusion 
protein and PfENR. The seven residue TEV protease binding site is highlighted by a 
black box. (b) A schematic representation of the purification scheme for PfENR. (c) 
SDS-PAGE of PfENR purification. Lane one shows Sigma markers with pure MBP-
ENR fusion protein produced by the pMALc2x vector in lane 2. Lane 3 contains the 
factor Xa-digested fusion and lane 4 shows the PfENR produced by il1 vivo cleavage 
using the pMALcHT vector. 
mature sequence of PtENR after the six His tag sequence, was renumbered as residue 
1 ((Alal)(Figure 3.1)). 
3.4 PtENR crystallisation 
Initial crystallisation trials were conducted using the Hampton research crystal 
Screens I, II, Peglon screen, Xtal screen lite and grid screen on PtENR complexed 
with NAD+, NAD+ and triclosan and in its apo form. The best crystals were grown 
using the hanging-drop vapour diffusion technique by mixing 2.5~1 of the protein 
solution (12mg/ml PtENR in 20mM Na/K phosphate pH 8.0, 150mM NaCI, with 
5~M NAD+ and 6~M triclosan) with 2.5~1 of the reservoir solution at 290K. This 
produced two promising crystallisation conditions for the PtENRlNAD+ Itriclosan 
complex in Crystal Screen I solution 4 (2M (NH4)2S04 and O.1M Tris-HCI pH8.5), 
taking three days to grow to a size of 0.2 X 0.3 X 0.5 mm3 and in Peglon screen 
solution 11 (20% (w/v) PEG 3350 and 250mM KI) taking four to five weeks to reach 
a maximum size of 0.1 x 0.1 x 0.1 mm3. 
3.4.1 Optimisation of crystallisation conditions 
The two promising crystallisation conditions were optimised by screening around the 
conditions changing both pH and precipitant concentration. Optimisation of the 
Screen I condition 4 reservoir solution gave crystals diffracting to only 6A. Crystals 
of the PtENRlNAD+/triclosan complex grown through the optimisation of Peglon 
screen 11 (Figure 3.5a) were of a better quality, with the optimised condition (19.5% 
(w/v) PEG 3350 and 230mM KI) producing crystals of an average size of 0.15 x 0.10 
x 0.10 mm3 diffracting to 2.8A "in house" and to 2.oA at the SRS Daresbury, 
labo.ratory. 
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3.5 Data Collection 
In order to perform data collection at cryogenic temperatures, crystals of the 
PfENRlNAD+/tric1osan complex were transferred to a solution identical to the well 
solution but containing 20% glycerol as a cryo protectant. These crystals were then 
flash frozen in a stream of nitrogen gas at lOOK using an Oxford Cryosystems 
Cryostream device. An initial dataset to 2.8A was collected by rotating the crystal by 
1 ° increments over a range of 190° and exposing for 15 minutes per image on a Mar 
Research Mar345 image plate mounted on a Rigaku RU200 X-ray generator. 
Analysis of the data were carried out using the DENZO suite of programs 
(Otwinowski & Minor, 1997) and the CCP4 suite of programs (CCP4, 1994). A 
second data set was collected on a similar crystal on a Quantum Q4 CCD detector o~ 
station 14.1 at the SRS Daresbury laboratory. The crystal was exposed for 15 seconds 
and rotated by 1 ° increments per image over a range of 190° to collect data to 2.oA 
resolution (Figure 3.Sb). Analysis of the processed 2.oA data set showed the Rmerge 
values at 2.18A and 2.1A were 0.395 and 0.5, respectively. Therefore the data were 
truncated to 2.18A. The statistics for the data collection can be seen in Table 3.1 
3.5.1 Space group determination 
Preliminary analysis of the data indicated that the crystal belonged to the monoclinic 
spacegroup P2 or P2J, with unit cell dimensions a= 88.2A, b= 82.4A, c= 94.8A, and a. 
= y = 90° B = 90.8°. Analysis of the X-ray diffraction pattern 'showed that reflections 
were observed along the OkO axis (b*) only where they satisfied the condition k = 2n, 
(Figure 3.6) indicating that the crystals belonged to the space group P21. 
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Figure 3.5. (a) Crystals of the PfENRlNAD+/triclosan complex grown in 19.5 % 
(w/v) PEG 3350 and 230 mM KI, with approximate dimensions of 0.15 x 0.10 x 0.10 
mm3. (b) A 10 oscillation frame of a PfENRlNAD+ Itriclosan complex crystal 
collected on a Quantum Q4 CCD detector at station 14.1 at the SRS Daresbury 
laboratory. The resolution at the edge ofthe diffraction plate is 2.oA. 
Space group P2. 
Wavelength (A) 0.9600 
Resolution (A) 20.0 - 2.18 (2.26 -2.18) 
Unique reflections 77321 (7521) 
Multiplicity 3.1 (3.0) 
Completeness (%) 97.2 (94.7) 
I/cr(l) > 3 (%) 72.6 (49.6) 
Rmerge (%) 0.095 (0.395) 
Table 3.1 Data collection statistics for the PfENRlNAD+/triclosan complex. 
Values in parentheses are for the highest resolution shell. 
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Figure 3.6 (a) The hkO zone for the PfENR data to 2.2A. (b) A zoomed in view along the OkO axis 
showing reflections are only present where k = 2n indicating that the crystals belong to the space 
group P21• 
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3.5.2 Vm Calculation 
Analysis of possible values ofVm for the PfENR crystal using a subunit Mr of 40400 
Da gives a value for a tetramer in the asymmetric unit of 2.1A3 Da-l and corresponds 
to a solvent content of 42%. This value is within the range ofVm values observed for 
protein crystals (Matthews, 1977). 
3.6 Molecular replacement 
3.6.1 The search model 
Analysis of the ENR sequence alignment showed PfENR had greatest similarity to 
B.napus ENR (Rafferty et al., 1995; PDB entry 1ENO), with approximately 44% 
sequence identity and therefore this structure was selected as a search model for 
molecular replacement (Figure 3.1). Differences between the two sequences 
suggested that the structures might differ around the two large loop regions between 
a2-~3 and ~3-a3 and in the loop region at 238-245, which had been shown to adopt 
several different positions upon inhibitor binding in EcENR (Roujeinikovab et a!., 
1999). These regions were deleted from the B.napus search model along with the 
coordinates of the NAD+ cofactor and triclosan inhibitor. 
3.6.2 Cross rotation function 
In order to obtain a molecular replacement solution the program Amore (Navaza, 
1994) was used. A cross rotation function was calculated using a radius of integration 
of 28A on data from 8.00 to 3.5A resolution. Four clear solutions were obtained, 
representing the four different ways of orientating the search tetramer. The highest 
scoring solution was at a = 102.6, ~ = 52.4 and y = 269.2, which had an Rfactor of 50, 
% ~d correlation coefficient (cc) of32.0. 
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3.6.3 Translation function 
The translation function was calculated using the program Amore (Navaza, 1994), 
producing a clear solution in the space group P21 with an Rfactor of 4S.1 % and cc of 
approximately 40.0 at x = 0.244 and z = 0.232. No translation was calculated for the 
y axis because in monoclinic space groups this is a "floating axis" and as such can be 
any value. The same procedure was tried for the space group P2, however no clear 
solution could be obtained, confirming the correct space group as P21. 
3.7 Phase improvement, Model building and refinement 
The correct molecular replacement model output by the program Amore was subject 
to various stages of refinement and model building to improve the PffiNR model. 
3.7.1 Rigid body refinement 
The model from molecular replacement was subjected to 10 rounds of rigid body 
refinement within the program REFMACS (Murshudov et al., 1997) using data in the 
resolution range 20A to sA with each of the four subunits within the tetramer being 
treated as an individual rigid body. There was only a small drop in the Rfactor from 
0.44 to 0.42 and a drop from 0.46 to 0.43 in the Rfree. 
3.7.2 Restrained least squares refinement 
The model from the rigid body refinement was then submitted to restrained positional 
refinement using REFMACS (Murshudov et al., 1997). Five cycles of refinement 
were carried out on data in the resolution range of 20A to 2.2A and sigma A maps 
were prepared. This reduced the Rfactor from 0.4 to 0.29 whilst the Rfree changed from 
0.42 to 0.4. Analysis of the initial electron density maps showed clear density for the 
S7 
NAD+ cofactor and triclosan. Given that both of these had been omitted from the 
model this provided confidence in the molecular replacement solution (Figure 3.7). 
3.7.3 Model building 
The graphics program TURBO-FRODO (Roussel et al., 1990) was used to change the 
residues of the BnENR search model to the corresponding residues in PfENR and to 
include the NAD+ and triclosan. The two extended loops which were omitted from 
the initial model could also be seen and were fitted accordingly. Initially only subunit 
A was constructed and this was rotated and superimposed onto the other three 
subunits. The model was refined and rebuilt in an iterative process to an Rfactor and 
Rfree value of 0.23 and 0.27, respectively. Analysis of the ENR family shows tha~ 
PfENR contains a large polar insert from Asn241 to Tyr282, positioned next to the a7 
helix which could not be found in the electron density maps. In order to try to locate 
and define the polar insert the map was flooded with water atoms using the 
ARP/WARP function in REFMAC5. However the procedure did not result in clear 
density for residues in the loop. The inability to locate the loop would suggest that it 
does not form any ordered structure within this crystal form of PfENR complexed 
with NAD+ and triclosan. 
3.7.4 Addition of solvent 
The 2.18A resolution data was high enough to be able to accurately assign several 
water molecules into the PfENR model using the program ARP/wARP version 5 
(Perrakis et al., 1997) in the final stages of refinement. Waters were assigned to 
peaks within the 1Fobs - 1Fcalc difference map with a sigma cut-off of >2.0 if they lay 
wit~in 2.2A to 3.3A of a protein 0 or N atom. Once solvent addition was completed 
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Triclosan 
Figure 3.7 The electron density contoured at O. 8a in the initial 2F obs -F calc maps 
which indicated the presence of triclosan and the NAD+ cofactor bound to 
PfENR. The density for subunit A is shown. The NAD+ and triclosan molecules 
are coloured with yellow for carbon, blue for nitrogen, red for oxygen, green for 
chlorine and orange for phosphorous. The triclosan and NAD+ molecules have 
been added as a guide to the electron density. The figure was produced in 
TURBO-FRODO (Roussel et al., 1990). 
each individual water molecule was visually inspected to check that it was in good 
electron density and that it was within hydrogen bond distance of surrounding atoms. 
The B-factors of all water molecules was also checked and any water which had a B-
factor over 60 A2 was removed. A total of 518 water molecules were added, resulting 
in a reduction of the Rfactor and Rfree to 0.2 and 0.25, respectively . 
.. 59 
CHAPTER 4 
Analysis of the Plasmodium Falciparum enoyl reductase structure 
4.1 Introduction 
The following chapter describes the final model of Plasmodium Jalciparum enoyl 
ACP reductase and the mode of binding tric10san and NAD+ 
4.2 Model stereochemistry 
The final model of the PtENRlNAD+/triclosan complex comprises 112 residues in a 
a-helical conformation (~40%) and 45 residues formed p-sheets (~16%) with a total 
of 483 hydrogen bonds being made as defined by the program Promotif (Hutchinson 
& Thornton). The final model contained the following residues defined by good 
density: ASp15 to Asn241, Ty~83 to Arg345 in both the A and B subunits, Asn13C to 
Asn241C and T~83c to Asn346C in subunit C and ASp15D to Ile240D and T~83D to 
Tyr344D in subunit D together with one molecule of NAD+ and triclosan per subunit 
and 518 water molecules. In all 7 residues had to be truncated back to Cp due to 
The final model has an Rfactor of 0.2 (Rfree of 0.25) for all data within the resolution 
range 20.0 to 2.18A (Table 4.1). Analysis ofthe PtENR model geometry was carried 
out using the program PROCHECK (Laskowski et al., 1993) and showed a tight 
geometry with most parameters being inside or better than the range expected for a 
model at this resolution (Figure 4.1 (a), (b), (c) and (d». The bond length and angle 
r.m.s.d from ideal geometry as defined by REFMAC5 (Murshudov et aI., 1997) are 
0.02A and 1.8°, respectively. Examination of the X1-X2 plots for all residue types 
showed the side-chains to be in favourable conformations in all four monomers 
(Figure 4.2 (a), (b), (c) and (d». A Ramachandran plot was calculated for PtENR 
and showed approximately 90% of residues to be in the most favoured regions and 
. 
10% in additionally allowed regions, with no residues in the generously or disallowed 
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Refinement statistics and model quality 
Total non-H atoms 
Water sites 
Average B-value (A2) 
Resolution limits (A) 
. Number of reflections 
R-value 
Rfree Value 
r.m.s. bond deviation (A) 
r.m.s. angle deviation (deg.) 
9911 
518 
30 
20-2.18 
65771 
0.2 
0.25 
0.02 
1.8 
Table 4.1. A table to show the refinement statistics for the refined PtENR complexed 
with NAD+ and tric10san to 2.2A resolution. 
Subunit A. 
3, 
~ 
~ 
~ 
oil g 
! 
ii 
'15 
~ 
~ 
~ 
~ 
~ 
Ii 
Sterochi!:roicll ~llJDdft 
•. ~u,g .Hid_in A,D,L 
b.Omrsungutck\· . 
c . Dx! aJn'X'1l 1 100 IHid_ 
d . :.ttl lnge • .;e, 
c. H-bctldcrrl'SY .. ~. 
f . OIn~1 (...(Ktol 
Main chain 
~ 
il 
~ 
a 
• 
LOr' --''-'--'''------, 
0.5 
0.0 
~ -0.5 
~ - 1.0 
-1.5 
-2.0 
1.0 I.S 2.0 2.S 3.0 3:5 
Rttoturioo IAng.Ulooul 
Plof imrisncs 
Complolilon \'111)($ No. o f 
'10." P.lUmctcl TyplC,l DJ.nd tDnd v. i(tttw c:b.Up. " ll~ '. lC .. icttn fl'Oml'Otln 
"" 
... IU 10.0 0 .7 l naidt 
:I' 0.4 0.0 ,  0.1 ,""" , ~, 0.' 10.0 ... ,""'" 
:::1:: 1 .. 7 l . ' ,. ... ,""'" , .. ~7 0 .• 0 = .. .  InrlidC' 
"'" 
~O ... , 0' 1.4 DETTER 
~ 
t 
.~ 
~ 
~ 
-e 
~ 
t 
t 
.~ 
" ~ 
il 
~ 
.;; 
StclC'OChelDicJIJY1~ft 
.. Cbi-I SJUChcmintsltdC'\' 
b, C Ii -1 tuIW II ck\' 
c . Chi-I S:uche ph&lIde,-
d .C Ii-1 pookd .. de, 
c , C'hj..:hJ.N.I de\-
Side chain 
~ 
t 
.~ 
~ 
~ 
-e j 
.;; 
so 
i~ 
.~ » 
" ~ 10 
il 
a '0 
b. Chi·1 uan 
I R~iOlution IAng.uiooH' 
cl Ch j· 1 poo4td Ulind:u'CI dt\iation 
1.5 2.0 .2.5 3.0 3.5 ~ .O 
RtlOIUl ioo IAngsrroclU l 
Plorsmrisrics 
Compm.on n lues No.of 
,10." P<trJ.mde1 T~'1o:11 Olnd b.:Ind ", idrtw 
-,- u lue ''''111: ". d1h &ommcln 
" 
II ': 10 .' .~ -1.1 DETTER 
" 
11.1,} 3D 
" 
-u. DETTER 
"' 
IJ. 11,0 4 .• -I.:: DETTER 
:~I 1:.5 to .} u -1.5 DETTER 
" 
10,0 :1. .. ,. ... > In.ide 
Figure 4.1. (a) Main chain and side chain parameters for subunit A, produced 
using the program PROCHECK (Laskowski et aI. , 1993). 
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Figure 4.2. (a) The Xl vs. X2 plots for subunit A. Favourable conformations are 
represented in the shaded areas. The figure was produced using the program 
PROCHECK (Laskowski et al., 1993). 
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Figure 4.1. (b) Main chain and side chain parameters for subunit B, produced 
using the program PROCHECK (Laskowski et al. , 1993). 
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Figure 4.2. (b) The X 1 vs. X 2 plots for subunit B. Favourable conformations are 
represented in the shaded areas. The figure was produced using the program 
PROCHECK (Laskowski et al., 1993). 
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Figure 4.1. (c) Main chain and side chain parameters for subunit C, produced 
using the program PROCHECK (Laskowski et aI. , 1993). 
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Figure 4.2. (c) The Xl vs. X2 plots for subunit C. Favourable conformations are 
represented in the shaded areas. The figure was produced using the program 
PROCHECK (Laskowski et al., 1993). 
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Figure 4.1. (d) Main chain and side chain parameters for subunit D, 
produced using the program PROCHECK (Laskowski et aI. , 1993). 
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Figure 4.2. (d) The Xl vs. X2 plots for subunit D. Favourable conformations are 
represented in the shaded areas. The figure was produced using the program 
PROCHECK (Laskowski et af. , 1993). 
regions (Figure 4.3). A representative part of the final electron density map and final 
model are presented in Figure 4.4. 
4.3 Overall fold 
Each monomer within the PfENR tetramer consists of a seven stranded parallel ~­
sheet (~1-~7), flanked by nine a-helices (al-a9), six 310 helices plus a number of 
loops (Figure 4.5 and 4.6) as defined by the program PROMOTIF (Hutchinson and 
Thornton, 1996). The secondary structure elements form a parallel ~-sheet flanked on 
one side by the helices of a4, as and a6 and by aI, a2, a7, a8 and a9 on the other, 
with a3 lying on top of the ~-sheet reminiscent to the Rossmann fold common to 
several NAD+ binding enzymes «Figure 4.7)(Rossmann et al., 1974)). The NAD+· 
cofactor binds at the C-terminal end of the ~-sheet and makes important interactions 
with a4, as and the ~lIal loop. Helices as, a6 and a8 form the inhibitor binding 
pocket with a7 forming a lid over the inhibitor with extensive van der Waals 
interactions. 
4.4 Comparison of the PfENR subunits 
In order to analyse differences between the individual monomers of the tetramer the 
program Lsqkab (Kabsch, 1976) was used to superimpose each subunit onto the other 
three subunits and calculate an r.m.s.d of the Ca atoms. The resulting values show 
little difference between the subunits with an average r.m;s.d of 0.34A, (Table 4.2, 
Figure 4.8). Analysis of the superimposed subunits showed three areas in which 
more significant differences were observed. Interestingly each of these areas 
corresponds to regions of the sequence, which represent insertions when compared to . 
the bacterial ENR enzyme (Asp71 - Mee6, Thr90 - Asn109 and Thr281 - Glu288). Re-
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Figure 4.3. Ramachandran plots for subunits A, B, C and D of PtENR. The shading 
of the Ramachandran plot is with red, dark yellow, yellow and white representing the 
decreasingly favoured regions respectively. Produced using PROCHECK 
(Laskowski et aI., 1993). 
Figure 4.4. A representative portion of the 2Fobs-Fcalc electron density map calculated 
using the refmed PfENR model. The model is coloured with yellow for carbon, blue 
for nitrogen and red for oxygen, the water molecules are represented as red spheres. 
The figure is centred on Arg235A which is present at the start of the a7 helix. The map 
is contoured at l.2a and the figure was produced using the graphics program 
TURBOIFRODO (Roussel et a/., 1990). 
Figure 4.5. (a) A stereo view of the PtENR monomer with both NAD+ cofactor 
and inhibitor bound. The PtENR monomer is coloured from blue to red with each 
secondary structure element being labelled, the region at which the large inserted 
sequence is present is indicated by a black star. (b) A stereo view of the PtENR 
tetramer. The figure was produced using the graphics program Pymol (Delano, 
2002). 
100 100 
Figure 4.6. A stereo image of the backbone representation of the A subunit of 
PfENR with every tenth residue numbered. Figure produced using MOLSCRIPT 
(Kraulis, 1991). 
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Figure 4.7. The sequence for PfENR with the secondary structural elements shown 
as blue cylinders and red arrows for a-helices and ~-strands respectively. Those 
residues not defmed by density within the PfENR crystal structure are coloured 
purple. The figure was produced using the program Alscript (Barton, G.J. 1993). 
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Figure 4.8. The superposition of subunit B, C and D onto the A subunit of 
PfENR, coloured green, blue, purple and yellow for subunits A, B, C, D 
respectively. Those areas where significant differences occur are labelled by a 
star and are numbered 1 (ASp7] - Met76), 2 (Thr9o - Asn109) and 3 (Thf28] -
Glu288). The figure was produced using the graphics program Pymol (Delano, 
2002). 
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Table 4.2. a, b. A set of tables to show the r.m.s.d in A of the subunits A, B, C and 
D superimposed onto each other. The columns across and below represent each 
subunit labelled A to D in red. (a) The r.m.s.d difference on each of the monomers 
with no residues removed. (b) The r.m.s.d deviation between the subunits after the 
removal of the three areas shown to differ significantly between the four subunits 
(ASp7] - Met76, Thr90 - Asn109 and Thf281 - Glu288). 
calculating the r.m.s.d of the Ca atoms with these regions omitted gave an average 
value of 0.25A and showed an approximate O.1A reduction in deviation per monomer 
revealing the close similarity in the conformation at the core of the molecule (Table 
4.2). 
4.5 Subunit interfaces and quaternary structure 
PfENR is formed by four monomers organized into a homo-tetramer containing four 
independent active sites, with each monomer and tetramer having the dimensions of 
approximately 50x50x60A and 90x90x50A, respectively. The solvent-accessible 
surface areas for the PfENR monomer and tetramer were calculated to be 
approximately 15,000A2 and 40,000A2, respectively, using the program ACCESS, 
(Roussel et al., 1990) with a probe radius of I.4A. On formation of the tetramer 
approximately 5000A2 of the solvent accessibility area is buried per monomer with 
each of the monomers within the tetramer making contact with all three of the other 
subunits. The PfENR tetramer has three different inter-subunit interfaces about three 
orthogonal twofold symmetry axis designated as P, Q and R (Figure 4.9). Contacts 
between subunits A-C and B-D are found around the P axis, between subunits A-B 
and C-D around the Q axis and between subunits A-D and B-C around the R axis. 
The program CONTACT (CCP4, 1994) together with a visual inspection was used to 
examine the subunit interfaces. 
4.5.1 The P axis 
The P-axis is the most extensive of the subunit interfaces with approximately 2400A 2 
of the solvent accessible area being buried on formation of the tetramer and is formed 
by 44, residues (Glu35, Arg39, Arg21O, Ala213 to His215, GI!17, Arg218, Asn22 \ Ile222, 
62 
Q-axis 
R-axis 
Figure 4.9. A stereo view of the PfENR tetramer viewed down each of the three 
molecular two fold axes. The subunits A, B, C and D are coloured yellow, blue, red 
and green, respectively and each of the three axes are labelled. The secondary 
structural elements which are important in producing major subunit contacts are 
labelled. The figure was created using the graphics program Pymol (Delano, 2002). 
Gly333, Asn335 to Met337, ASp341 and Tyr344). The main contacts are formed through 
the packing between 0.9 and ~7 to the equivalent residues in the P axis interface 
which run antiparallel to each other (Figure 4.9). In addition to this packing there are 
additional residues involved in forming the interface which are at the end of the 0.6 
helix (Arg210 to Arg223) and the loop regions: Tyr295 to Leu304, Glu319 to Gln326, 
ASp341, Tyr344 and Arg345. A hydrogen bond network is formed in the main by Arg218, 
which hydrogen bonds to Ala297, pro298, Asp341, and depending on the orientation of 
the Arg218 gaunidine moiety the main chain carbonyl group of either Lys295 or Tyr296. 
Furthermore in the case of the BD but not AC interface, Arg218 forms two hydrogen 
bonds to Arg300 (Figure 4.10a). Additional hydrogen bonds are formed between the· 
ASp307 side chain oxygen and the Arg321 side chain nitrogen atom. Also between the 
Ser310 and the side chain of GIU319, the carbonyl group of Ala322 and the main chain 
nitrogen of ASp331 and finally the side chain nitrogen of Gln326 to the Asn335 side chain 
oxygen. Hydrophobic packing is also present involving the 19 residues: Gly217, 
Ala232 pro298 Leu299 Gln301 Leu303 ASp307 Ser310 Vae ll Phe314 Ile323 Thr324 , , , , , , , , , , , 
Gly325, Ile328, Vae30, Asn332, Glr33 Ile336 and Met337. The phenylalanine ring from 
the strongly conserved Phe314 stacks on top of its symmetry equivalent residue 
forming 7t-7t stacking interactions and extensive van der Waals interactions (Figure 
4.11). 
4.5.2 The Q axis 
The interface down the Q axis is dominated by a four helix bundle composed of the 
0.5 and 0.6 helices and their respective symmetry equivalents. Looking down the axis 
of the. AB interface the first interaction is between the a5A helix and preceding loop 
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Figure 4.10. (a) The hydrogen bonding network created by the Arg218B residue to 
the ASp341, Tyr296, Ala297, pro298 and Arg300 of subunit D fonning part of the P-axis 
interface. (b) The hydrogen bonding network which fonns part of the Q axis 
interface in which Arg l48 from subunit C is hydrogen bonded to Asp89, Ala86, Ser156 . 
and Tyrl60 of subunit D. For both figure hydrogen bonds are represented by red 
dashed lines, all residues are coloured with yellow for carbon, red for oxygen and 
blue for nitrogen. Water atoms are represented by red spheres. Those residues 
involved in fonning the hydrogen bonding network are labelled. The figure was 
produced using the graphics program TURBOIFRODO (Roussel et at., 1990) 
Figure 4.11. A graphical representation of the packing interface between the 
PfENR subunits Band D, coloured green and blue respectively. The Phe314 residue 
is shown with yellow for carbon and red for oxygen. The figure was produced 
using the graphics program Pymol (Delano, 2002). 
regIOn composed of the residues ASpl42 to Lysl67 packing against the aSB and 
preceding loop. Behind this the residues Serl87 to Leu216 which in part form the a6A 
helix pack against the symmetry equivalent residues including the a6B helix, with 
additional interactions being produced by Ile ll2, Tyr220 and the loop region Ala86 to 
ASp89. The formation of the interface allows for extensive hydrophobic interactions, 
supplemented by a hydrogen bonding network. The hydrophobic packing interactions 
are formed in the main by the 14 residues (LeuI43, Leu144, Tyr151, Leu152, LeulSS, 
Tyr160, Ile163, Va1190, Pro192, Ala203, Ala204, Val211 , Leu212 and His215). The hydrogen 
bond network along the Q axis is formed by the residues TyrlSl , Tyr160, Ser187, Asn188, 
ASp208, Arg210 and Asn218. Furthermore the Argl48 residue forms up to 7 hydrogen 
bonds to the neighbouring Ser156, Ala86, ASp89 and Tyrl60 with some residues forming· 
more than one hydrogen bond to Arg148 (Figure 4.10b). On formation of the interface 
approximately 1700A 2 of the solvent accessible area is buried per monomer. 
4.5.3 The R axis 
The smallest of the interfaces is between the A, D and B, C subunits (Figure 4.9) with 
approximately 900A2 of the solvent accessible area being buried per monomer on 
production of the tetramer. A total of 22 residues are involved in the formation of the 
R axis interface: ASp142, Tyrl84, His186, Glnl88 to Gly193, Tyr288, Tyr292 and His334 to 
Tyr344. The hydrophobic interactions are formed by a total of 10 residues Va1190, 
Va1191, Pro192, Gly193, Leu334, Phe338, Leu339, Pr0340, Ile343 and Tyr344. A total of five 
hydrogen bonds are formed between Asn335 and Lys189, Phe340 and Tyr288 and Val190 
to both Ile336 and Phe338. 
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4.6 Cofactor and inhibitor binding sites 
4.6.1 Triclosan binding site 
The electron density for the triclosan inhibitor within the PfENRlNAD+ Itriclosan 
complex was of very good quality and allowed for its unambiguous placement into the 
active site in all four subunits (Figure 4.12a). The triclosan binds in a non-covalent 
manner to the active site, forming one hydrogen bond to Tyr184 and extensive van der 
Waals interactions. The 4-chloro phenoxy ring oftriclosan (ring A) interacts in a face 
to face manner with the NAD+ nicotinamide unit allowing 7t-7t stacking interactions 
and the formation of van der Waals interactions with the side chains of Tyr184, Tyr194, 
pro231 , Phe285, Ala237, Ile240 and Ile286. The 2,4-dichlorophenoxy ring oftriclosan (ring 
B) is located within a pocket bounded by the peptide backbone of residues Leu133 to . 
Ala136, the pyrophosphate and nicotinamide moieties ofNAD+ and by the side chains 
of Ala236, Met198 and Val139 (Figure 4.12b). It has been shown using the E.coli ENR 
that triclosan binding is reversible and that neither the NAD+ or triclosan are modified 
. during inhibition, consistent with the non-covalent binding seen within the active site 
(Ward et al., 1999). 
4.6.2 NAD+ binding site 
In all four subunits of the PfENR model the nicotinamide adenine dinucleotide 
(NAD+) cofactor can be clearly seen within the electron density permitting its 
unambiguous identification (Figure 4.13a). The adenine ring binds within a pocket 
formed by the main chain atoms of residues: Ala20 to Gly22, Ser132 to Asn135, Phe84 to 
Ser87 and Ala229 to Ala234 and the side chains of residues: Trp48, Leu133 and Asn135• 
The adenine unit interacts with the Trp48 side chain in a face to face manner allowing 
7t-7t stacking interactions, with Leu133 making van der W~ls interactions with the 
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Figure 4.12. (a) Triclosan bound within the PfENR active site and its corresponding 
2Fobs-Fcalc electron density map contoured at 1.00". The NAD+ cofactor can also be 
seen packing in a face to face manner with the triclosan inhibitor. The model is 
coloured with yellow for carbon, blue for nitrogen, red for oxygen and green for 
chlorine. This figure is based on subunit C of PfENR. The figure was produced 
using the program TURBO-FRODO (Roussel et ai., 1990). 
Figure 4.12. (b) A stereo diagram of the triclosan binding site of subunit C of 
PfENR with the active site residues Tyr191, TyrZ°l, Lys209 and Met205 labelled. The 
figure is coloured with yellow for carbon, red for oxygen, orange for phosphorous, 
blue for nitrogen and green for the chlorine atoms of triclosan and the sulphur 
atom of the active site Mee05. The figure was produced using the program 
TURBO-FRODO (Roussel et ai., 1990). 
Figure 4.13. (a) The NAD+ cofactor bound within the PtENR active site and its 
corresponding 2Fobs-Fcalc electron density map contoured at LOa. The model is ' 
coloured with yellow for carbon, blue for nitrogen, red for oxygen and orange for 
phosphorous. The figure was produced using the program TURBO-FRODO 
(Roussel et al., 1990). 
Figure 4.13. (b) A stereo diagram of the residues responsible for forming a 
hydrogen bonding network to the NAD+ cofactor. All the residues are labelled 
and coloured with yellow for carbon, blue for nitrogen, red for oxygen and orange 
for phosphorous. The Arg242 residue is only present in a hydrogen bonding 
position in the D subunit and does not form hydrogen bonds in any of the other 
subunits. The figure was produced using the program TURBO-FRODO (Roussel 
et al., 1990). 
opposite face of the adenine unit. A large hydrogen bond network allows for the 
binding and positioning of the NAD+ substrate into the active site (Figure 4.13 b). In 
all subunits the adenine ring is hydrogen bonded by both the carbonyl of ASp85 and 
the Asn 135 hydroxyl groups. The adenine ribose unit forms a hydrogen bond from its 
hydroxyl group to the main chain nitrogen of Gll3 and in subunit D only an 
additional hydrogen bond is made by the terminal nitrogen of Arg235D to the same 
hydroxyl group of the ribose unit (Figure 4.13b). This is due to the movement of the 
Arg235D side chain around the C8 and NE atoms, which permits its closer contact with 
the NAD+ cofactor and is not present in any other subunit of the tetramer. The density 
is well defined in all subunits for Arg235 with no significant change in B-factor 
between the two conformations. The pyrophosphate group is involved in hydrogen 
bonding to the main chain nitrogen of Ala236, the Ser234 hydroxyl side chain and the 
Tyr28 main chain nitrogen. The nicotinamide ribose moiety forms hydrogen bonds 
from both of its hydroxyl oxygen atoms to the NE atom of the Lys202 side chain. The 
nicotinamide unit forms two hydrogen bonds from its terminal nitrogen atom to the 
main chain carbonyl unit of Leu232 and the Ser234 side chain hydroxyl group. It also 
forms one hydrogen bond from its terminal hydroxyl group to the main chain nitrogen 
of Leu232• 
Surolia and Surolia initially reported that PfENR can utilise NADPH as a cofactor, 
but at a lower level than NADH during enzyme catalysis (Surolia et al., 2001). In 
order to investigate this modelling of NADPH into the NADH active site was carried 
out (Figure 4.14 a). Interestingly a sequence change of alanine to glycine found 
within the PfENR sequence but not in the equivalent position of the plant or bacterial 
ENR enzymes produces an increase in pocket size around the position of the extra 
phosphate (Figure 4.14 b). In addition those residues which form the lid of the 
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(a) 
(b) 
E.coli X23 Y Q N 0 
H.pylori X23 Y L N E 
B.subtilus X23 Y A G E 
S.aureus X23 Y L P 0 
B.napus X23 T W V P 
P.falciparum X23 W P P 
23 47 51 
Figure 4.14. (a) A stereo diagram of the modelling of NADPH into the PfENR 
active site. The extra phosphate group can be seen to protrude into a cavity formed 
in the main by the side chains of Val 51 and Ile47. The side chain of Arg235 has been 
moved within allowable X l-X2 values to maximise the hydrogen bonding potential 
of this residue but this does not represent its position within the PfENR structure. 
The diagram is coloured with yellow for carbon, blue for nitrogen, red for oxygen 
and orange for phosphorous. The hydrogen bonds are represented by dashed red 
lines. The diagram was produced using the graphics program TURBOIFRODO 
(Roussel et al., 1990). 
(b) A table to show the equivalent residues found within the E.coli, Hpylori, 
B.subtilis, s'aureus and B.napus ENR enzymes at the site of the extra phosphate 
compared to PfENR. The residues are numbered with respect to the P Jalciparum 
sequence and are also shown in Figure 4.11a. The amino acids are given in one 
letter code and X 23 represents a 23 amino acid gap. 
binding pocket of the extra phosphate within the PfENR structure are relatively small 
when compared to the equivalent residues within the bacterial ENR enzymes 
resulting in an increase in space around the extra phosphate group (Figure 4.14 b). 
Furthermore the terminal nitrogen groups of the conserved Arg235, within the 
apicomplexan family, which has been shown to occupy two different conformations, 
would be able to stabilise some of the negative charge of the extra phosphate (Figure 
4.14 a). However the increase in space about the position of the extra phosphate in 
comparison to other ENR enzymes it is not sufficient to allow for the utilisation of 
NADPH for catalysis due to close contacts with the residues Gly3, Val5l and Trp48 
which are approximately 2.4A, 2.sA and 3.oA away from the extra phosphate group. 
This is consistent with more recent studies which found no activity was present for 
PfENR in the presence ofNADPH (Perrozo et al., 2002). 
4.7 Substrate modelling and enzyme mechanism 
Substrate binding to PfENR was investigated by modelling, based on both the 
MtENRINADH/C16 fatty acid substrate complex and the previously published 
modelling studies based on butyryl-CoA (Roujeinikovaa et al., 1999). In order to 
model the butyryl-CoA into the PfENR active site the coordinates were taken from the 
X-ray crystallographic structure of acyl-CoA dehydrogenase (Djordjevic et al., 1995; 
PDB entry IBUC). The double bond between the C2 and C3 position of butyryl-Co A 
was superimposed upon the CS and C6 positions in the phenolic ring oftriclosan, with 
the triclosan mimicking the enolate anion intermediate (Roujeinikovaa et al., 1999). 
The growing fatty acid chain is positioned in the base of the active site formed by pS 
and p6 and the helices a6 and a8, the substrate exits the binding pocket and protrudes 
into the solvent (Figure 4.15 a and b). The binding pocket is formed by the residues: 
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Trp48 , Glu97, Alal3\ Asn135, Ala136, Lys137, Val 139, Lys149, Tyrl8\ Tyr194, Met198, 
Lys202, pro23 I , Ala236, Ala237, Ala239, Ile240, Phe285, Ile286 with hydrogen bonds being 
made to the fatty acid substrate by Asn135, Glu97 and Lys137. The residues producing 
this binding pocket are predominantly hydrophobic and are strongly conserved 
between the Pfalciparum and B. napus ENR sequences with full sequence 
conservation of all but Ala136 and Lysl37. However a lower level of sequence 
conservation is observed for those residues which make up the binding pocket within 
the bacterial sequences of E.eoli, Hpylori, B.subtilis and Mtubereulosis with 
approximately 30% sequence identity although they are predominantly hydrophobic. 
Substrate modelling into the active site of PtENR showed the proposed distance 
between the C4 position of the nicotinamide ring and the C3 position of the modelled 
substrate, between which hydride transfer occurs, to be approximately 3.4A. The 
phenolic oxygen atom of the catalytic Tyrl94 is approximately 2.4A away from the 
enolate anion, consistent with the tyrosine residue being the proton donor to the 
enolate anion. The catalytic Lys202 residue is positioned within 4.sA of the substrate 
and may allow its positive charge to playa role in stabilising the intermediate of the 
reaction (Figure 4.16). This is consistent with the proposed catalytic mechanism of 
the ENR enzyme (Section 1.2.3). 
Modelling of the C 16 fatty acid substrate in a "U" shaped conformation as 
described for the MtENR enzyme ((Figure 4.15)(Rozwarski et al., 1999)) 
demonstrated that without increasing the size of the binding pocket there is not 
sufficient room for the substrate to bind in the PtENRlNAD+/triclosan complex 
(Figure 4.15c). However of those residues which form close contacts with the 
substrate, in particular Tyr184, Alal86 and Phe285, both the Ala and Phe residues are 
situated in an area predicted to be flexible within the ENR structure (Roujeinikovab et 
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Figure 4.16. Modelling of the butyryl-CoA substrate into the active site ofPfENR 
showing the proximity of the critical catalytic residues. The distances from the 
substrate to the active site residues are in A and shown by a black dashed line. The 
C2 and C3 positions of the substrate are superimposed upon the C5 and C6 atoms 
of the triclosan phenolic ring. The triclosan inhibitor is shown in blue, the fatty 
acid substrate is coloured white for carbon, blue for nitrogen and red for oxygen. 
The PfENR enzyme is coloured with yellow for carbon, blue for nitrogen, red for 
oxygen, green for sulphur and purple for phosphorous. The figure was produced 
using the graphics program Pymol (Delano, 2002). 
al., 1999). Those residues involved in forming the binding pocket (Ala13\ Asn135, 
Val 139, Tyr184, Ala186, Va1191, Pro 192, Gly 193 , Tyr194, Met198, Lys202, Ala236, Ala237, 
Ile240 and Phe285) are predominantly hydrophobic and all but Val191 are completely 
conserved in BnENR. A striking feature of MtENR which may aid in the binding of 
larger fatty acid substrates is the presence of a ten residue insert not found within any 
other bacterial or plant ENR enzyme which extends the substrate binding pocket 
(Figure 4.17). However, although PfENR also contains a significantly larger insert at 
this position it does not share a similar fold for the substrate binding pocket. 
4.8 Important active site features 
It had been previously reported for the SDR family of enzymes, whose catalyt~c 
mechanism is thought to be similar to the ENR family that two water molecules are 
present within the active site, where their proposed role is to form part of a proton 
relay mechanism to the bulk solvent (Benach e/ al., 1998 & Filling e/ al., 2002). This 
proton relay system may act as a proton bridge linking the catalytic Lys residue to the 
bulk solvent, creating a temporary proton reservoir during catalysis. In order to 
investigate a possible role for water molecules within the ENR family, the positions of 
any active site waters were investigated. Within the PfENR active site two water 
molecules are present which are clearly defined by density at an equivalent positions 
to the SDR enzymes. The position of these water molecules is such that the terminal 
hydroxyl atoms at the Ns group of Lys202 make a hydrogen bond to the first of the 
water molecules, W29 as well as to both of the oxygen atoms of the nicotinamide 
ribose group and the main chain carbonyl of Leu182, forming a hydrogen bond 
network (Figure 4.18). The second of the water molecules is positioned 3.5A away 
fro~ W29 and forms a hydrogen bond to the main chain nit~ogen of Leu 182. These two 
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Figure 4.17. The structures of the PfENRlNAD+/triclosan complex in blue 
and MtENRlNADHlC-16 fatty acid substrate complex in green. The fatty 
acid can be seen in a "U" shaped conformation within the binding pocket 
with the NAD+ cofactor underneath, both are coloured with yellow for 
carbon, red for oxygen, blue for nitrogen and purple for phosphorous. The 
substrate binding helix which lies on top of the helix can be seen to adopt 
different positions for the two enzymes. The figure was produced in Pymol 
(Delano, 2002). 
Figure 4.18. The binding o.f two. water mo.lecules near to. the PfENR active site. 
The catalytic Lys and Tyr are labelled. The diagram is co.lo.ured with yello.w fo.r 
carbo.n, blue fo.r nitro.gen, red fo.r o.xygen, green fo.r chlorine and purple for 
pho.spho.rous. The two. water mo.lecules are represented as black spheres with red 
dashed lines representing the hydro.gen bo.nd netwo.rk fo.rmed. The figure was 
created using the graphics program Pymo.l (Delano., 2002). 
Figure 4.19. The PfENR active site with bo.und triclo.san and NAD+. The 
superimpo.sed water mo.lecules are co.lo.ured green, magenta and red representing 
the E.coli, B.napus and P jalciparum co.mplexed with NAD+ and triclo.san 
respectively. The yello.w do.ts represent the active site waters o.f Mtuberculosis 
ENR co.mplexed with NADH and the blue represents the Mtuberculosis ENR 
co.mplexed with fatty acid substrate and NAD+. The figure was created using the 
graphics program Pymo.l (Delano., 2002). 
waters reside in a pocket fonned by the residues: His131, Leui33, Ala134, Ser158, Ser159, 
Ser181, Leu182, Lys202 and Leu205. The hydrophilic nature of this pocket fonned in part 
by the presence of several serine residues would allow for the positioning of the two 
water molecules and produce a net negative charge which may help to stabilise the 
positive charge of the Lys202. Analysis of the sequence conservation of the 9 residues 
involved in fonning this pocket showed all residues were fully conserved within the 
T.gondii and Plasmodium ENR family. Examination of the E.coli, Hpylori, 
B.subtilis, Mtuberculosis and B.napus showed the full conservation of four residues 
(His 131 , Ser158, Lys202 and Leu205). 
The superposition of the high resolution structures of ENR from B.napus, 
M tuberculosis and E. coli shows that the position of these two water molecules .is 
conserved (Figure 4.19). Interestingly it has been reported that a conserved Asn 
residue, present within the SDR reductase family is critical for enzyme catalysis with 
the replacement by an Ala residue in C. Testosteroni 3 ~/17~ Hydroxysteroid 
dehydrogenase leading to loss of activity (Filling et al., 2001). In C.Testosteroni 
3 ~/17~ Hydroxysteroid dehydrogenase this residue is responsible for fonning a 
hydrogen bond network within the active site in particular to one of the active site 
waters. This residue is not however conserved within the ENR family or present 
within the PfENR. 
4.9 Comparisons to the previously solved PfENR 
During the structure solution of PfENR as reported within this chapter another group 
also solved and published the structure for PfENR in complex with NAD+ and both 
triclosan and two triclosan analogues (Perozzo et al., 2002). The superimposition of 
their structure with that described here showed that they are very similar especially in 
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the mode of tric10san and NAD+ binding. Significant differences between the two 
structures occur at the final three residues of the N terminal region and between 
residues ASp93 to Leul07 (Figure 4.20). The large polar 42 amino acid insert could not 
be assigned in either crystal structure and would suggest that this loop does not adopt 
an ordered fold within either crystal structure. 
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Figure 4.20. A stereo diagram of the superposition of PfENR as reported in 
this chapter and as solved by Perozzo et at., 2002, coloured green and blue, 
respectively. The figure was produced using Pymol (Delano, 2002). 
CHAPTER 5 
Initial attempts to solve the structure of Toxoplasma gondii Enoyl 
ACP reductase 
5.1 Introduction 
This chapter outlines the initial attempts to clone, overexpress, purify, crystallise and 
solve the structure of Toxoplasma gondii enoyl acyl carrier protein reductase 
(TgENR). 
5.2 Location and sequence analysis of the TgENR gene 
In order to identify and characterise TgENR, a cDNA library was screened using ENR 
DNA sequences from P Jalciparum by the collaborating group of Prof Rima McLeod 
(Samuel et al., 2003). Analysis of the sequence showed it to be similar to B.napus 
and P Jalciparum ENR to which it showed approximately 57 and 42% sequence 
identity, respectively (Figure 5.1). In addition a 27 amino acid signal sequence was 
identified using SIGNALP V1.1 as well as a 66 residue chloroplast transit peptide 
sequence using CHLOROP 1.1. Analysis of a structure based sequence alignment 
showed not only strong sequence identity around the active site region, but also the 
presence of a smaller six residue insert at an equivalent position to the 42 amino acid 
seen between the B. napus and PJalciparum enzymes. 
5.3 Overexpression and purification of TgENR 
A construct of TgENR containing residues 103-417 (lacking the putative signal and 
transit peptides) was over expressed and purified in the same manner as that reported 
for PfENR by the collaborating group of Prof Sean Prigge (Section 3.4, Muench et al., 
2003). The TgENR sequence was renumbered such that the first residue after the 6 
His tag which was part of the mature TgENR sequence became residue 1 (Serl) 
(Figure 5.1). 
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Figure 5.1. A multiple structure-based alignment of the ENR enzyme from E. coli, 
Hpylori, B.subtilis, Tgondii, P Jalciparum and B,napus. The secondary structural 
elements shown as red arrows and blue cylinders for , the f3-strands and a-helices, 
respectively and sequence numbers for the E.coli and B.napus ENR are given on top 
and below the alignment, respectively. Those residues completely conserved are in 
reverse type and those involved in triclosan binding have a black circle above. 
Residues conserved between the B.napus, Tgondii and P Jalciparum ENR enzyme are 
in red. The start of the mature TgENR sequence used for crystallographic studies is 
indicated by a green arrow. The sequences were aligned using ClustalW (Higgins & 
Thompson 1994) and the figure was produced using the program Alscript (Barton, 
G.J. 1993). 
5.4 TgENR crystallisation 
Initial crystallisation experiments were carried out by the hanging drop method of 
vapour diffusion on three complexes of TgENR (TgENRlNAD+/triclosan, 
TgENRlNAD+ and TgENR). For the complexes 5/lM and 6/lM NAD+ and triclosan 
were used, respectively. All three complexes were screened by mixing 2/l1 of 
20mg/ml protein solution (20mM tris pH 7.25 with 100mM NaCl) with 2/l1 of the 
Hampton research screens, Screen I, Screen 2, PegIon Screen and the (NH4)2S04 Grid 
screen. For the TgENRlNAD+/triclosan complexes 11 different conditions were 
isolated, producing six different crystal morphologies. After testing the diffraction 
properties of each of the crystal morphologies, only those crystals grown in 1.6M 
(NH4)2S04 (Grid screen condition B6), diffracted beyond 4A. 
5.4.1 Optimisation of crystallisation conditions 
Optimisation of the promising conditions led to crystals of TgENR complexed with 
NAD+ and triclosan being grown by mixing 2/l1 of (NH4hS04 solutions ranging from 
1.0M to 2.0M and pH8.0 to pHIO.O with 2/l1 of 20mg/ml protein solution (20mM tris 
pH 7.25 with IOOmM NaCl). This led to an optimal condition of 1.75M (NH4)2S04 
and O.1M Bicine pH 9.2. The resulting crystals took around three days to reach a size 
of approximately 0.15 x 0.15 x 0.4 mm3 (Figure 5.2). These crystals were then tested 
in several cryo conditions, with 20% glycerol producing crystals whose diffraction on 
the in-house rotating anode X-ray source was beyond 2.5A at lOOK. 
5.5 Initial data collection 
An initial data set was collected in house on a Mar Research Mar345 image plate 
mounted on a Rigaku RU200 X-ray generator using crystals of the 
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(a) 
Figure 5.2. Crystals of the TgENRlNAD+/triclosan complex grown in 1.6M 
(NH4)2S0 4 and 0.1 M Bicine pH9 .2 .. 
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Figure 5.3 (a) A representative 0.10 oscillation frame of data collected from the 
TgENR complexed with NAD+ and triclosan crystal collected on a CCDQ4 image 
detector on station 14.4 at the European synchrotron radiation source (ESRF). The 
resolution at the comers of the image plate is 1.6A resolution. (b) An enlarged 
view of part of the image, highlighted by a black square showing the close spot 
separation at high resolution. 
TgENRlNAD+/triclosan complex. An oscillation of 0.5° per image was used over a 
total of 100° with an exposure time of 10 minutes per image. Initial analysis using the 
DENZO/SCALEP ACK package (Otwinowski & Minor, 1997) showed the crystals to 
belong to the orthorhombic P222 system with approximate unit cell parameters a = 
61A, b = 153A, c = 283A, and a = ~ = 'Y = 90.0°. These crystals were then taken to 
the European Synchrotron Radiation Facility (ESRF) station ID 14.4 for data 
collection. Nine hundred images were collected with a 0.1 ° oscillation and 1 second 
exposure times on an ADSC Quantum 4 detector (Figure 5.3). A small oscillation 
angle was used to overcome the poor spot separation on the images, caused by the 
large unit cell dimension along c of 283A. The data were indexed and integrated in 
the program Mosflm (Leslie, 1999) using the space group P222. The reflections were 
subsequently scaled and merged in the program Scala (Evans, 1993). Although 
reflections were seen out to 1.7 A the data were initially only processed to 2.2A. A 
total of 5786779 measurements were made of 128948 independent reflections and the 
data merged to an overall Rmerge of 0.095 with 96.4% completeness in the resolution 
range 30A to 2.2A. Data collection and processing graphs and statistics can be found 
in Figure 5.4 and Table 5.1. 
5.6 Initial Xray analysis of TgENR crystals 
5.6.1 Space group determination 
Analysis of the diffraction data showed that the crystals belong to the orthorhombic 
P222 system, with unit cell parameters a = 60.6 A, b = 152.9 A, c = 282.9 A, and a = 
~ = 'Y = 90.0°. Initial analysis of the X-ray diffraction pattern showed that no 
reflections were recorded along the OkO axis (b*) but along the 100 (a*) they satisfied 
the .condition 1 = 2n (Figure 5.5). Similarly reflections were recorded along the hOO 
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Figure 5.4 a, b, c and d. Mosflm statistics for the TgENRlNAD+/triclosan 
complex data to 2.2A. The graphs show (a) Rtactor vs. image number (~ 0 to 900 ) 
(b) Rtactor vs. resolution (c) I/crI vs. image number (~ 0 to 900 ) (d) completeness 
vs. resolution. 
"Pou 
[III'P0 
AnoaClapl 
An0M7ro 
Spacegroup P222 
Wavelength (A) 0.97620 
Resolution (A) 30.0 - 2.2 ( 2.32 -2.2) 
Total reflections 5786779 
Unique reflections 128948 
Multiplicity 3.6 (3.4) 
Completeness (%) 96.4 (96.0) 
1/(0") 1 5.6 (4.2) 
Rmerge (%) 0.095 (0.149) 
Table 5.1 Data collection statistics for the TgENRlNAD+/tric1osan complex collected 
at the ESRF source to 2.2A. Values in parentheses are for the highest resolution shell. 
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Figure 5.5 (a) The hkO zone for the TgENR data to 2.2 A, with a zoomed in view 
on the right hand side showing reflections along the h axis where h = 2n except for 
three exceptions (h=7, 15 and 19) labelled with an arrow. (b) The Okl zone for the 
TgENR data to 2.2 A, with a zoomed in view on ~e right hand side showing 
reflections along the 1 axis. 
axis where they appeared to satisfy the condition h = 2n, except for three reflections 
where h = 7, 15 and 19 (Figure 5.5). Given this uncertainty the crystals could belong 
to any 4 orthorhombic space groups (P2122, P212)2, P21221 and P212121)' 
5.6.2 Vm calculation 
Gel filtration studies had indicated that TgENR is a tetramer and as such the number 
of molecules in the cell must be a multiple of 4. Calculation of the Vm values of 
either one or two tetramers within the asymmetric unit gives a Vm value of 4.8 and 
2.4 A3 Da-l , respectively within the range of Vm values observed for protein crystals 
(Matthews, 1977). 
5.6.3 Self Patterson 
The self Patterson for the TgENR data calculated using the program POLARRFN 
showed a peak at (0 Yz 0), consistent with two tetramers in the asymmetric unit cell 
related by a 0.5 translation along the b axis (Figure 5.6). The height of the second 
peak was dependent on resolution (Figure 5.6) with the strongest peak being present 
when the self Patterson was calculated using data from 20A to loA, indicating that at 
low resolution the orientations of the two tetramers are very similar. Interestingly the 
presence of two tetramers within the unit cell related by a 0.5 translation causes a 
change in the distribution of reflections such that the reflections are systematically 
strong and weak for data below 5A resolution in zones with k even or odd, 
respectively (Figure 5.7). 
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Figure 5.6. The y=O section for self Pattersons of the TgENR crystal data 
calculated using data in the resolution ranges (a) 20-10A, (b) 20-8.oA, (c) 20-6.oA 
and (d) 20-4.oA in spacegroup P222 using POLARRFN (CCP4, 1994). All the 
sections cover the range x = 0 - 1/2 and z = 0 - 1/2. The map is contoured with the 
maximum at the origin set to 100 and the contours are drawn at intervals of 10%. 
In all maps a clear peak can be seen at 0, 0.5, 0.0. This peak decreases from 77% 
of the origin for the data to loA resolution to 70%, 58%, and 20% using data to 
8A, 6A and 4A, respectively. 
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Figure 5.7. The hOI, hll, h2/, h3/, h41 and h51 zones for the TgENR data to 2.2A. 
The weak area in the centre of the hll, h31 and h51 zones extends to approximately 
5A resolution. 
5.7 Molecular replacement 
5.7.1 The search model 
In initial attempts to solve the structure of TgENR the coordinates of PfENR were 
used as a search model for molecular replacement. Those areas which were predicted 
to adopt a different fold between the P jalciparum and T.gondii ENR enzyme were 
removed from the coordinate file which included the final ten residues at the C 
terminus, the loop regions between a2-p3 and p3-a3, the substrate binding helix, the 
triclosan inhibitor and the NAD+ cofactor. 
5.7.2. Anticipated problems 
Although there must be significant structural similarity between TgENR and PfENR 
several problems were anticipated in the solution of the structure by molecular 
replacement. Firstly the presence of two tetramers within the asymmetric unit meant 
that solving the rotation and translation of the first tetramer will only account for half 
of the scattering matter of the crystal, hence a low signal to noise ratio. Secondly 
given the spacegroup ambiguity molecular replacement would have to be carried out 
in space groups P2122, P21212, P21221 and P212121. 
5.7.3 Molecular replacement 
In order to solve the TgENRlNAD+/triclosan complex by molecular replacement the 
programs Amore, CNS, BEAST, Molrep and TF~C, all part of the CCP4 suite of 
programs (CCP4, 1996) were used. In order to obtain a correct solution within 
molecular replacement several values for both the resolution and search radii were 
used in conjunction with changing the overall model B-factors to 20 and using a 
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polyalanine search model. For each program a clear rotation function was obtained, 
however a clear solution could not be found for the translation function. 
5.8 Intrinsic problems with the data 
5.8.1 Twinning 
The formation of twinned crystals is a feature which occurs naturally in crystals when 
different domains are joined together according to a specific symmetry operation 
(Parsons, 2003). This results in a crystal made up of two different domains whose 
diffraction patterns are reflected, inverted or rotated with respect to each other, 
depending on the symmetry operation: the twin law (Figure 5.8). The ratio of the two 
different domains within the crystal (twinning fraction), determines the contributiqn 
of each of the domains diffraction to the overall crystal diffraction. Twinning occurs 
broadly into two categories, in which either all or part of certain zones are affected by 
overlap. 
Within the orthorhombic space group P222 and its derivatives only one twinning 
operation can be present in which a monoclinic space group P21 whose unique angle, 
p, is equal to or very close to 90°, results in an apparent higher P222 space group. 
This results in a crystal whose lattice has point group mmm but a crystal structure 
point group of 21m. Furthermore, the point group mmm contains symmetry elements 
not in point group m and as such mistakes may occur in which unit cells may be 
related by symmetry operations about the a or c axes during crystal growth. This 
ambiguity not only produces problems associated with processing in the wrong space 
group, but also problems are encountered with measuring the correct intensities of 
reflections, when some are the sum of two separate reflections. 
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(0) (b) 
(c) (d) 
Figure 5.8 a,b, c and d. The effect of twinning on the diffraction pattern of a 
monoclinic crystal. (a) represents the diffraction pattern from one domain of a 
crystal. (b) represents the diffraction pattern from the second domain of the twinned 
crystal where it has been rotated by 1800 about the h axis. Both (c) and (d) represent a 
twin caused by a crystal containing both domains (a) and (b). (c) Representation of a 
0.5 twin fraction in which the crystal is made up of an equal amount of domain (a) 
and (b). (d) A crystals whose twin fraction is 0.2 such that the crystal contains 80% 
of domain (a) and 20% of domain (b). The figure is taken from Parsons, 2003. 
5.8.2 Calculating the twinning fraction of the TgENR crystal 
There are several methods which may be employed to calculate the correct twinning 
fraction, if any, within a crystal. The presence of twinning will effect the distribution 
of the weak and strong reflections within the dataset and as such the calculation of the 
Wilson ratio (Fif(l), the "moments of intensities distribution". In a "normal" 
untwined dataset a value of 0.785 would be expected for this ratio, whereas with a 
twinned dataset a higher value of around 0.885 would be expected. Calculation of the 
(F)2f(I) ratio for the TgENR data showed the value to be approximately 0.87 (Figure 
5.9). However he presence of two tetramers related by a 0.5 fractional shift along the 
b axis within the unit cell would also affect the moments of intensities distribution and 
as such this ratio could not be used as a reliable indicator for twinning in the case' of 
TgENR. As an alternative a Britton plot calculated by applying a range of twinning 
fractions from 0.0 to 0.5 and calculating the number of negative intensities produced 
(Britton, 1972) can be used. The basis of detwinning data requires the assessment of 
the twinning fraction, which determines the contribution of the reflections from one 
domain onto another and determination of the twinning operator which states which 
reflections will be affected by the twinning within the data set. By applying too great 
a twinning fraction the contribution of a reflection to its twinned counterpart is 
overestimated and the reflection becomes negative. Applying a twinning fraction to 
data which is not twinned results in the production of negative intensities which 
increases linearly with the twinning fraction applied.. Calculation of too low a 
twinning fraction on twinned data will result in the production of no negative 
intensities. This can be seen by calculating a Britton plot for the PfENR data which is 
in P21 and is not twinned, within the program Detwin (CCP4, 1994). A straight line 
can be seen which passes through 0 indicating no twinning is present (Figure 5.10a). 
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Figure 5.9. The acentric moments for the TgENRlNAD+/triclosan data to 2.2 A. 
The approximate value for the ratio of (Fl /(1) is 0.87. The figure was produced in 
the program truncate. 
Figure 5.10. Britton plots created using the program Detwin (CCP4, 1994), 
showing the number of negative intensities as a function of the assumed twin 
fraction on data from (a) the PtENRlNAD+/tric1osan complex, (b) the 
TgENRlNAD+/tric1osan complex and (c) the TgENRlNAD+/tric1osan data after. 
detwinning with a twinning fraction of 0.45. The Britton.plot shows the number of 
negative intensity reflections and the applied twin fraction across the y and x axes, 
respectively. 
Carrying out the same procedure on the TgENR data processed in P2 produces a very 
different graph in which a linear relationship between the number of negative 
intensities and the twinning fraction is not observed (Figure 5.10b). 
5.8.3 Detwining the TgENR data 
The program Detwin (CCP4, 1994) was used to detwin the TgENR data which had 
been processed in spacegroup P2 using a twinning fraction of 0.45 and the twinning 
operator h, -k, -1. After detwining the data a Britton plot was recalculated which 
showed a plot with a near linear line passing through 0 (Figure 5.10c). However the 
data does not look fully detwinned indicating that a twinning fraction of 0.5 is present 
which is indicative of a perfect merohedral twin which in the absence of strong non 
crystallographic symmetry is very difficult to solve. Therefore a search for a new 
crystal form was initiated. 
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CHAPTER 6 
Structure determination and refinement of the Toxoplasma gondii 
ENRlNAD+/triclosan complex 
6.1 Introduction 
This chapter describes the structure determination of Toxoplasma gondii enoyl ACP 
reductase (TgENR) by molecular replacement and its subsequent model building and 
refinement. 
6.2 TgENR crystallisation 
6.2.1 Preliminary crystallisation 
The inability to solve the structure of TgENR from the twinned crystals described in 
chapter 5 led to a new set of crystallisation trials being conducted, using the Hampton 
research crystal Screens I, II, PegIon screen, Xtal screen lite and grid screen on 
TgENR complexed with NAD+, NAD+ and triclosan and for the free enzyme. In 
comparison to previous crystallisation attempts where a protein concentration of 
20mg/ml was used, the TgENR concentration was lowered to between 5 and 
lOmg/ml. The crystals were grown using the hanging-drop vapour diffusion 
technique by mixing 1.5!J.I of the protein solution (20mM Tris 7.5 and 100mM NaCI) 
with 1.5!J.I of the reservoir solution at 290K. In order to form the complexes the 
protein solution was brought to a concentration of 5 and 10mg/ml by diluting the 
protein solution in additional buffer (20mM Tris 7.5 and 100mM NaCI) after which 
5!J.M NAD+ and 6!J.M tric10san were added to form the respective complexes. Of 
those conditions which produced crystals, the best quality crystals were of the 
TgENRlNAD+ltric1osan complex and these grew in crystal screen 1 condition 36 
(O.lM Tris-HCI pH8.5 and 8% PEG 8,000), reaching a size of approximately 0.2 x 0.2 
x 0.3 mm3• Several images were collected on a tube mounted crystal to 4.5A on a 
Mar Research Mar345 image plate mounted on a Rigaku RU200 X-ray generator and 
processed in the DENZO suite of programs (Otwinowski & Minor 1997). Analysis of 
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these data showed the crystals to belong to the trigonal space group P3 with 
approximate unit cell dimensions a = 78A, b = 78A, c = 188A, a = p = 900 and y = 
1200. This crystal form had been noted in the initial crystal screening experiment in 
which 20mg/ml of TgENR was used as detailed in chapter 5, however the diffraction 
properties of the original crystals were poor with a diffraction limit of approximately 
6.oA. 
6.2.2 Optimisation of crystallisation conditions 
Optimisation of the crystallisation conditions for the TgENRlNAD+/triclosan complex 
was carried out by varying the concentration of TgENR from 5 to 10mg/ml, the 
percentage of PEG 8,000 from 0% to 20% and by changing the pH of the Tris-HCI 
buffer in the range of 7.5 to 9.5. The concentration of the NAD+ and triclosan were 
not changed from 5!!M and 6!!M, respectively. This resulted in an optimal condition 
ofO.lM Tris-HCI pH9.0 with 6% PEG 8,000 and 10mg/ml of protein (Figure 6.1a). 
6.3 Data Collection 
Crystals of TgENR complexed with NAD+ and triclosan were tested in a variety of 
cryo protectants, the most effective of which was to flash freeze them in 30% glycerol 
at lOOK. A dataset was collected on a Mar Research Mar345 image plate mounted on 
a Rigaku RU200 X-ray generator to a resolution of 3.2A. These crystals were then 
sent to the BESSY synchrotron radiation source for data collection. A dataset to 2.8A 
was collected on a Mar165CCD image plate using a rotation oscillation of 10 over 
1650 and an exposure time of 15 seconds (Figure 6.1h). Analysis of the data was 
carried out using the HKL suite of programs (Otwinowski and Minor, 1997). 
Analysis of each image showed that those images representing 1300 and 1310 had a 
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Figure 6.1 (a) Crystals of the TgENRlNAD+/triclosan complex grown in O.lM 
Tris-HCL pH 9.0 and 6% PEG 8,000 with approximate dimensions of 0.2 x 0.2 x 
0.3 mm3. (b) A 10 oscillation frame of a TgENRlNAD+/triclosan crystal taken on a 
Mar16S CCD image plate. The resolution at the edge ofthe plate is 2.sA. 
significantly higher Rsyrn and Chi2 value than the other images in the dataset. These 
images were subsequently removed from the data processing, reducing the overall 
Rmerge value from 0.071 to 0.069. A total of 102465 measurements were made of 
14012 independent reflections. The data processing graphs and statistics for the data 
collection can be seen in Figure 6.2 and Table 6.1. 
6.4 Initial X-ray analysis of TgENR crystals 
6.4.1 Space group determination 
Preliminary analysis of the data indicated that the crystal belonged to the trigonal 
spacegroup of P3, with unit cell dimensions a = 78.01A, b = 78.01A, c = 188.45A, 
a = p = 90° and 'Y = 120°. Analysis of the X-ray diffraction pattern in the hkO zone 
showed clear 6mmm symmetry, but clear 3 mmm symmetry is seen in the hkl zone 
indicating that the space group is a derivative of P3 symmetry (Figure 6.3). Analysis 
of the X-ray diffraction pattern showed that reflections were observed along the 001 
axis (c*) only where they satisfied the condition 1 = 3n suggesting the correct space 
group to be either P31 or P32. Furthermore the hkO and hkl zones also shows a mirror 
plane to be present along both the h and k axis indicating the crystals to belong to 
either P3121 or P3221 as opposed to a derivative of P312. 
6.4.2 Vm Calculation 
Analysis of the Vm for the TgENRlNAD+/triclosan crystals suggests that the 
asymmetric unit contains a dimer, with a Vm of 2.4A3 Da-1, which is within the range 
ofVm values observed for protein crystals (Matthews, 1977). 
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Figure 6.2. Scalepack statistics for the TgENRlNAD+/triclosan complex data to 
2.8A. The graphs show (a) ~ym vs. image number ($ 0 to 165°) (b) ~ym vs. 
resolution (c) Vcrl vs. image number ($ 0 to 165°) (d) Vcrl vs. resolution (e) 
completeness vs. resolution. The images were numbered from 101 to 265 and as 
~uch no values are given within the R syrn vs. image number for the first 100 
tmages. 
Space group P3221 
Wavelength (A) 0.993185 
Resolution (A) 30.0 - 2.8 ( 2.9 -2.8) . 
Unique reflections 14012 
Total reflections 465355 
Multiplicity 7.3 
Completeness (%) 82 (33) 
I/cr(l) > 3 (%) 76.4 (75.1) 
Rmerge (%) 0.069 (0.32) 
Table 6.1 Data collection statistics for the TgENRlNAD+/triclosan complex collected 
at the Bessy synchrotron radiation source to 2.8A. Values in parentheses are for the 
highest resolution shell. 
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Figure 6.3 a, band c. (a) The hOI zone for the TgENR data to 2.8A, with a zoomed 
in view on the right hand side showing reflections along the I axis where I = 3n when 
hand k = O. (b) The hkO and hkl zone for the TgENR data to 2.8A which shows 
mirror symmetry along both the h and k axis indicating the space group to be a 
derivative ofP321 symmetry. 
6.4.3 Possible packing within the asymmetric unit cell 
Given that the asymmetric unit cell contains a dimer, one of the three 2-fold axes of 
the tetramer must lie along the crystallographic 2-fold axis to produce the biological 
tetramer. Given that the relationship of the crystallographic 2-fold axis to the 3 
molecular 2-fold axes is unknown the molecular replacement solution needs to be 
attempted with more than one model. In practice the search model should not consist 
of 2 subunits related by the crystal 2-fold axes. To achieve this anyone subunit can 
be selected (subunit A) and it should be paired with either B or C, B or D or C and D. 
For each pair at least one correct molecular replacement solution will be found with 
two equivalent correct solutions being found for one ofthe three pairs. 
6.5 Molecular replacement 
6.5.1 The search model 
In order to carry out molecular replacement the structure of PfENR was used as a 
search model with those areas suggested to be different between the two structures 
removed (Figure 6.4), as described in section 5.7.1. As the Vm for the 
TgENRlNAD+/triclosan crystals suggested that the asymmetric unit contains a dimer 
the PfENR tetramer was split into two dimers one containing subunits A and B the 
other containing A and C. 
6.5.2 Cross rotation function 
The program Amore (Navaza, 1994) was used to carry out both the rotation and 
translation functions. Both the PfENR AB and AC dimers were used as search 
models to calculate the cross rotation function, using a radius of integration of 30.oA 
on ~ata from 8.0 to 3.oA resolution. Of the two dimer search models it was the AB 
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Figure 6.4 The PfENR search dimer formed by subunits A and B coloured blue 
and red, respectively. The areas where residues were removed are shown as stars 
with number 1 being 63 to 75, 2 being 93 to 108, 3 being 238 to 241 and 4 being 
336 to 346. The figure was produced using the graphics program Pymol (Delano, 
2002). 
dimer which produced the clearer solutions of which the highest scoring was at a = 
11.7, ~ = 85.9 and y = 127.4, achieving an Rfactor of 0.55 and correlation coefficient of 
0.46. 
6.5.3 Translation function 
The translation function was carried out in P3121 and P3221 with a clear solution 
being obtained for the space group P3221 giving an Rfactor of 0.48 and correlation 
coefficient of 0.56 at x = 0.328, Y = 0.152 and z = 0.100. No solution could be 
obtained in P3121 indicating the correct spacegroup to be P3221. In order to test the 
validity of the solution the PfENR AB search dimer was translated to the suspected 
solution and its symmetry related partner was displayed showing the production of a 
tetramer like that observed for ENR from other species, indicative of a correct 
solution (Figure 6.5). 
6.6 Phase improvement, Model building and refinement 
6.6.1 Rigid body refinement 
The solution output by Amore was subjected to 20 rounds of rigid body refinement 
within the program REFMAC5 (Murshudov et al., 1997). Only data in the resolution 
range 20.0 A to 4.0 A were used and each of the subunits within the dimer was treated 
as an individual rigid body or domain. This resulted in a small drop in Rfactor to 0.46 
(Rfree 0.47). 
6.6.2 Restrained least squares refinement 
The model was then subject to x, y, z refinement over 10 cycles on data in the 
resolution range of 20.oA to 2.8A, with sigma A weighted maps being calculated 
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Figure 6.5. The TgENR dimer shown in green with its symmetry generated 
partner shown in red producing a TgENR tetramer. The figure was produced using 
the graphics program TURBOIFROOO (Roussel et aI. , 1990). 
Figure 6.6. The 2F obs-F calc electron density maps of the triclosan and NAD+ 
cofactor within the TgENR model contoured at 0.8cr ~ The maps were produced 
through refmement of the initial TgENR model without the addition of either 
NAD+ or triclosan. The NAD+ and triclosan molecules are coloured with yellow 
for carbon, blue for nitrogen, red for oxygen and orange for phosphorous in NAD+ 
and chlorine in triclosan. The triclosan and NAD+ molecules have been added as a 
guide to the electron density. The maps were produced using the graphics program 
TURBOIFROOO (Roussel et al., 1990). 
using 2Fobs-lFca1c and 1Fobs-1Fcalc coefficients. The Rfactor and Rfree dropped to 0.30 
and 0.42, respectively. The initial rigid body and x, y, z refinement was carried out 
without the inclusion of the triclosan inhibitor or NAD+ cofactor, yet clear density 
was present within the active sites of both the A and B subunits showing a low level 
of bias in the maps (Figure 6.6 a, b). 
6.6.3 Model building 
The first stage in model building was the replacement of those residues within TgENR 
which differed from the corresponding residues in the PfENR search model. Analysis 
of the maps showed a low level of bias for those residues that were incorrect. The 
two loops which were removed in the search model, were partly rebuilt and the NAD+ 
cofactor and triclosan inhibitor added and the model subsequently refined. This 
resulted in a drop in Rfactor to 0.274 (Rfree 0.343). The resulting maps were used again 
for a further round of model building in which all the residues were checked for an 
optimal fit into the electron density maps. The two extended loops were rebuilt using 
the improved map as a guide although some residues still remained un-defined and as 
such were not placed into the model. The resulting refinement led to a drop in both 
the Rfactor and Rfree to 0.270 and 0.33, respectively. It was also possible within the A 
subunit of TgENR to model in the extra six residue insert, with both clear and 
continuous density within the electron density map contoured at 0.75cr and large 
positive peaks within the difference map contoured ,at 2.5cr. After the addition of the 
loop within the A subunit the model was refined resulting in clear and continuous 
density within the refined map with no negative peaks within the difference map. 
There was however a slight increase in the Rfree of 0.01, but the quality of the refined 
electron density map indicated a correct solution in the placing of the chain. 
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6.6.4 NCS averaging and TLS refinement 
Throughout the initial refinement medium to loose NCS restraints were placed upon 
the dimer. The poor resolution of the data resulted in an inability to refine the 
individual B-factors of the atoms due to the poor observation to parameter ratio. As a 
result an overall B factor was refined and the TLS program was used to model the 
motion of the molecule. By defining each of the subunits and its respective NAD+ 
and triclosan cofactors as independent TLS units both the Rfactor and Rfree dropped to 
0.25 and 0.3, respectively. 
6.6.5 The final 2.8A TgENR model 
Although the model was not at this point fully refined or built, with some residu~s 
within the extended loop regions not yet fitted model building was halted until a 
higher resolution data set could be obtained. 
6.7 Collection of a higher resolution data set 
A major problem with the TgENRlNAD+/triclosan crystal form was its fragile nature 
which results in the cracking of the crystals upon freezing, resulting in a split 
diffraction pattern. Several crystals diffracted to beyond 2.8A but all had two or more 
lattices present on the image. In order to obtain crystals with an increased stability 
within the cryo protectant solution, the crystals were grown in O.IM Tris-HCI pH9.0 
and 6% PEG 8,000 with 51lM NAD+ and 61lM triclosan with an additional 5%, 10%, 
15%,25% or 30% glycerol. Crystals grew under all conditions but those containing a 
higher percentage of glycerol diffracted poorly (approximately 4A). However those 
crystals which grew in 5% glycerol were more stable when placed into a cryo solution 
con~ining the same conditions as in the hanging drop but with an additional 25% 
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glycerol. Flash freezing of the crystals within a stream of nitrogen gas at 100K with 
the new cryo conditions resulted in a higher resolution data set being collected to 
2.6A. 
6.7.1 Data collection 
A dataset on TgENRlNAD+/triclosan crystals was collected to beyond 2.6A on a Mar 
Research Mar34S image plate mounted on a Rigaku RU200 X-ray generator using a 
rotation oscillation of 10 over 900 and an exposure time of 10 minutes (Figure 6.7). 
Analysis of the data was carried out using the HKL suite of programs (Otwinowski & 
Minor, 1997) with a total of 110634 measurements being made of 211 OS independent 
reflections. The data processing graphs and statistics can be seen in Figure 6.8 and 
Table 6.2. The data were cut to 2.6A due to the poor quality of data beyond this 
resolution. 
6.7.2 Higher resolution refinement 
Analysis of the processed data showed approximately the same unit cell dimensions 
of a = 78.07SA, b = 78.07SA, c = 188.4SA, a =~ = 900 and y = 1200 as those refined 
for the crystal used for the data collection to 2.8A. The refined model of the TgENR 
was subsequently refined using REFMACS (Murshudov et al., 1997), with the new 
data to 2.6A giving an Rfactorand Rfree value of 0.24 and 0.31, respectively. The maps 
from refinement were then inspected to look for improvements in quality. The map 
showed areas of clear improvements allowing for the positioning of several previously 
un-defined residues (Figure 6.9). 
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Figure 6.7. A 10 oscillation frame of a TgENRJNAD+/tric1osan complex crystal 
taken on a Mar Research Mar345 image plate mounted on a Rikagu rotating copper 
anode. The resolution at the edge of the plate is 2.3A. 
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Figure 6.S. Scalepack statistics for the TgENRlNAD+/triclosan complex data to 
2.6A. The graphs show (a) R sym vs. image number ($ 0 to 95°) (b) R sym VS. 
resolution (c) I/crl VS. image number ($ 0 to 95°) (d) I/crl VS. resolution (e) 
completeness VS. resolution. 
Space group P3221 
Wavelength (A) 1.54189 
Resolution (A) 30.0 - 2.6 ( 2.69 -2.6) 
Total reflections 310044 
Unique reflections 21105 
Multiplicity 5.2 
Completeness (%) 99.9 (99.4) 
1/0'(1) > 3 (%) 74.4 (42.0) 
Rmerge (%) 0.082 (0.48) 
Table 6.2 Data collection statistics for the TgENRlNAD+/triclosan complex collected 
in house on a Mar Research Mar345 image plate mounted on a Rigaku RU200 X-ray 
generator to 2.6A. Values in parentheses are for the highest resolution shell. 
r----------------------------------------- ------------- - -----------------------------
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Figure 6.9 A representation of the difference in map quality for certain areas of the 
TgENR model. Both maps represent the 2F obs-F calc maps after refmement for the 
2.8A and 2.6A data shown as a red and blue map, respectively. Both maps are 
contoured at 1 a. The figure was produced using the graphics program 
TURBOIFRODO (Roussel et al., 1990). 
6.8 Model building 
The increase in resolution showed areas of improvement within the TgENR model 
and in particular in the region of Lys63 to Gll7 and Lys93 to Arg97 and the inserted 
loop region (Gly236 to Lys241). The resulting .mtz file from each stage of refinement 
was used to create both the 2Fobs-Fcalc and 1Fobs-1Fcalc maps but was also subject to 
density modification using the program Dm (Cowtan, 1994), which performed solvent 
flattening, histogram matching and NCS averaging over the two subunits within the 
asymmetric unit cell. The resulting maps from DM were used for model building. A 
visual inspection was made on each residue, examining both the main chain and 
sidechain positions, taking into account both the Ramachandran and )(1-)(2 values. 
Subsequent refinement of the model gave an overall Rfactor and Rfree value of 0.224 and 
0.28, respectively. 
6.8.1 Addition of solvent 
For the final cycles of refinement water atoms were placed into the model using 
ArpWarp version 5. The maps from REFMACS (Murshudov et al., 1997) were used 
by ArpWarp to look for peaks within the 1Fobs-1Fcalc difference map with a sigma cut-
off of> 2.5 cr and which lay within 2.2A to 3.3A of a protein Nor 0 atom. All water 
atoms closer than 2.2A were merged to a single water before refinement in 
REFMACS, with the maps from REFMACS again being used for ArpWarp. This was 
continued for 10 cycles. Each of the individual water molecules was then visually 
inspected to check it was placed within a discrete spheroid of density and within 
hydrogen bonding distance to neighbouring atoms. All water molecules with a B-
factor over 60A2 were removed. A total of 39 water atoms were added to the TgENR 
model resulting in a reduction of the Rfactor and Rfree to 0.216 and 0.279, respectively. 
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CHAPTER 7 
Analysis of the structure of the Toxoplasma gondii 
ENRlNAD+/triclosan complex 
7.1 Introduction 
The following chapter describes the final model of Toxoplasma gondii enoyl ACP 
reductase (TgENR) and the mode of binding tric10san and NAD+. 
7.2 Model stereochemistry 
The final model of the TgENRlNAD+/tric1osan complex comprises 606 residues with 
Pro4 to Pr0306 in the A subunit and Phe3 to Gly39 and Lys241 to Pr0306 in the B subunit. 
Two residues in the A subunit were truncated due to weak or no density (Lys64 was 
truncated to CB and Lys94 to C3). The model has an Rractor of 0.22 (Rfree of 0.28) for 
all data within the resolution range 20.0 A to 2.6 A (Table 7.1). Analysis of the 
TgENR model geometry was carried out using the program PROCHECK (Laskowski 
et al., 1993) and showed a tight geometry with most values being inside or better than 
the range expected for a model at this resolution (Figure 7.1 a and 7.2 a). 
Examination of the X1-X2 plots for all residue types showed the sidechains to be in 
favourable conformations for the two monomers in the asymmetric unit (Figure 7.1 b 
and 7.2b). The bond angle and length r.m.s.d from ideal geometry as defined by 
REFMAC5 (Murshudov et al., 1997) are 0.015A and 1.7°, respectively. The 
Ramachandran plot for the TgENR dimer showed 87% of residues to be in the most 
favoured regions and 13% in additionally allowed regions, with no residues in the 
generously or disallowed regions (Figure 7.3 a and b). A representative part of the 
electron density map for the final refined TgENR m?del is presented in Figure 7.4. 
7.3 Overall fold 
The TgENR monomer has overall dimensions of 45 x 50 x 60A and is formed from 
nine a-helices (a1-a9) comprising 108 residues (~36 %), seven B-sheets (B1-B7) 
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Refinement statistics and model quality 
Total non-H atoms 4678 
Water sites 39 
Average B-value (A2) 30 
Resolution limits (A) 20-2.6 
Number of unique reflections 21105 
R-value 0.22 
Rfree Value 0.28 
r.m.s. bond deviation (A) 0.015 
r.m.s. angle deviation (deg.) 1.7 
Table 7.1. A table to show the refinement statistics for the TgENRJNAD+/triclosan 
complex to 2.6A resolution. 
Arg ll4) 
~ 70 
-, 
5 
., 
Chi-L 
13J 170 170 '"' '" ., ., ~ :~ ~ 
C hi- I 
Asp (2 1) 
eh"'L 
C~ l---.:;:---;..,:;--;~:---;!l.-=JL!-; 
Chi- I ChH 
1 :rncysro) :GGlnIS) :SGIUIII) ~, ,,,, TIP (31 :OTyrIl3) 
5 ISO Lt) ItO D :. e uo 
" OJ ,, ' " : 
40 I 1 ., ! JOi) ! ~ !---.:;:---;t-~I;;;' ~-;!JaIl CI() :. )CO 
. 
5 
Cni- I Chi- l Chi-l ChI-I Chi- I 
His (6) \Ie( 12) Leu 13 11 
-[E I,. . . 
'" 
" . . 
)0() I" ! )0 .., :1<1 
C hi- l Chi-l C h;"'( 
Figure 7.1. (a) The Xl vs. X2 plots for subunit A of the TgENR. Favourable 
conformations are represented in the shaded areas. The figure was produced using 
the program PROCHECK (Laskowski et aI. , 1993). 
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Figure 7.1. (b) Main chain and side chain parameters for subunit A, produced 
using the program PROCHECK (Laskowski et ai., 1993). 
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Figure 7.2. (a) The Xl vs. X2 plots for subunit B of the TgENR. Favourable 
conformations are represented in the shaded areas. The figure was produced using 
the program PROCHECK (Laskowski et ai. , 1993) . 
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Figure 7.2. (b) Main chain and side chain parameters for subunit B of TgENR, 
produced using the program PROCHECK (Laskowski et aI. , 1993). 
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Figure 7.3. Ramachandran plots for subunits A and B of TgENR. The shading of the Ramachandran plot is with red, dark 
yellow, yellow and white representing the decreasingly favoured regions, respectively. Produced using PROCHECK (Laskowski 
et ai., 1993). 
Figure 7.4. Representative portions of the 2F obs - F calc electron density map 
calculated using the refmed TgENR model. The model is coloured with yellow for 
carbon, blue for nitrogen and red for oxygen. The map is contoured at 1.5a and the 
figure was produced using the graphics program TURBOIFRODO (Roussel et aI. , 
1990). 
formed by 43 residues (~ 14 %), six 310 helices formed by 18 residues (~ 6 %) and a 
number of loops ((defined by the program PROMOTIF (Hutchinson and Thornton, 
1996)), (Figure 7.5 and 7.6). The secondary structure elements form a parallel B-
sheet flanked on one side by the helices of a4, as and a6 and by aI, a2, a7, a8 and 
a9 on the other, with the a3 helix lying on top of the B-sheet, reminiscent to the 
Rossmann fold common to several NAD+ binding enzymes ((Rossmann et al., 
1974)(Figure 7.7)). The NAD+ cofactor binds at the C-terminal end of the B-sheet 
and lies against the a4 and a5 helix with important interactions to the residues in the 
B Val loop. The inhibitor is bound in a pocket bounded by residues from a5, a6 and 
a8 with a7 forming a lid on top of the inhibitor making extensive van der Waals 
interactions. 
7.4 Comparison of the TgENR subunits 
Analysis of the differences between the individual monomers of the TgENR dimer 
was investigated by using the program Lsqkab (Kabsch, 1976) to superimpose each 
monomer onto the other and calculate an r.m.s.d of the Ca atoms. An overall value of 
OAA was obtained after overlaying monomer A onto B, showing three areas of 
difference at Pr090 to ASpl03, Ser56 to Ser69 and Ala234 to Ser43 (Figure 7.8). 
Interestingly these areas correspond to regions of the sequence that represent 
insertions when compared to the bacterial family of ENR enzymes. Removal of these 
areas and a recalculation of the r.m.s.d value for the Ca'atoms gave an average value 
ofO.2A revealing the close similarity in the conformation of the core of the molecule. 
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Figure 7.5. Sequence of TgENR with the secondary structural elements shown as 
blue cylinders and red arrows for a-helices and 13-strands, respectively. Those 
residues not defmed by density within the TgENR crystal structure are coloured 
purple. The figure was produced using the program Alscript (Barton, G.J., 1993). 
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Figure 7.6. A stereo image of the backbone representation of the A subunit of 
TgENR with every twenty residues being numbered. The figure was produced 
using the program MOLSCRlPT (Kraulis, 1991). 
Figure 7.7. A diagrammatic representation of the TgENRlNAD+/triclosan 
complex. Both the NAD+ and triclosan are coloured with yellow for carbon, red for 
oxygen, blue for nitrogen, purple for phosphorous and black for chlorine. 
(a) A stereo view of the TgENR monomer with both NAD+ cofactor and inhibitor 
bound. The TgENR monomer is coloured from blue to red and each secondary 
element is labelled. (b) A stereo view of the TgENR tetramer with a-helices in red 
and ~-sheets in blue. Both figures were created using the graphics program Pymol 
(Delano, 2002). 
*3 
Figure 7.S. A superposition of subunit A (green) onto subunit B (purple) of the 
TgENR dimer. Those areas marked by stars represent areas in which the two 
models show slight differences, where 1 = the N terminal residues, 2 = Ser56 to 
Ser69, 3 = Pro90 to ASpI03, 4 = Ala234 to Ser43 and 5 = C terminal region. The only 
significant region of difference is at Ala234 to Ser43 which is in the region of the 
insert characteristic of the apicomplexan ENR family. The figure was produced 
using the graphics program Pymol (Delano, 2002). 
7.5 Inserted loop 
The insert that is characteristic of apicomplexan ENRs and which varies in size from 
42 residues in P jalciparum to 6 residues in T.gondii can be clearly seen between a7 
and a8 in the structure of TgENR in the A subunit but is partly disordered within the 
B subunit (Figure 7.9). Examination of the loop within the A subunit (GI~36 to 
Lys241) shows it to be close to the bound inhibitor but making no direct contacts. Two 
lysine residues at the beginning and end of the loop point out towards the solvent with 
the Ser238 and Glu240 residues facing the solvent in an opposite direction (Figure 7.9 a 
and b). A total of three hydrogen bonds are formed from the main chain carbonyl 
oxygen of Ile235, GI~36 and Glu240 to the main chain nitrogen atoms of Lys237, Se?38 
and Ser242, respectively. An ion pair is formed between the side chains of Lys241 and 
ASp249. Inspection of the ENR sequences from various apicomplexan parasites shows 
apparent conservation of Lys237 and of an SGE motif, except in Eimeria tenella ENR 
(Figure 7.10). However with the exception of Lys237 the difference in insert size 
makes it difficult to envisage conservation of the position of the SGE motif within the 
apicomplexan family and the sequence similarity maybe chance resemblance. In the 
structure of PfENR this loop region is disordered. 
7.6 Subunit interfaces and quaternary structure 
The two subunits in the asymmetric unit cell of the crystal interact with its symmetry 
related molecule around a crystallographic two fold axis to create a tetramer identical 
to that seen in other ENR enzymes (Rafferty et al., 1995 & Baldock et al., 1998). The 
solvent-accessible area surface area for the TgENR monomer and tetramer was 
calculated to be approximately 15,500A2 and 42,000A2, respectively, using the 
program access (Roussel et al., 1990). There are three interfaces within the TgENR 
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(b) 
(c) 
Figure 7.9. a, band c. The inserted loop region of subunit A (a) and subunit B (b) 
of TgENR and the corresponding electron density in the [mal 2F obs-F calc map 
contoured at 1 cr. (c) A stereo view of the loop region in the A subunit of T gENR. 
All residues involved in forming the loop are shown along with ASp249 which forms 
an ion pair to Lys241. All figures are coloured with yellow for carbon, red for 
oxygen and blue for nitrogen. Both figures (a) and (b) were produced in the 
graphics program TURBO-FROnO, figure (c) was produced using Pymol (Delano, 
2002). 
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Figure 7.10. A sequence alignment of the ENR enzymes from Plasmodium ( falciparum, chabaudi, yoelii, berghei, 
reichenowi, knowlesi and vivax) Toxoplasma gondii and Eimeria. The alignment shows the sequence inserts common to the 
apicomplexan parasites with two black arrows representing the start and stop of the insert compared to bacterial ENRs. The 
coloured boxes represent the level of sequence identity between the nine sequences with red, orange, yellow green and blue 
representing 100, 89, 78, 67 and 56% sequence identity, respectively. The sequences were obtained from both BLAST 
searches of the PlasmoDB ( ) and the Swissprot gene database (Boeckmann et al., 2003). 
tetramer with contacts between subunits A-B and C-D being found on the P axis, 
between subunits A-C and B-D around the Q axis and between subunits A-D and B-C 
around the R axis (Figure 7.11). On formation of the tetramer approximately 
2400A 2, 1800A 2 and 1400A 2 of the solvent accessible area is buried by the P, Q and R 
axis, respectively. The program CONTACT (CCP4, 1996) together with visual 
inspection was used to examine the subunit interface. 
7.6.1 The P axis 
The P-axis interface between the A and B subunits of the TgENR dimer and tetramer, 
is formed by 40 residues: Pro\ Ile5, His3o, Arg205, Ala208, Trp209, Glil2, Gln213, Glil6 
to Arg218, Asn254 to Arg259, Leu261 , Asp26S, Gli68, Ala269, Leu271 , Phe272, Leu~77, 
Arg279, Ala280 to Vae8\ Leu286 to Gli91 , His293 to Met295 and Val299 (Figure 7.12 a). 
The P-axis is formed through the packing between p7 and a9 and its preceding 
residues of subunit A to the equivalent residues in subunit B with additional contacts 
by the packing of the a6 helices, the loop region joining a9 to p7 and the C terminal 
loop region composed of residues ASp289 to Va1299. A total of six hydrogen bonds are 
formed by the sidechain nitrogen of Gln213 to the main chain carbonyl groups of 
Ala255 and pro256, the main chain carbonyl group of Ala280 to the main chain nitrogen 
of Asn290 and ASp289, the main chain carbonyl group of Ser282 to the sidechain 
nitrogen of His293 and by the sidechain oxygen of ASp289 to a water molecule which in 
tum hydrogen bonds to the main chain carbonyl group of Ser282. Hydrophobic 
packing is also present involving the residues: Trp209, Leu257, Gli68, Phe272, Leu277, 
Arg279, Val28 I , Leu286 and Va1288. Phe272 of subunit A packs against its equivalent 
residue in subunit B forming extensive van der Waals interactions and 7t-7t stacking 
interactions (Figure 7.12 b). 
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P-axis 
Q-axis 
R-axis 
Figure 7.11. Three views of the modelled TgENR tetramer viewed down each of 
the three molecular two fold axis. The axis are coloured with subunit A in green, B 
in blue, C in purple and D in yellow. The figure was produced using the graphics 
program Pymol (Delano, 2002). 
(b) 
(a) 
Figure 7.12. (a) The subunit interface between the A and B subunit of the TgENR 
dimer with the A subunit and B subunit coloured purple and green, respectively. 
The Phe272 residue from each subunit can be seen to stack on top of each other. (b) 
The hydrogen bond network formed by the Argl43 residue of subunit A to the 
residues of the modelled TgENR tetramer subunit C. The figure is coloured with 
yellow for carbon, red for oxygen and blue for nitrogen. Figure (a) was produced 
using the graphics program Pymol (Delano, 2002) and figure (b) was produced 
using TURBO-FRODO (Roussel et al., 1990). 
7.6.2 The Q axis 
The Q axis interface is formed by 44 residues: Ala81 to ASp8\ Ile107, Pro137 to Arg143, 
"' 
Ala211 , Lys214 and Tyr215. The Q axis interface is dominated by a four helix bundle 
formed by helices a5 and a6 and their preceding loop regions which pack against 
their symmetry equivalents in the neighbouring subunit (Figure 7.11). A total of 16 
hydrogen bonds are formed between the Q axis interface, several of which are formed 
by Arg143 which forms six hydrogen bonds to Ala81 , ASp8\ Ser151 and Tyr155 (Figure 
7.12 c). The remaining hydrogen bonds are formed between residues Leu138 to Glu210 
Ser195 to ASp203 and also Arg205 to Alal82 and Glul83• Extensive van der Waals 
interactions are formed between the interface along with several hydrophobic packing 
interactions involving the residues Leu138 Leu139 Arg143 Tyr146 Tyr155 Val158 , , , , , , 
7.6.3 The R axis 
The smallest of the interfaces is that around the R-axis which involves 29 residues 
and His293 to pro306). The main interactions are formed between helix a8 and the N 
terminal loop region and their symmetry related; residues. A total of 5 hydrogen 
bonds are formed between Val185 to Ala294 and Gly96, Tyr250 to Ala298, Asn253 to 
Ser303 and Arg302 to Mee04. Hydrophobic packing interactions are formed by 6 
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7.7 Cofactor and inhibitor binding sites 
7.7.1 Triclosan binding site 
The electron density for the triclosan inhibitor within the TgENRlNAD+/triclosan 
complex was of very good quality and allowed for its unambiguous placement into the 
active site of both subunits (Figure 7.13a). The 4-chloro phenoxy ring of triclosan 
(ring A) interacts in a face to face manner with the NAD+ nicotinamide unit allowing 
1t-1t stacking interactions and the formation of van der Waals interactions with the side 
triclosan inhibitor forms one hydrogen bond to Tyr189. The 2,4-dichlorophenoxy ring 
of triclosan (ring B) is located within a pocket bounded by the peptide backbone of 
residues Leu 128 to Glyl3l, the pyrophosphate and nicotinamide moieties of NAD+ and 
by the side chains of Val 134, Met193, Ala231 and Ile235 (Figure 7.13b). 
7.7.2 NAD+ binding site 
Density for the entire nicotinamide adenine dinucleotide (NAD+) cofactor could be 
clearly seen for both subunits permitting its unambiguous identification (Figure 
7.14a). The adenine ring binds within a pocket formed by the main chain atoms of 
residues: Glyl6 to Alal8, Leu79 to Ala82 and Leu128 to Asn130 and the side chains of 
residues: Trp43, Leul28, Asn130, ASp80, and Asn152, One face of the adenine ring forms 
1t-1t stacking interactions with Trp43, with Leul28 making van der Waals interactions 
with the other, A hydrogen bond network allows for the binding and positioning of 
the NAD+ substrate into the active site (Figure 7.14 b). In both subunits the adenine 
ring is hydrogen bonded by the carbonyl of ASp80, The adenine ribose forms van der 
. Waals interactions with the main chain of Gly16 to Alal8 and the side chain residues of 
L 128 d T 43 Th h h . ak", 'th h 'h ' eu an rp, e pyrop osp ate mOIety m es mteractIOns WI t e mam c am 
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Figure 7.13. (a) Triclosan bound within the TgENR active site and its 
corresponding electron density 2Fobs-FcaIc map contoured at l.Oa. The NAO+ 
cofactor can also be seen packing in a face to face manner with the triclosan 
inhibitor. The model is coloured with yellow for carbon, blue for nitrogen, red for 
oxygen and green for chlorine. This figure is based on subunit A of the TgENR 
dimer. The figure was produced using the program TURBO-FRODO (Roussel et 
at., 1990) . 
Figure 7.13. (b) A stereo diagram of the triclosan binding site of subunit A of 
TgENR with the active site residues Tyr179, Tyr189, Lys197 and Phe243 labelled. The 
figure is coloured with yellow for carbon, red for oxygen, orange for phosphorous, 
blue for nitrogen and green for the chlorine atoms of triclosan and the sulphur atom 
of the active site Met. The figure was produced using the program TURBO-
FRODO (Roussel et at., 1990). 
Figure 7.14. (a) The NAD+ cofactor bound within subunit A of the TgENR act~ve 
site and its corresponding 2F obs - F calc electron density map contoured at 1. Ocr. The 
model is coloured with yellow for carbon, blue for nitrogen, red for oxygen and 
orange for phosphorous. The figure was produced using the program TURBO-
FRODO (Roussel et aI. , 1990). 
Figure 7.14. (b) A stereo diagram of the residues responsible for forming a 
hydrogen bonding network to the NAD+ cofactor in subunit A of TgENR. All the 
residues are labelled and coloured with yellow for carbon, blue for nitrogen, red for 
oxygen and orange for phosphorous. The hydrogen bonds are represented as red 
dashed lines. The figure was produced using the. program TURBO-FRODO 
(Roussel et aI. , 1990). 
Leul28 and Trp43. The pyrophosphate moiety makes interactions with the main chain 
of Glr2, Tyr23 and Ala231 and the sidechain atoms of ASpI9, Ser29, Ala231 and the di-
chloro ring of triclosan. Three hydrogen bonds are formed to the pyrophosphate group 
from the main chain nitrogen of Ala231 to the first phosphate and to the second 
"' 
phosphate from the side chain oxygen of Ser129 and the main chain nitrogen of Tyr23. 
Th ' . 'd 'b . £ k" . . h T 23 S 127 Al 129 e mcotmami e nose mOIety orms pac mg mteractIOns WIt: yr , er , a , 
Leul77, Lys197 and the bound inhibitor triclosan. Moreover one hydrogen bond is 
formed from the nicotinamide ribose to the main chain nitrogen of Leul28. The 
nicotinamide ring which is responsible for 1t-1t stacking interactions with the triclosan, 
forms two hydrogen bonds, one from its amide nitrogen to the main chain carbonyl of 
the Leu227 unit and a second from its amide oxygen of the main chain nitrogen of 
Leu227. In addition to the close packing interactions with the triclosan inhibitor the 
nicotinamide ring forms interactions to the side chain atoms of: Ty?3, Ser29, Ala224 
7.8 Similarities in the active site of TgENR and other ENRs 
Comparison of the high resolution structures of complexes of ENR with NAD+ and 
triclosan show that two waters are located within the ENR active site and whilst the 
resolution of the TgENR model does not permit their unambiguous identification 
superposition of PfENR shows that the waters in this structure lie very close to 
positive density within the final IFobs-1Fcalc map for the TgENR enzyme (Figure 
7.15). The role of these waters has been implicated in forming a proton relay 
mechanism to the bulk solvent ((Section 4.8)(Benach et al., 1998 & Filling et al., 
2002» 
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Figure 7.15. The TgENR active site with the 2Fobs - 1Fcalc electron density map 
shown in purple, contoured at 10' and the 1 Fobs - 1 F calc electron density map 
contoured at 30' coloured in green. The PfENR structure, coloured in blue is 
superimposed onto the TgENR with the two PfENR active site waters, shown as 
blue spheres being present in positive areas of the 1Fobs - 1Fcalc map. The TgENR 
structure is coloured with yellow for carbon, blue for nitrogen, red for oxygen and 
orange for phosphorous. The figure was produced using the program TVRBO-
FRODO (Roussel et al., 1990). 
Substrate modelling studies for both the butyryl-CoA and C16 fatty acid substrate in 
a manner as previously described for PfENR (Section 4.8) showed that the binding 
pocket for the C 16 fatty acid substrate which consists of the predominantly 
Tyr189 Met193 Lys197 Ala231 Ala232 Ile235 Phe243) shares both 100% sequence , , , , , , 0 
identity to PfENR but also strong structural conservation of the binding site. As with 
PfENR the modelled C-16 fatty acid substrate within TgENR makes close contacts to 
Tyr179 Phe243 and Ile235, with a significant movement of these residues being required 
for substrate binding. Modelling of the butyryl-CoA substrate showed that the base of 
the binding pocket which is formed by the residues: Val134, Tyr179, Tyr189, Met193, 
when compared to PfENR with a lower sequence conservation across the ENR family 
with approximately 30% sequence identity. 
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CHAPTER 8 
Sequence and structural comparisons between the ENR family 
8.1 Structural comparisons across the ENR family 
In order to investigate the similarities and differences between members of the ENR 
family the ENR structures for the B.napus, E.coli, T.gondii and P jalciparum in 
complex with NAD+ and triclosan were used for comparative studies. By 
superimposing all of the ENR structures onto each other (Table 8.1) it was possible to 
see that all have a very similar core structure made up of a well conserved central 
parallel ~-sheet with strong positional conservation of several flanking a-helices in 
particular the helices 1,4,5,6 and 9 (TgENR structure numbering) (Figure 8.1). The 
Ca atom r.m.s.d variation of each of the ENR structures when superimposed onto 
each other is low with the highest difference being between the EcENR to the B.napus 
and apicomplexan ENR structures. A strong similarity was noted between the two 
members of the apicomplexan ENR family with an average r.m.s.d value for the Ca 
atoms being o.sA. The closest members of the ENR family based on the currently 
available structures are between the T.gondii and B.napus ENR enzymes with an 
r.m.s.d value for the Ca atoms of o.6A. The plant and apicomplexan enzymes both 
contain significant inserts both before and after ~3 compared to the bacterial enzymes 
(Figure 8.2). These inserts form extended loops including a small additional helix 
which runs parallel to a2. Analysis of the structure based sequence alignment shows 
the vast majority of conserved residues lie within the active site and NAD+ binding 
pocket (Figure 8.2 and Figure 8.3). 
8.2 Surface comparisons of the ENR family 
In order to investigate the surface characteristics of each of the solved ENR structures 
the program GRASP (Nicholls et al., 1991) was used to calculate the surface potential 
for the apicomplexan P jalciparum and T.gondii ENRs and the representative plant 
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Table 8.1. A table to show the r.m.s.d of all Co, atoms upon superposition of the 
ENR structures currently available. All values were calculated using the program 
Lsqkab (Kabsch, 1976) and are in A. 
Figure 8.1. The superposition of the ENR family of enzymes with the Tgondii, 
P falciparum, B.napus and E.coli ENR enzymes coloured in green, yellow, blue and 
magenta, respectively. (a) The superposition of the Tgondii and P falciparum ENR 
enzyme. (b) The superposition of the Tgondii, P falciparum and B.napus ENR 
enzyme. (c) The superposition of the Tgondii, Pfalciparum, B.napus and E.coli 
ENR enzyme. All figures were produced using the graphics program Pymol (Delano, 
2002). 
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Figure 8.2. A structure based sequence alignment of ENR from P jalciparum, 
T.gondii, B.napus, Mtuberculosis and E.coli. The numbering and secondary 
structural elements are for the P jalciparum enzyme with blue cylinders 
representing a-helices and red arrows for ~-strands. Those residues in black box 
and reverse type are fully conserved across the five sequences. The sequences were 
aligned using ClustalW (Higgins & Thompson, 1994) and the figure was produced 
using the program Alscript (Barton, G.J. 1993). 
Figure 8.3. A stereo view of the TgENR enzyme with those residues fully 
conserved between the B.napus, E.coli, Mtuberculosis, T.gondii and P jalciparum 
ENR structures in red. Those residues for which there is strong sequence identity 
(>80%) are shown in green. The figure was producedysing the graphics program 
Pymol (Delano, 2002). 
and bacterial ENR enzymes from B.napus and E.coli, respectively. (Figure 8.4). 
Analysis of the surface representation shows that due to the presence of the insertion 
before and after p3 within the plant and apicomplexan ENR enzymes (Section 8.1) a 
large groove is formed on the top and bottom of the ENR tetramer. Moreover the 
groove forms areas of negative electrostatic charge, can be seen by looking down the 
Q-axis (Figure 8.4). 
A striking feature of the surface potential calculations is the overall positive charge 
of PfENR when compared to the T.gondii, B.napus and E.coli ENR enzymes, all of 
which are more neutral. This observation is consistent with the calculation of the pI 
value for each of the ENRs which are 5.4, 5.6, 6.3 and 8.2 for the B.napus, E.coli, 
T.gondii and P jalciparum enzymes, respectively. One possible explanation may JJe 
that in order to maintain both a hydrophilic exterior and a high A + T gene content a 
selective pressure must be placed upon those amino acids which are both hydrophilic 
and have a low G+C codon content which includes the positively charged lysine. 
8.3 Genetic comparisons of the plant and apicomplexan ENR enzymes 
The striking difference in the surface potential and A + T content of PfENR in 
comparison to other members of the ENR family led to an investigation into the 
patterns of codon usage for the T.gondii, B.napus and P jalciparum ENR enzymes 
which have an ENR gene A+T content of 42,54 and 72%, respectively. A sequence 
alignment of the P jalciparum, T.gondii and B.napus ENR enzymes at both the amino 
acid and DNA level showed approximately 40% sequence identity at the amino acid 
level with a much larger differences between the sequences at the DNA level with 
only 6% codon identity (Figure 8.5). Analysis of the percentage of each amino acid 
within the different ENR sequences revealed a strong bias within P jalciparum for 
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and bacterial ENR enzymes from B.napus and E.coli, respectively. (Figure 8.4). 
Analysis of the surface representation shows that due to the presence of the insertion 
before and after ~3 within the plant and apicomplexan ENR enzymes (Section 8.1) a 
large groove is formed on the top and bottom of the ENR tetramer. Moreover the 
groove forms areas of negative electrostatic charge, can be seen by looking down the 
Q-axis (Figure 8.4). 
A striking feature of the surface potential calculations is the overall positive charge 
of PfENR when compared to the Tgondii, B.napus and E.coli ENR enzymes, all of 
which are more neutral. This observation is consistent with the calculation of the Pi 
value for each of the ENRs which are 5.4, 5.6, 6.3 and 8.2 for the B.napus, E.coli, 
T.gondii and P jalciparum enzymes, respectively. One possible explanation may be 
that in order to maintain both a hydrophilic exterior and a high A + T gene content a 
selective pressure must be placed upon those amino acids which are both hydrophilic 
and have their respective codon low in G+C. These residues would include lysine. 
8.3 Genetic comparisons of the plant and apicomplexan ENR enzymes 
The striking difference in the surface potential and A+T content of PfENR in 
comparison to other members of the ENR family led to an investigation into the 
patterns of codon usage for the Tgondii, B. napus and P jalciparum ENR enzymes 
which have an ENR gene A+T content of 42,54 and 72%, respectively. A sequence 
alignment of the P jalciparum, Tgondii and B.napus ENR enzymes at both the amino 
acid and DNA level showed approximately 40% sequence identity at the amino acid 
level with a much larger differences between the sequences at the DNA level with 
only 6% codon identity (Figure 8.5). Analysis of the percentage of each amino acid 
~ithin the different ENR sequences revealed a strong' bias within P jalciparum for 
98 
R-axis P-axis Q-axis 
Figure 8.4. A surface potential representation for the P jalciparum, Tgondii, 
B.napus and E.coli ENR enzymes as seen down the P, Q and R axes. All four 
structures were placed on the same scale as shown at the top of the figure and 
coloured by electrostatic charge ranging from -35.0 in red to +35.0 in blue 
KcaV[mol·electron]. The surface potential figures were produced using the program 
GRASP (Nicholls et al., 1991). An approximate view of each of the ENR enzymes 
down the R-axes without a surface representation is shown on the left hand side and 
were created using the program Pymol (Delano, 2002). 
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Figure 8.5. A sequence alignment for both the amino acid and gene sequences for 
the P Jalciparum, Tgondii and B. napus ENR enzyme sequences. Those residues 
which are fully conserved are highlighted by a red box, those which are conserved 
between the P Jalciparum and Tgondii sequences are highlighted by a green box, 
those residues similar between the PJalciparum and B.napus sequences are 
highlighted by a yellow box and those residues conserved between the Tgondii and 
B.napus sequences are highlighted by a blue box. . Those codons which are 
conserved between two sequences are in red and those fully conserved are in blue. 
certain amino acids (Figure 8.6). This is exemplified by the asparagine residue which 
makes up approximately 12% of all residues within PfENR, in contrast to around 4% 
for the T.gondii and B.napus ENR enzymes. Furthermore the frequency of the small 
hydrophobic residue alanine is approximately 6%, 14% and 13% for the Pfalciparum, 
T.gondii and B.napus ENR enzymes, respectively. Analysis for the frequency of 
larger hydrophobic residues shows a significant reduction in the use of valine and to a 
lesser extent leucine, but an increase in isoleucine within PfENR when compared to 
TgENR and BnENR. Moreover the overall content of the charged residue lysine in 
PfENR is almost double the value seen for the B.napus and T.gondii ENR enzyme, 
which in part is responsible for the increase in positive charge on the surface of 
PfENR. Examination of the codon frequency for each of the amino acids sh~ws 
P falciparum to have a large bias for the A + T rich codons, exemplified by the 
histidine residue which can be encoded for by either the CAC or CAT codon and yet 
all of the histidines within PfENR are encoded by the CAT codon (Figure 8.7). 
These observations are consistent with those reported by Singer et al., 2000, which 
suggested that the amino acid composition of a protein is heavily influenced by the 
A+T percentage of the organism's genome and that a correlation between mean 
nucleotide content and amino acid content can, in the case of 22 tested sequences be 
plotted in a linear fashion (Figure 8.8). The P falciparum, T.gondii and B.napus 
sequences all fall upon the line when considering the observed distribution correlating 
an organisms genomic A + T ratio and the frequency of amino acids which are encoded 
for by G+C rich (Gly, Ala, Arg and Pro) and A+T rich (Phe, Tyr, Met, lIe, Asn and 
Lys) codons. For the PfENR sequence the inserted loop, due to its high asparagine 
and lysine composition is responsible for an Increase in A + T rich codons of 
approximately 4%. 
99 
16 
14 
12 r-
10 r-
r- - - - -
6 
- - -
4 
- - - - l- I---
-
rrt IT ~ l ,-----nn rIl o 
A CD E F G H K M N P Q R S T V W Y 
ImlnolCld 
Figure 8.6. The amino acid composition of the mature ENR enzymes from 
P jalciparum, T.gondii and B.napus coloured in blue, red and yellow, respectively. 
The amino acids are displayed as one letter codes along the x axis with the overall 
protein percentage of each residue along the y-axis. 
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Figure 8.7. The codon frequency within the ENR enzyme gene for the 
P jalciparum, Tgondii and B.napus ENR enzyme coloured blue, red and yellow, 
respectively. The amino acid which each graph represents is shown above and the 
codon used is shown along the x-axis with the percentage occurrence along the y-
axis. 
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Figure 8.8. A graphic representation as to the way in which the A + T percentage of a genome 
can influence the amino acids encoded for within a protein. The corresponding approximate 
values for the P jalciparum, B.napus and Tgondii ENR enzymes are shown as blue, yellow 
and red dots, respectively. The figure is adapted from Singer et aI., 2000. 
8.4 Comparisons between the Plasmodium ENR family 
As a continuation of the study of the ENR family the DNA and amino acid sequences 
were aligned for the ENR enzymes of all the currently sequenced Plasmodium species 
(Figure 8.9). P Jalciparum and P. vivax are responsible for human malaria, P. berghei, 
P.Chabaudi and P.yoelii are responsible for rodent malaria and P.Knowlesi is 
responsible for malaria within monkeys. The A+T content of these ENR genes is 
approximately 72% except for the P.knowlesi and P. vivax which are lower at 57 and 
52%, respectively. Whilst only 12% of codons are conserved between species the 
overall amino acid sequence identity is 60%. 
Analysis of the ENR enzyme from the Plasmodium family shows that a sequence 
insert with respect to the plant and bacterial ENR enzymes is maintained across .the 
family, however both the size and composition of the insert varies (Figure 8.9). One 
characteristic of the insert which is maintained throughout all insert sequences is the 
conservation of a lysine residue as the second residue of the insert. An additional 
feature of this insert is the presence of an SGE motif which is conserved in all but one 
of the Plasmodium sequences, the role of which is yet to be determined. The presence 
of such inserts is not unusual within Plasmodium proteins and a comparative study 
showed that Plasmodium proteins can be up to 50% longer than their yeast 
orthologues (Aravind et al., 2003). It had been previously reported that the presence 
oflow complexity inserts may be required to raise the A+T content of a specific gene 
(Pizzi & Frontali, 2001) and in the case of the P Jalciparum ENR sequence the 
presence of the insert results in a 4% increase in the A+T content. However the 
Plasmodium chabaudi, yoelii and beghei which all have approximately the same ENR 
gene A+T content as P Jalciparum contain a much smaller insert. The role for these 
l~w complexity inserts have in some cases been assigned to a catalytic or important 
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Figure 8.9. A sequence alignment for both the amino acid and gene sequences for the 
Plasmodium: Jalciparum, knowlesi, vivax, chabaudi, yoelii and berghei ENR enzyme 
sequences. Those residues which are fully conserved are highlighted by a blue box, 
those which are conserved between five sequences, four sequences and three 
sequences are highlighted by a red, yellow and green box, respectively. Those codons 
which are conserved between all sequences, five seql;lences and four sequences are 
coloured in blue, red and yellow, respectively. 
structural role within an enzyme (Kappes et at., 1995, Yuvaniyama et at., 2003 & 
Clarke et at., 2003). There has been speculation that the role of low complexity 
inserts may produce a variable antigenic landscape in order for the parasites to avoid 
an immune response (Anders, 1986). PfENR is however intracellular and as such 
would not come into contact with any immune response making the role of the PfENR 
insert with respect to an immune response unlikely. 
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CHAPTER 9 
Inhibitor binding and modelling studies for the apicomplexan T.gondii and 
P.falciparum ENR enzyme 
9.1 ENR is the target for the development of novel antiparasitic agents 
Sequence analysis and modelling studies (section 3.2) along with the subsequent 
structure determination of P.faiciparum and T.gondii ENR in complex with triclosan 
suggested that these enzymes would be strongly inhibited by this compound and that 
it might act to inhibit parasite growth in vivo. Therefore, in collaboration with the 
group of Prof Rima Mcleod at the Department of Visual Sciences at the University of 
Chicago, the ability of triclosan to inhibit ENR and to retard the growth of these 
parasites was tested. The results from these inhibition assays showed that triclosan 
acts as an ENR inhibitor and arrests the growth of Pfaiciparum and T.gondii in 
culture with an ICso of 150ng/ml and 62ng/ml, respectively (McLeod et ai., 2001, 
Figure 9.1). Subsequently this finding has been reported for both TgENR and PfE~R 
by several groups (Kapoor et ai., 2001 & Surolia et ai., 2001). 
9.2 Drug delivery within apicomplexan parasites 
Although triclosan has been shown to be a good inhibitor of the apicomplexan 
T.gondii and Pfaiciparum ENR enzymes consideration in the development of new 
novel antiparasitic drugs must be given to the problems in delivering the drugs to their 
appropriate target. In targeting pathways unique to the apicoplast the drug must not 
only gain entry into host cells, but cross the parasitophorous vacuole and the four 
membranes surrounding the apicoplast organelle. This is made more difficult for the 
T.gondii bradyzoites which reside in cysts composed of both host and parasite 
constituents. 
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Figure 9.1. Inhibition of the apicomplexan parasite T.gondti'by triclosan. (a) The 
host cells show little change in thymidine uptake after the addition of triclosan. (b) 
The uptake of uracil by the T.gondti' parasite is reduced after the addition of 
triclosan, 4 days after the initial infection. The ICso was approximately 62ng/ml. 
The effect of triclosan was increased over time such that after 125 ng/ml was added 
to a culture of T.gondti; percentage inhibition on day1 was 20% and 72% on day 4. 
For pyrimethamine/sulfadiazine these values for day 1 and 4 were 63% and 100% 
respectively. 
Abbreviations: Rh, RH strain of T.gondti' within fibroblasts; No RH is control 
with fibroblasts alone; DMSO is the fibroblast cells alone but with the highest 
DMSO concentration used for triclosan administration; PIS, a positive control of 
fibroblast cells with T.gondti' and pyrimethamine and sulfadizine; CPM, counts per 
minute. 
Inhibition levels were determined by measuring the the CPM (counts per minute) 
of radio labelled thymidine by host cells and ·uracil by the T.gondti' parasite. 
Inhibition of either host cells or parasites would result in a decrease in radio 
labelled thymidine or uracil uptake and as such result in a decrease in counts per 
minute. The figure is taken from McLeod et aL, 2001. 
9.2.1 Poly arginine tails 
Studies on the nuclear transcription activator protein (Tat) from the RIV type 1 virus 
showed it was able to cross the plasma membranes of cells in an energy dependent 
fashion. . Of particular interest was a region of highly basic amino acids 
(RKKRRQRRR) which assisted transport across membranes (Wender et al., 2000). 
Furthermore it has been shown that polymers of six or more arginine amino acids 
were more efficient at crossing membranes than polymers of histidine, lysine or 
ornithine. Cellular uptake of these polymers was not inhibited by low temperatures 
but was inhibited by preincubation of the cells with sodium azide, indicative of an 
energy dependent transport system (Mitchell. 2000). Analysis of the mode of 
triclosan binding in TgENR suggested that attachment of a linker arginine via ~he 
phenolic OR would prevent inhibition of the enzyme when the linker is attached but 
should the linker be removed then triclosan would be free to bind. The triclosan 
inhibitor was attached to the arginine linker by the hydroxyl group forming a 
hydrolysable ester linkage or a non releasable ether linkage (Figure 9.2d, e). 
Furthermore studies carried out by the collaborating laboratory of Prof Rima McLeod 
showed that the addition of a releasable eight residue arginine linker to the 
antimicrobial inhibitor triclosan (TrS) improved the speed of delivery and enabled 
triclosan to enter both the extracellular and intracellular T.gondii tachyzoites and 
bradyzoites (Samuel et al., 2003, Figure 9.2a, b & c). One limiting factor in the use 
of several ENR inhibitors is that their ability to mimic the lipophilic substrate makes 
them inherently hydrophobic. This is true with triclosan which must be dissolved in a 
solvent such as DMSO before addition to samples, severely limiting its medical 
applications. The addition of a releasable arginine linker not only allows for the 
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Figure 9.2. (a) An R8 conjugate of triclosan linked in either a releasable or non 
releasable manner having little or no toxic effect on host cell replicataion as 
measured by 3H thymidine uptake. The releasable triclosan does however have an 
effect on the 3H uracil uptake by toxoplasma cells. For both graphs the control Cis 
Tgondii-infected host cells in medium and PIS represents Tgondii host cells treated 
with O.IJlglml pyrimethamine and sulfadiazine 25 Jlg/ml which inhibits parasite 
growth. (b) The administration of releasable r8-triclosan (Tr8) and triclosan (T) "in 
vivo" to Tgondii tachyzoites. The releasable r8-triclosan but not triclosan alone 
reduces parasite numbers significantly 5 days after challenge. (e) Fluorescein and 
DIC microscopy images showing the uptake of labelled Tr8 by T gondii 
tachyzoites and excysted bradyzoites and the inhibition of uptake of arginine 
triclosan conjugates by azide indicative of an energy dependant transport system 
(Scale bar = 10 Jlm.). (d) and (e) Representation of triclosan bound to an eight 
residue arginine linker by a hydrolysable ester linkage (d) and by a non releasable 
ether bond (e). 
efficient transport over membranes but also increases the hydrophilic nature of the 
drug. 
9.3 The mode of inhibitor binding for E.coli ENR 
As part of a study of inhibitor binding to ENR from the apicomplexan parasites 
T.gondii and P jalciparum it is important to identify those residues which may be 
critical to inhibitor binding in order to maximise drug binding and minimise the 
chance of the development of drug resistance. Although the structure of P jalciparum 
and T.gondii ENR in complex with NAD+ and triclosan has been solved it is also 
important to characterise the range of conformations that these enzymes can adopt on 
inhibitor binding. The structure of EcENR is useful in this regard as it has 1:?een 
solved in complex with a range of inhibitors (triclosan, diazaborines, imidazole, 
benzamide and acrylamide based aminopyridine derivatives). This information can 
then be used to evaluate inhibitor development for the TgENR and PffiNR enzymes. 
9.4 Plasticity on inhibitor binding in E.coli ENR 
9.4.1 Main chain movements within EcENR upon inhibitor binding 
In order to evaluate the residues which are critical to inhibitor binding and which may 
adopt different conformations in EcENR, all of the deposited pdb files that were 
derived from the analysis of crystals formed by co-crystallisation of the ENR enzymes 
with inhibitors were compared. Restricting the study to these structures should ensure 
that any conformational change which may occur on inhibitor binding would be 
allowed to develop fully. Of the EcENR inhibitor complexes only those of the 
diazaborines, triclosan and compound 29 were solved through co-crystallisation 
(~aldock et al., 1996, Levy et al., 1999 & Seefeld et al.:2002). In order to investigate 
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significant main chain movements within EcENR upon inhibitor binding the program 
Escet (Schneider, 2002) was used to compare the position of the Ca atoms between 
the EcENRlNAD+ complex and any co-crystal inhibitor complex (Figure 9.3). 
Comparisons between the EcENRlNAD+ complex and the various EcENR inhibitor 
complexes showed three significant regions of difference between the various 
complexes (41 to 57, 190 to 223 and 249 to 259). Of these regions of flexibility that 
between residues 190 to 223, which corresponds to helix a6 and its flanking residues 
shows the greatest movement. Comparison of the region 190 to 223 within the 
various complexes of EcENR shows it to adopt a variety of conformations depending 
on the nature of the inhibitor bound. In the structure of EcENRlNAD+ this region 
forms a disordered loop with no interpretable density for residues 196 to 205, 
however on binding of the diazaborine family of drugs this region adopts either an 
ordered loop (Baldock et al., 1996) or an helical fold (Levy et al., 2001) as seen for 
either tric10san or compound 29 (Figure 9.4). Furthermore analysis of the position of 
the helix formed in the tric10san and compound 29 complexes shows it to adopt a 
different position in each complex in order to maximise the van der Waals interactions 
formed between the ENR enzyme and its bound inhibitor (Figure 9.4 & Figure 9.5). 
This observation is consistent with those previously reported (Roujeinikovab et al., 
1999 & Qiua et al., 1999). 
9.4.2 Sidechain movements within E.coli ENR u~on inhibitor binding 
Analysis of EcENR in complex with tric1osan, thieno-diazaborine and compound 29 
showed that significant changes in the conformation of the sidechains was restricted 
to residues 190-223 which form part of the protein which displayed the greatest 
fle.xibility in inhibitor binding (Figure 9.6). In EcENR inhibitors are bound within a 
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Figure 9.3. Analysis of mainchain movement as a result of inhibitor binding 
between the EcENRlNAD+ complex and the EcENRlNAD+/inhibitor complexes 
with (a) triclosan (b) compound 29 (c) thieno diazaborine and (d) benzo 
diazaborine using the program Escet (Schneider, 2002). For each complex a 
difference matrix shows movements within the range of 0.5 - l.oA (left) and 1.0 
-5.oA (right). The EcENR structure is displayed at the right of the Escet plot and 
coloured red for areas that undergo conformational change upon inhibitor binding. 
Figure 9.4. Changes in the substrate binding helix upon the binding of different 
inhibitors. The figure shows E.coli ENR (a) with no bound inhibitor, and bound to 
the inhibitors (b) compound 29, (c) thieno-diazaborine and (d) triclosan. In all 
figures the NAD+ cofactor and inhibitors are coloured with yellow for carbon, blue 
for nitrogen, red for oxygen, green for chlorine, orange for sulphur and purple for 
phosphorus in NAD+ and boron in thienodiazaborine. The figure was produced 
using the program Pymol (Delano, 2002). 
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Figure 9.5. Analysis of main chain differences between the EcENRlNAD+/triclosan 
and EcENRlNAD+/compound 29 complexes using the program Escet (Schneider, 
2002). A difference matrix shows movements within the range of 0.5 - 2.oA (left) 
and 1.0 - 5.oA (right). The EcENR structure is displayed above the Escet plot and 
coloured red for areas that undergo conformational change upon inhibitor binding. 
Figure 9.6. A stereo view of the EcENR active site in complex with triclosan 
(red), compound 29 (black) and thieno diazaborine (blue). For simplicity the 
NAD+ cofactor, which occupies the same position in all complexes is only shown 
for the compound 29 complex and is coloured black. The figure was produced in 
TURBOIFRODO (Roussel et al., 1990). 
pocket formed on one side by helix a4 and as and show no significant sidechain 
movement, except for very small changes of LeulOO which lies in the ~4 - a4100p and 
Metl59 at the start of as. A surface representation of the inhibitor binding site for 
EcENR in complex with NAD+ and the inhibitors thienodizaborine, triclosan and 
compound 29 showed that the top of the inhibitor binding pocket formed by helix a4 
remains unchanged in the different complexes. However the base of the inhibitor 
binding pocket which in part is formed by helix a6 and a7 (190 to 223), changes to 
adapt to different sized inhibitors both in size and shape (Figure 9.7). 
9.4.3 Similarities between inhibitor and substrate binding in EcENR 
Analysis of the mode of substrate by a modelled butyryl-CoA within EcENR shows 
that triclosan and the imidazole based ENR inhibitors occupy the same space (Figure 
9.8). However the other inhibitors occupy additional space at the top of the substrate 
binding pocket formed by helix a6 and a7 in EcENR (Figure 9.8). Interestingly, 
modelling of the larger C-16 fatty acid in EcENR based on the observed position in 
the structure of the MtENRlNAD+/CI6 fatty acid complex (Rozwarski et aI., 1999) 
showed that the larger inhibitors such as the aminopyridine based inhibitors bind in a 
position equivalent to the C-16 fatty acid substrate and as such they may make contact 
to possible key substrate binding site residues (Figure 9.8). Furthermore these areas 
have been shown to have plasticity within the EcENR structure upon binding of the 
different inhibitors. One possibility is that the conformational differences seen on 
inhibitor binding may be a mimic of flexibility within the active site to adapt to and 
handle different length substrates. However analysis of the structure of 
MtENRlNAD+ reveals that the substrate binding helix (196 to 219), which is at an 
equivalent position as a6 in EcENR is formed in the absence of an inhibitor or 
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Figure 9.7. A surface representation of the E.coli ENR active with (a) no 
inhibitor bound, (b) compound 29 bound, (c) triclosan bound and (d) thieno-
diazaborine bound. All inhibitors are coloured. with yellow for carbon, blue for 
nitrogen, red for oxygen, green for chlorine and orange for boron and the NAD+ 
cofactor is shown in orange. The secondary structural elements are labelled where 
visible for the EcENRlNAD+ complex. (e) The EcENRlNAD+ complex in an 
equivalent view as figure a, b, c and d but without a surface representation. All of 
the secondary elements are numbered except for 0.6 which is not present within 
the EcENRlNAD+ complex but is present in many EcENR inhibitor complexes. 
The figure was produced using the program Pymol (Delano, 2002). 
(a) 
(c) (d) 
(e) 
(h) 
Figure 9.S. The EcENRlNAD+/tric1osan complex with various inhibitors modelled 
into the active site. (a) C-16 fatty acid substrate, (b) butyryl substrate, (c) acrylamide 
based inhibitor, (d) tric1osan, (e) compound 29, (f) imidazole based inhibitor and (g) 
benzamide based inhibitor. (h) The overlay onto the C16 fatty acid substrate 
coloured yellow, with compound 4, benzamide and imidazole based inhibitors 
coloured in purple, white and blue respectively. EcENR is coloured with magenta 
for a-helices, blue for rJ-strands and for the inhibitors and NAD+ cofactor yellow for 
carbon, red for oxygen, blue for nitrogen, purple for phosphorous, orange for 
sulphur and green for chlorine. The figure was produced using the graphics 
program Pymol (Delano, 2002). 
substrate. Interestingly companng the MtENRlNAD+ complex both bound and 
unbound to a C 16 fatty acid substrate reveals that the substrate binding helix is shifted 
by up to 4.oA demonstrating the flexibility present within this region of the ENR 
enzyme to bind a large fatty acid substrate. 
9.5 Comparisons between the T.gondii and P.falciparum ENR active sites 
Analysis of the inhibitor binding site in PfENR and TgENR shows only one sequence 
difference at position 131 (TgENR numbering) in which Ala is replaced by Gly. This 
substitution does not however have a significant effect on the shape of the binding 
pocket as the sidechain of the alanine points away from the pocket. However nearby 
on the lip of the pocket a shift in the main chain occurs caused by the substitutio,n of 
ProI32 which is replaced by Lys within PfENR (Figure 9.9 a). Interestingly 
comparing the Pf and TgENR complexes with triclosan the position of a7 and a8 
(equivalent to a6 and a7 in EcENR) can be seen to be slightly different again 
suggesting that this region readily adapts different positions(Figure 9.9 b). A 
difference in the sidechain rotamers of residues Ile237 and Ile283 in PfENR compared to 
TgENR also causes slight changes in the inhibitor binding pocket (Figure 9.9 a). 
Given the similarity between Pf and TgENR the modelling of other inhibitors was 
carried out on the TgENR enzyme. 
9.6 Inhibitor modelling within T.gondii ENR 
To examine how the various inhibitors can be accommodated in the TgENR enzyme 
the structures of the EcENRlNAD+/inhibitor complexes were superimposed. A 
dominant feature of inhibitor modelling is that compound 29 and the related 
benzamide and acrylamide based inhibitors all form steric clashes within the binding 
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Figure 9.9. a A stereo diagram showing a comparison between the inhibitor binding 
site of the PfENRlNAD+/triclosan (blue) and TgENRlNAD+/triclosan (red) 
complexes. The NAD+ and triclosan are coloured with yellow for carbon, blue for 
nitrogen, red for oxygen, green for chlorine and purple for phosphorous. The figure 
was produced using the graphics program TURBOIFRODO (Rousell et aI., 1990). 
Figure 9.9. b A comparison between the . inhibitor binding loop of the 
PfENRlNAD+/triclosan (blue) and TgENRlNAD+/triclosan (red) complexes. The 
NAD+ and triclosan are coloured with yellow for carbon, blue for nitrogen, red for 
oxygen, green for chlorine and purple for phosphorous. The figure was produced 
using the graphics program Pymol (Delano, 2002). 
site (Figure 9.10) which primarily involves Phe243• However were the TgENR 
enzyme to show the same plasticity on inhibitor binding as has been observed with 
EcENR the clash would be partially relieved. One possible exception may be Phe243 
which forms the start of helix a8 in TgENR, which although in an area shown to be 
flexible within EcENR, a significant main chain movement may only partly reduce 
the steric hindrance caused by the sidechain aromatic ring and a steric clash may only 
be removed by movement of the sidechain into allowable XI-X2 values (Figure 9.11). 
Preliminary kinetic studies of inhibition of TgENR by Prof Sean Prigge (Johns 
Hopkins Bloomberg School of Public Health) showed compound 4, which is closely 
related to compound 29 to be an effective inhibitor of TgENR, but with a 1Cso value 
of approximately I to 10 JlM (Prigge. S., Personal communication) compared to 0.06 
JlM for EcENR ((Table 1.1)(Seefeld et al., 2003)). This lower binding affinity may 
be a direct result of steric hindrance within the TgENR enzyme binding site but 
without a crystal structure of either PfENR or TgENR in complex with compound 4 
or a related inhibitor it is difficult to make reliable conclusions on the mode of 
inhibitor binding 
9.7 The Pf and Tg ENRs have a larger binding pocket 
A comparison of the inhibitor binding pockets for the E.coli, T.gondii and 
P jalciparum ENR enzymes showed a methionine in the bacterial enzymes (Met206 in 
EcENR) is substituted by an alanine residue within the. apicomplexan ENR enzymes 
(Figure 5.1). Sequence analysis of the ENR family shows that the bacterial and plant 
ENR sequences all contain a bulky hydrophobic residue (Met, Leu or He) but the ENR 
enzymes from T.gondii, Eimeria and the Plasmodium family have a fully conserved 
alanine residue. This sequence change produces an increase in space at the base of 
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(a) Imidazole (b) Benzamide 
(c) Benzo diazaborine (d) Acrylamide 
(e) Compound 29 (I) Triclosan 
Figure 9.10. a-f A surface representation of the TgENRlNAD+/triclosan complex 
active site with various ENR inhibitors modelled in. The active sites surface is 
represented in blue and all inhibitors are coloured with yellow for carbon, blue for 
nitrogen, red for oxygen, green for chlorine, orange for sulphur and purple for boron. 
(g) The TgENRlNAD+ complex in an equivalent view as figure a-f but without a 
surface representation. All of the secondary elements are numbered. The NAD+ 
cofactor is coloured orange. In the modelled complexes the acrylamide and 
benzamide based inhibitors can be seen to penetrat~ the surface of the enzyme 
binding pocket. The figure was produced using the graphics program Pymol 
(Delano, 2002). 
Figure 9.11. The TgENR structure with compound 4 modelled into the active site. 
The position of the Phe243 residue in the solved structure is shown in magenta and 
can be clearly seen to clash with the inhibitor. Phe243 is also shown in an 
additionally allowed conformation which is not present within the TgENR 
crystallographic structure but would remove the steric clashing with the inhibitor 
coloured blue. The inhibitor is coloured yellow for carbon, blue for nitrogen and 
red for oxygen. The figure was produced using the graphics program Pymol 
(Delano, 2002). 
the binding pocket and reduces the van der Waals packing interactions with the 
triclosan inhibitor in comparison to EcENR (Figure 9.12). The production of a 
triclosan analogue which contains an additional atom at this position may allow for 
the van der Waals contacts to be optimised improving inhibitor binding. As most 
drug screening programs against the ENR enzyme have currently been based on 
enzymes of bacterial origin this suggests that the increase in binding pocket space has 
not yet been utilised in the development of lead compounds. Comparisons of the 
superimposed structures of the various drug complexes would appear to confirm this 
(Figure 9.13). Interestingly, recent studies have suggested that triclosan is a more 
potent ENR inhibitor after the removal of the two chlorine atoms on the di-chloro 
ring, improving the affinity for ENR by approximately 7 fold more than triclqsan 
((Sivaraman et al., 2004)(Figure 9.14, table 9.1)). However the replacement of the 
chlorine atom on the chI oro-phenoxy ring of triclosan by either a fluorine or methyl 
group caused a decrease in the affinity towards the EcENRlNAD+ complex 
(Sivaraman et al., 2004). These observations may suggest that small changes on the 
chloro-phenoxy ring of triclosan which introduce subtle changes in the electronic and 
steric properties may reduce the affinity of triclosan to ENR. Importantly, although 
there is very strong sequence conservation across the apicomplexan family of an 
alanine residue at the base of the triclosan binding pocket, this conservation is not 
maintained across the ENR family and as such an alanine residue is not essential for 
catalysis or substrate binding and the chance of a mutation causing drug resistance 
through steric hindrance may be increased. 
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Figure 9.12. Representative van der Waals interactions within the ENR active 
site of Ecoli, P falciparum and Tgondii. The van der Waals surface of the 
triclosan inhibitor is shown in blue and the van der Waals surface for the ENR 
enzyme active site residues is shown in red. All figures are coloured with yellow 
for carbon, red for oxygen, blue for nitrogen and gr~en for chlorine. The figure 
was produced in the graphics program TURBOIFRODO (Roussel et aI., 1990). 
Figure 9.13. The TgENR inhibitor binding site with the modelled inhibitors 
triclosan, benzodiazaborine, compound 29 and the acrylamide, benzamide and 
imidazole based inhibitors coloured yellow, gold, dark blue, magenta, orange and 
light blue, respectively. The increase in space within the TgENR binding sitein 
contrast to the bacterial ENR enzymes at the base of the pocket is shown with a 
star. The NAD+ cofactor is coloured with yellow for carbon, blue for nitrogen and 
red for oxygen. The figure was produced using the graphics program Pymol 
(Delano, 2002). 
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Figure 9.14. The structural formulae for several triclosan derivatives, 
produced using the program Isis draw. 
Compound MIC E.coli MIC S.aureus 
(1l2/ml) (1l2/ml) 
Triclosan (A) 0.3" :$;0.06b 
B 3.7" 
-
C 0.07" 
-
D 0.6" 
-
E 1.0" 
-
F 2.0' 
-
G >40' 
-
H >100" 
-
Hexachlorophene >64e 1e 
Table 9.1. The MIC values (f..lg/ml) for the triclosan derivatives given 
in Figure 9.14. The values are taken from a Sivaraman et al., 2004, b 
Miller et al., 2002 and c Heath et al., 2000. 
9.8 The possible development of resistance to new ENR inhibitors 
9.8.1 Sequence conservation of residues involved in inhibitor binding 
Analysis of the sequence conservation for those residues shown to be within 4A of the 
compound 29 inhibitor in complex with EcENR showed that of the 11 residues 
.. 
identified (Gly93, Phe94, Ala95, LeulOO, Tyr146, Tyr156, Met159, Alal96, Ile200, Lys201 and 
Met206) three residues are not conserved and may be hot spots for sequence variation 
(Met206, Lys201 and Leu1oo) ((Figure 9.15a)(Figure 5.1». In contrast of those 
residues which are within 4A of the inhibitor tric10san in the EcENR tric10san 
(Figure 9.15b) all are either fully or strongly conserved. Seven residues form 
packing contacts with both triclosan and compound 29 (Gly93, Phe94, Ala95, Tyr146, 
Tyr156, Alal96 and Ile200). 
9.8.2 Reported resistance of the ENR enzyme to triclosan 
Although tric10san has been used in a variety of household products few cases of 
tric10san resistant bacterial strains have been reported. However tric10san resistance 
can occur through both the overexpression of the FabI gene and as a result of amino 
acid changes in ENR (Fan et at., 2002). Several mutation within s'aureus ENR have 
been shown to decrease triclosan susceptibility and include G93V/S, which would 
introduce some steric hindrance within the binding site and A198G, L208F and 
F204C the latter of which reportedly reduces the v~n der Waals packing interaction to 
the inhibitor in the NAD+/triclosan complex ((Brenwald & Fraise 2003)(Fan et at., 
2002». Interestingly the F203C mutation does not change s'aureus ENR 
susceptibility to compound 29 or related compounds. Of the currently reported 
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Figure 9.15 (a). A stereo view of the EcENRlNAD+/compound 29 complex 
structure. Only those residues which are within 4.oA of the bound inhibitor are 
shown and labelled. The figure is coloured with yellow for carbon, red for oxygen, 
blue for nitrogen, green for sulphur and orange for phosphorous. Those residues 
with low sequence conservation across the ENR family are highlighted by a star. 
The figure was produced in the graphics program TURBOIFRODO (Roussel et a/. , 
1990). 
Figure 9.15 (b). A stereo view of the EcENRlNAD+/triclosan complex structure. 
Only those residues which are within 4.oA of the bound inhibitor are shown and 
labelled. The figure is coloured with yellow for carbon, red for oxygen, blue for 
nitrogen, green for sulphur and orange for phosphorous. The figure was produced 
in the graphics program TURBOIFRODO (Roussel et al., 1990). 
mutations within the ENR enzyme of clinical strains of S.aureus which confer 
triclosan resistance non totally abolish triclosan inhibition. 
9.9 Conclusions 
Overall this analysis shows how EcENR can adapt to bind different inhibitors in a 
process which may be related to the enzymes ability to handle different substrates 
with different chain lengths. However analysis of the substrate/inhibitor binding 
pocket in P jalciparum and T.gondii ENRs showed that whilst they are similar to the 
bacterial enzymes there are distinct differences. This would suggest that a full drug 
discovery program to develop an antiparasitic agent would need to utilise the parasite 
enzymes themselves in the screening and would require a full structural study. of 
inhibitor binding to the Tg or Pf ENR enzyme. Moreover it is clear that such studies 
also have to address the problem of crossing the additional membrane of the 
apicoplast and entry into cysts of T.gondii bradyzoites. Despite these apparent 
problems the prospect of the design of a family of drugs which could target the 
parasite family is good and the current study has provided a tool kit which may be 
utilised for future drug discovery programs. 
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Abstract 
Pab I, enoyl acyl carrier protein reductase (ENR), is an enzyme used in fatty acid synthesis. It is a single chain polypeptide in plants, 
bacteria, and mycobacteria, but is part of a complex polypeptide in animals and fungi. Certain other enzymes in fatty acid synthesis in 
apicomplexan parasites appear to have multiple forms, homologous to either a plastid, plant-like single chain enzyme or more like the animal 
complex polypeptide chain. We identified a plant-like Fab I in Plasnwdium falcipamm and modelled the structure on the Brassica nopus and 
Escherichia coli structures, alone and complexed to triclosan (5-chloro-2-[2,4 dichlorophenoxy] phenol]), which confirmed all the requisite 
features of an ENR and its interactions with triclosan. Like the remarkable effect of triclosan on a wide variety of bacteria, this compound 
markedly inhibits growth and survival of the apicomplexan parasites P.falciparum and Toxoplasma gondii at low (Le. IC50 == 150-2000 and 
62 ng/ml, respectively) concentrations. Discovery and characterisation of an apicomplexan Fab I and discovery of triclosan as lead 
compound provide means to rationally design novel inhibitory compounds. © 2001 Australian Society for Parasitology Inc. Published by 
ElseVier Science Ltd. All rights reserved. 
Keywords: FAB I; Triclosan; Toxoplasma gondii; Plasmodiumfalciparum; Lipid synthesis 
---------------------------------------------------------------------------------------------
New medicines are greatly needed for the treatment of 
apicomplexan infections. Recently a number of plant-like 
biochemical pathways associated with the vestigial plastid 
organelle of Toxoplasma gondii and Plasmodium species 
have been suggested as new targets for such medicines 
(ROberts et aI., 1998; Waller et al., 1998; Zuther et aI., 
1999; Jomaa et aI., 1999). A particularly attractive target 
in this respect is the fatty acid biosynthesis pathway as there 
are major differences between the structure of the plastid-
associated enzymes found in plants and the cytosolic 
enzymes found in mammals (Roberts et aI., 1998; Zuther 
et al., 1999; Waller et aI., 2000). Most significantly, 
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2850. 
enzymes of mammalian lipid synthesis form domains on a 
multi-functional protein, whereas those enzymes in plants, 
and certain bacteria are found on discrete mono-functional 
polypeptides. These differences have already been exploited 
by a number of compounds which selectively inhibit bacter-
ial or plant enzymes, but not mammalian enzymes (Roberts 
et al., 1998; Walleret al., 1998; Zuther et al., 1999; Payne et 
al., 2000). Notably, both T. gondii and Plasmodium falci-
parum have been shown to possess mono-functional, plant-
or bacterial-like fatty acid biosynthesis enzymes which are 
targeted to the plastid organelle via a bipartite, N-terminal 
transit sequence (Waller et aI., 1998; Zuther et aI., 1999; 
Roos et al., 1999; DeRocher et al., 2000). Compounds such 
as aryloxyphenoxypropionates (Zuther et al., 1999) and, 
cyc1ohexanedione (Zuther et al., 1999) herbicides and thio-
lactomycin (Waller et aI., 2000) which inhibit acetyl-CoA 
carboxylase (ACC) and ~-ketoacyl-ACP synthase (Fab H), 
respectively, have been demonstrated to restrict the growth 
of T. gondii in vitro. l:Ierein, we describe the first apicom-
0020-7519/011$20.00 © 2001 Australian Society for Parasitology Inc. Published by Elsevier Science Ltd. All rights reserved. 
J>rr: S0020-7519(O 1 )00111-4 
11 0 
E.ooIi 
H.pytori 
a.subtillS 
S.aureus 
PJalclparum 
B,napus 
E.ooIl 
H.pylori 
a.subUII! 
S.auleus 
P.fak:iparum 
B.napu$ 
E.coli 
H.pylori 
B.subli!!, 
S.Burous 
P.falciparum 
B.napus 
E.ooIi 
H.pytori 
B.wbblls 
S.8ureus 
P.ra~iparum 
a,nepus 
E.coIi 
H.pylon 
B.'ubti~s 
S.aureus 
P.falciparum 
B.napu. 
E.ooIi 
H.pylori 
B.subtills 
S.8ureus 
PJaJciparum 
B.napus 
E.coIi 
H.pytori 
B.subtills 
S.aureus 
P.fatciparum 
a.napus 
E.ooIi 
H.pylori 
a.Subtills 
S.aureus 
PJak:lparum 
B.napus 
R. McLeod et 01. / Illternatiollal Journalfor Parasitology 31 (2001) 109- 113 
MNKI SORl.l.Fl.Fl.HFYT I VCFI ONNTOKTFHNVlHNEO I RGKEKAFYRKEKRENI F I G 
__ MAATAAASSlOMATTRPS I SAASSKARTYVVGANPRNAYKI ACTPHlSNlGC 
~I "I 
1 10 20 
__ _ ____ - - - - - - - - - - - - - - - - - - - - - - - - - - M G F l S G K R I l v T I V ASK lSI A Y G I  
___ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - MGFlKGKKGll V VANNKSI AYGI 
_ _____ _ - - - - - - - - - - - - - - - - - - - - - - - - - M N F S lEG R N I V V M V AN K R S 1 A WG I 
_ - - - - - - - - - - - - - - - - - - - - - - - - - - M T T K ISM l N l T G K N A l V T I ANN R S 1 A WG I 
N K M K H l N N M N NTH N N N H Y ME K E E 00 A S N I Y K IKE E N K NED I C F 1 A 1 G O T N G Y G W G I 
l R NOS ALP A SK K S F SF S T K AM S E SSE S K ASS G l PI 0 l R G K R A F 1 A 1 A D D N G v G W A V 
1 10 20 30 
~I " I 
u> ~.l • 
30 ~ ~ W 
OAM H REGAElAF T YONOK l KGRVEEFAAO - lGSOI VlOCDVAE -
OSCFNOGATlAFTYlNESlEKRVRP I AOE - lNS P YVYElOVSK -
RSlHEAGARll FTVAGERlEKSVHElAGT - lORNOSI 1 lPCOV-
OOlHAAGANlGI TYlPOERGKFEKKVSEl - VEPlNPSlFlPCN -
K E l S K R N V K I I F G I W P P v Y N 1 F M K N Y K N G K F 0 NOM I 10K 0 K K M N i l 0 M l P F DA S F 0 T A 
K S L A A A G A E l l V G T WV P AL N 1 F E T S l R R G K F D OS R V l P 0 G S l M E l K K v Y P l OA V rO N P 
~ ~ w ro ~ 00 
...... -_...I~2_ .. -T f ~3 
-------------------------o ........... (s ........ --------J~:... -------------------------
••• 70 80 00 100 
- - - - - - - - - - - - - - - - - 0 A SID T MFA E L G K v WP K FOG F V I S I G FA P GOO LOG 0 Y V N A V 
- - - - - - - - - - - - - - - - - EEHFKSLYNSVKKOlGSlOFI V SVAFAPKEALEG - SlLET 
- - - - - - - - - - - - - - - TNOAEI ETCFASI KEOVGVI HGI A CI AFANKEElVG EYlNT 
- - - - - - - - - - - - - - VON 0 E 0 lOS T F 0 T I R 0 K WG R L 0 I L I C L A FAN RO~ LTG 0 F SOT 
N O I O E ET K N NKRY NMLO N Y T I EOV A NLI H O KY G K I NM LV S L AN AK - - EV O KK O ll N T 
E 0 v P E 0 V K A N K R v A G S S N W T V 0 E A A E C v R O D F G S I D I L V 5 l A N G P - - E V S K K P l l E I 
100 110 120 130 140 150 
---------------~ •••••• '.!' .... ~---...I~;.~ " . ------------------
-! • • • 
110 120 '30 '40 150 160 ~~~x~~~ I~~: le~IEY~~~~~f~~~t~~g~;~t+I~ltg;¥~~~~~I: ~~Igt.~ NROGFll HNI SY lTAVVKAARPMMTEGGSI VT T lGGElVMPN - NV GV S 
SRAGFAT LOI TF LVOlSGAAKPLMTEGGSI ITS LGGVRAVPN - NV GV G 
5 R K G Y L 0 L S K 5 Y LI S L C K Y F V N I .I K P 055 I 1ST H AS OK v v P G G G G S 5 A 
SRKGVL A I S A SV FV SL lSH F lP I M N P GGAS I S T I AS ERI I PG GGG SS A 
'00 170 180 '00 200 
ESAVRYL VOL - KHHI V AL 
OASVKYL AOl - KEN I V S I 
EASVRYL SEL • SONI V A I 
•• • 200 
RTLAASGI -. 
RTLASSGI •• 
RTlSAKGI - -
RTlASSAV --I A N ~7~ Y MIN A MI - P ~8g V I I  I ESOTR - V YHL R NY N I I T I FSDTR VL FEA R KO N I V T I K SRAA T AI NKLNNTYENNTNONKNRNSHOV G S RA A K A 1 - - - - - - - - • - - - - • - • - - - - • -10 220 2 0 240 
'f Jl6 
• 
N 
2'0 220 230 
H N I 
- - - - - - - •••• - - -. - - - KDFRKMlAHCEAVT l 1 RRTVTI EOV I NSAAF I C I DLS 
·--· -· ---··· - --- - - AOFRMI L KWNEINA lRKNVSlEEV NAGMY L SLS 
-------- -- --------SOFNSILKOIEERA lRRTTTPEEV OTAAF F OMS 
------------------GG llOMIHHVEOVA LRRTVTOLEV NTAAF A OLA 
MNNSGEKEEKKNSASONYT F I O YA I EYS EKY A LROK L l STOI SV A S F L RES 
· -· --· ---- ------- - G F I O TM IEYS YNN A IOKT L TAOEV NA A A r V PlA 
250 60 270 2~ 
r:r. n 
________ .p.7 •• ~ ------------------------------
240 E 260 AG I S EVVH G FSIAAMNElELK --- - --
SGvs l EVHF I A YHVMGMGAVEEKONKATLlWDLHKEO 
RGIT ENlH S FHITAR ·- --· --- --- -
SG I T OVlY A YEIMGM - - -- - ----.--
R A IT O T I V N l N I T.! F l P 0 0 I Y R N ENe - -
S Al T A TI Y L N S M GVAL O SPVFKOlNK 
200 300 310 
117 
• 
Fig. I. A multiple strucrure-based sequence alignment of the enoyl reductases from E. coli, H. pylori, B. subtilis, S. aureus, P. falciparum and B. napu.l'. The 
secondary structures and sequence numbers of the E. coli and B. lIapus enzymes are shown above and below the alignment, respectively. The residues which 
are completely conserved are in reverse type and those involved in triclosan binding arc indicated with a black, filled circle above. Residues in red are 
cOnserved between B. lIapus and P. jalciparum ENRs. 
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Table 1 
IC50· of Triclosan, chloroquine, and mefloquine when cultured with P Jalciparum (nglmI) 
Antimicrobial Agents Parasite strain 
D6 TM9OC2A W2 1M9OC28 TM91C235 
Triclosan 387.1 1891.4 154.4 1330.4 1800.5 
Mefloquine 5.3 24.5 2.0 19.3 19.6 
Chloroquine 3.8 57.3 162.4 82.7 46.1 
• TIle activity of triclosan, mefloquine, and chloroquine were tested against a series of P. Jalciparum isolates and clones with differing susceptibilities to 
antimalarial drugs. D6, a clone from the African Sierra I{{JNC isolate, is chloroquine and pyrimethamine susceptible; W2 is a cloneofthe Indochina I isolate and is 
chloroquine and pyrimethamine resistant. TM9OCZA, TM9OC28, and TM91 C235 are isolates from Thailand and all are chloroquine and mefloquine resistant. 
TM91 C235 was isolated from a patient that failed mcfloquine twice, whereas TM9(}.C2Aand TM90-CB are admission and recrudescent isolates, respectivcly, of 
the first patient who failed treatment with atovaquone (alone) in 111ailand. Subsequent susceptibility testing demonstrated that the recrudescent isolate (28) was 
approximately 2000-fold resistant to atovaquone. when compared with the admission isolate and other atovaquone - susceptible isolates from Thailand. 
plexan Fab I (enoyl acyl carrier protein reductase (ENR» 
and investigate the effects of tricIosan, a potent and specific 
inhibitor of this enzyme, on the in vitro growth of T. gondii 
and P. Jalciparum. 
ENR catalyses the N AD (P)-dependent reduction of a 
trans-2,3 enoyl moiety into a saturated acyl chain, the 
second reductive step in the fatty acid biosynthesis pathway. 
Recent studies on the inhibition of ENR by compounds such 
as the diazaborines (Turnowsky et aI., 1989; Baldock et al., 
1996) and triclosan (McMurray et aI., 1998; Heath et al., 
1998; Levy et al., 1999; Payne et al., 2000; Jones et aI., 
2000) have validated this enzyme as a target for the devel-
opment of new antibacterial agents. In particular, triclosan, 
Which is found in many house-hold formulations including 
soaps, deodorants, hand lotion, toothpaste and impregnated 
into plastic as an anti-bacterial agent is an extremely potent 
ENR inhibitor (Ward et aI., 1999). 
We located a sequence for a putative P.Jalciparum Fab I 
on the aggregate P. Jalciparum chromosomes referred to as 
'blob' (Asn no. AF338731). The deduced amino acid 
sequence and a multi sequence alignment with representative 
enoyl acyl carrier protein reductases are shown in Fig. 1 (Asn 
nO.AF338 731). The gene sequence ofPlasmodiumENRwas 
obtained with a Blast search using the sequences from both 
the B. napus and E. coli enzymes within the P. Jalciparum 
database 'PlasmoDB' (found at www.PlasmoDB.org).This 
sequence was then converted to an amino acid sequence at 
WWw.expasy.chltoo)s/dna.html. The sequence was aligned 
Using the 'Multiple Sequence Alignment' at http://sear-
chlaun.bcm.tmc.edu. 
Analysis of the pattern of sequence conservation confirms 
that this protein has all the residues that have been identified 
as crucial for enzyme activity. Interestingly, there is much 
greater sequence similarity with the plant enzyme than with 
the ENRs of bacterial origin. The P. Jalciparum ENR 
appears to have a plastid targeting sequence (Waller et aI., 
20(0) and has a number of internal inseltions. In addition, 
~he P. Jalciparum protein has an extremely polar additional 
Internal insertion for which no counterpart exists in any of 
~e previously described ENRs. The function of the latter 
Insertion remains to be determined. 
We studied the effect of tricIosan on P. Jalciparum and 
T. gondii in vitro (Mack and McLeod, 1984; Milhous et al., 
1985; Oduola et al., 1988; Roberts et aI., 1998; Zuther et 
aI., 1999; Jones et al., 2000). For P. Jalciparum, the in vitro 
assays (Milhous et aI., 1985; Oduola et aI., 1988) were 
conducted using a modification of the semiautomated 
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Fig. 2. Inhibition of T. gondii by triclosan. (a). No effect of triclosan on the 
host cells uptake of thymidine. Appearance of the monolayer also was 
unchanged. (b). Effect of trlclosan on T. gondii uracil uptake. Triclosan 
reduces uracil uptake by intracellular T. gondii 4 days after infection. IC50 
was '" 62 nglml. Effect increased between days 1 to 4. For example, in a 
separate experiment, for 125 nglmI of tric10san on day I, percentage inhibi-
tion was 20% and on day 4 was 72% and for pyrimcthamine/sulfadiazine 
percentages of inhibition at these times were 63 and 100%, respectively. 
Abbreviations: RH, RH strain of T. gOlldii within fibroblasts; No RH, 
Control with fibroblasts alone; DMSO, fibroblasts with highest concentra-
tion of DMSO; PIS, fibroblasts, T. gondii, pyrimethamine and sulfadizine 
used as a positive control for the assay; CPM, counts per minute. 
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Fig. 3. A stereo view of the three dimensional arrangement of the atoms that form the binding pocket for tricloS3n, in E. coli enoyl reductase, with the II 
residues that have any atom within 4 A of the inhibitor, labelled and coloured red. TIlis is important in assigning the relative contributions made to the 
interaction with triclosan by the critical amino acids that are also present in the P. falciparum enzyme. 
microdilution technique for assessing antifolate antago-
ni sts. Instead of dialysed human plasma, 10% Albumax I 
(Gibco BRL), a serum-free substitute, was used to supp.le-
ment the RPMI 1640 medium. All test compounds were 
dissolved in DMSO and diluted 400-fold into complete 
medium before serial dilution over 11 concentrations. Incu-
bation was at 37°C in 5% O2, 5% CO2 and 90% N 2 for 48 
h. r3H]-Hypoxanthine incorporation was measured as 
described previously (Mi lhous et al., 1985; Oduola et aI. , 
1988). P. Jalciparum strain W2is susceptible to me flo-
quine, but resistant to pyrimethamine, sulphadoxine and 
quinine and less susceptible to chloroquine than P. Jalci-
parum strain D6. Strain D6 is susceptible to pyrimethamine 
and sulphadox ine, but simi lar to P. Jalciparum strai ns 
TM9OC2A and TM90C2B, and strain TM91 C235 is less 
susceptible to mefloquine. The effect of triclosan on P. 
Jalciparum in vitro was studied with pyrimethamine sensi-
tive and resistant organisms and those with varying sensi-
tivities to chloroquine and mefloquine, simultaneously with 
stud ies of effect of chloroquine or mefioquine on these 
parasites (Table 1). Triclosan was effective against pyri-
methamine resistant P. Jalciparum (W2) at low concentra-
tions (IC50s of 150 ng/rnl [triclosan] and 160 ng/ml 
[Chloroquine], respectively) (Table 1). Interestingly, the 
pattern of relative susceptibility of triclosan and mefto-
quine were identical. This similarity suggests that triclosan 
and mefioquine may share a common mechanism of influx 
Or efflux, because such differences in transporters are 
believed to be the basis of the differences in susceptibility 
of malaria parasites to mefloquine although other mechan-
isms also are possible. 
For T. gondii, growth inhibition was a<;sessed over a 4-
day period as described previously (Mack and McLeod, 
1984; Roberts et aI. , 1998; Zuther et a1., 1999) using 
human foreskin fibroblasts (HFF) infected with 105 tachy-
wites of the RH strain of T. gondii . Triclosan also was 
effective against T. gondii, in nanomolar amounts (Fig. 2). 
IC50 was 62 ng/rnl. There was no toxicity to host cells at 
these concentrations. 
Analysis of the binding site for triclosan in B. napus and 
E. coli ENR shows that 11 residues have contacts less than 4 
A with one or more atoms of the triclosan (Fig. 3). Inspec-
tion of the sequence for P. Jalciparum ENR reveals that it 
shares sequence identity at each of these positions with 
either the sequence of the B. rtapus or E. coli enzymes 
providing a clear explanation for the inhibitory properties 
of this agent against P. Jalciparum. 
The discovery and characterisation of an apicomplexan 
Fab I and discovery of triclosan as a lead compound 
provide means to rationally design novel inhibitory 
compounds with considerable promise. These findings 
may provide novel ways to counteract the increasing resis-
tance of Plasmodium species to the current armoury of 
antimalarial agents and provide a new approach to the 
great need for additional, less toxic antimicrobial agents 
effective against T. gondii. We (Zuther et a1., 1999) and 
others (Waller et al ., 1998) also have identified other novel 
inhibitors of sequential enzymatic steps in the apicom-
plexan lipid synthesis pathway, that we predict will be 
synergistic with triclosan and other inhibitors of Fab I 
(Baldock et aI. , 1996). This also raises the exciting possi-
bility of a rational .basis for discovery of synergistic inhi-
R. McLeod et aL I illtemational loumalfor Parasitology 31 (2001) 109--113 113 
bitors of this pathway effective against mUltiple different 
microorganisms (Payne et al., 2000). 
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Expression, purification and crystallization of the 
Plasmodium falciparum enoyl reductase 
New hope has been gained in the control of the malaria parasite 
Plasmodium faiciparum (pf) with the discovery that the parasite 
contains a prokaryotic type II fatty-acid synthase (FAS). Since 
enzymes of this type are absent in humans, they are potential targets 
for the development of new drugs. The enoyl reductase enzyme 
(ENR) belonging to this pathway is of particular interest because it 
has been shown to be inhibited by submicromolar concentrations of 
the antimicrobial agent triclosan. Here, the development of an 
efficient overexpression system for pfENR as a fusion protein with 
maltose-binding protein, its simple one-step purification and cleavage 
from its fusion protein and crystallization under new conditions with 
bound NAD+ cofactor and triclosan are reported. The crystals belong 
to the space group n h with approximate unit-cell parameters a = 88.2, 
b = 82.4, c = 94.8 A., fJ = 90.77°, and contain a tetramer in the 
asymmetric unit. Cryocooled crystals (100 K) diffracted to beyond 
2.2 A. resolution at the Daresbury Synchrotron Radiation Source. 
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1. Introduction 
The malaria parasite, P. faiciparum, is 
responsible for over 500 million cases of 
malaria per year, killing more than 2 million 
people annually (Breman, 2001). Recently, a 
new area for drug development has come to 
light with the discovery of a prokaryotic type II 
fatty-acid synthase (FAS) in this parasite 
(Waller et ai., 1998; Waters et ai., 2002). Type II 
FAS systems, in which the enzymes of this 
pathway are found on separate polypeptides, 
are common in bacteria and plants (Magnuson 
et ai., 1993). In contrast, in -the type I FAS 
systems found in metazoans the domains that 
carry out the equivalent catalytic steps are 
quite different in amino-acid sequence and 
reside on one or two much larger multi-
functional proteins (Smith, 1994). Thus, the 
enzymes of type II FAS systems are prime 
targets for the discovery of drugs with poten-
tially low toxicity in man. Previous studies have 
shown that enoyl reductase (ENR) is a key 
enzyme in type II systems and is the target of 
several classes of antimicrobial compounds, 
including the diazaborines and triclosan 
(Baldock et ai., 1996; Levy et ai., 1999, 2001). 
More recently, it has been shown that triclosan 
also inhibits pfENR with a Ki of 0.4 nM 
(Kapoor et ai., 2001) and inhibits the growth of 
P. faiciparum in culture with an ICso of 0.7 11M 
(Surolia & Surolia, 2001). 
The sequence of the pfENR shows signifi-
cant sequence similarity to enoyl reductases 
from other species with, for example, 47% 
identity to the enzyme from Brassica napus. 
However, the pfENR sequence differs from an 
other ENR sequences determined to date in 
that it contains a 43 amino-acid insert in a looP 
which in the ENRs from other species is knoWn 
to undergo substantial conformation change 
on inhibitor (and presumably substrate) 
binding (Levy et ai., 1999, 2001; Qiu et ai., 
1999). The structure of this loop is therefore of 
particular interest in the exploitation of pfENR 
for drug discovery owing to its possible inter-
actions with substrate, cofactor or inhibitors. 
Recently, the structure of pfENR has been 
solved to 2.4 A. (Perozzo et ai., 2002), but 
unf~rtunately no density could be seen for tb.e 
43 amino-acid insert owing to disorder in tblS 
part of the structure, thus leaving an important 
piece of the structure undetermined. In order 
to address this problem, we have developed a 
new expression system for this enzyme. we 
report the successful expression and purifica-
tion of pfENR to give crystals of a new form 
which diffract to high resolution. 
2. Materials and methods 
2.1. Expression and purification of pfEN R 
using the pMALc2x vector 
The coding sequence of P. faiciparum ~N~ 
was amplified from gDNA of the 3D7 strain 0 
P. faiciparum using PfuThrbo polymera~ 
(Stratagene). The primers (forward) 5'-00 'f 
GGTGAATTCTCAAACATAAACAAAA; 
TAAAGAAG-3' and (reverse) 5'_00TOO -
----------------------------------------------------------------~----~------------------~ 1246 Muench et al . • P. falciparum enoyl reductase Ac. C,y<' (2003). 059, 124&-124~ 
GTCGACTTATTCATTTTCATTGCGAT-
ATATATC-3' were used to amplify nucleo-
tides encoding amino acids 85-432 and to 
introduce a proximal EcoRI and distal SaIl 
site (bold) in the PCR product. Nucleotides 
encoding the amino-terminal 84 residues of 
pfENR were excluded because this region is 
principally composed of a signal peptide and 
an organellar transit peptide. The resulting 
amplicon was digested with EcoRI and Sail 
and ligated into the pMALc2x vector (New 
England Biolabs). The resulting pSTP6 was 
transformed into BL2l Star(DE3) cells 
(Invitrogen). These cells were cotrans-
formed with the pRIL plasmid isolated from 
BL2I-CodonPlus(DE3) cells (Stratagene) 
and used for the expression of MBP-ENR 
fUsion protein. Cells were grown in LB 
medium at 310 K to an optical density at 
600 nm of 0.8 and then induced by addition 
of IPTG to a final concentration of 0.4 mM. 
'Ibe culture was maintained in shaker flasks 
at 293 K for 12 h and then harvested by 
centrifugation. 
Cells were resuspended in lysis 
bUffer [20 mM sodium/potassium phosphate 
PI! 7.5, 1 mg ml-1 lysozyme (Sigma), 
2.5 Ilg ml-1 DNAse I (Sigma), 200 mM 
~aCI] and sonicated. Cell lysate was clar-
Ified by centrifugation and applied to a 10 ml 
amylose column (New England Biolabs) for 
affinity purification (Fig. la, lane 2). Purified 
MBP-ENR fusion protein was digested with 
factor Xa (New England Biolabs) at a ratio 
of 1 mg factor Xa per 500 mg of fusion 
Protein in the presence of 1 mM calcium 
Chloride at 277 K (Fig. la, lane 3). The 
reaction mixture was desalted with a HiPrep 
26/10 desalting column (Pharmacia) and 
apPlied to an SP Sepharose cation-exchange 
ColUmn (Pharmacia). Column fractions 
2 3 4 
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4S kDa 
-
....... _MBP 
-
-"-ENR 
containing pure pfENR protein were pooled 
for further analysis. 
2.2. Expression and purification of pfENR 
using the pMALcHT vector 
A . second construct of pfENR also 
containing residues 85-432 was designed for 
in vivo cleavage by the TEV (tobacco etch 
virus) protease. The amplicon described 
above was ligated into a modified version of 
the pMALc2x vector (pMALcHT) in which 
the linker region was altered to contain 
nucleotides encoding a TEV (tobacco etch 
virus) protease cleavage site followed by a 
six-histidine tag (Fig. 1b). The reSUlting 
ligation product, pSTP7, was transformed 
into BL2l Star(DE3) cells (Invitrogen). 
These cells were cotransformed with the 
pRIL plasmid from BL21-CodonPlus(DE3) 
cells (Stratagene) and plasmid (pKM586) 
encoding the TEV protease (Kapust & 
Waugh, 2000). Cells were grown, harvested 
and lysed as above. Cell lysate was clarified 
by centrifugation and applied to a 5 ml 
HiT rap Chelating HP column (Pharmacia). 
Column fractions containing cut pfENR 
were desalted with a HiPrep 26/10 desalting 
column (Pharmacia) and loaded onto as ml 
HiTrap SP Fast Flow column (Pharmacia). 
Pure pfENR (Fig. la, lane 4) was then 
concentrated to 12 mg ml-1 for crystal-
lization trials. 
2.3. Crystallization of pfENR and data 
collection. 
Crystals of pfENR were grown using the 
hanging-drop vapour-diffusion technique by 
mixing 2.5 III of the protein solution 
(12 mg ml-1 pfENR in 20 mM sodium/ 
potassium phosphate pH 8.0, 150 mM NaCl, 
• 
crystallization papers 
5 11M NAD+ and 6 11M triclosan) with 2.5 III 
of the reservoir solution at 290 K. Initial 
screening of crystallization conditions was 
conducted using Crystal Screen 1, Crystal 
Screen 2 and PEG/Ion Screen (Hampton 
Research), of which PEG/Ion screen solu-
tion 11 [20%(wlv) PEG 3350 and 200 mM 
KI] produced the best-quality crystals. This 
aforementioned screen was optimized, 
changing both the pH and precipitant 
concentrations, to achieve an optimal reser-
voir solution composed of 19.5%(wlv) PEG 
3350 and 230 mM KI. This condition 
produced good-quality crystals which took 
four to five weeks to reach dimensions of 
0.15 x 0.10 x 0.10 mm. X-ray analysis at the 
Daresbury Synchrotron Radiation Source 
(SRS) of crystals frozen at 100 K using 20% 
glycerol as a cryoprotectant showed that 
they diffracted to beyond 2.2 A. Rotation 
images were collected with 10 oscillation 
width and 1 min exposure times on an 
ADSC Quantum 4 detector at station 14.1. 
These crystallization conditions were very 
different to those previously reported by 
Perozzo et al. (2002), which were based on 
ammonium sulfate. They also give crystals 
whose diffraction properties appear to be 
superior, giving a lower Rmerge (0.095 
compared with 0.123) at a higher resolution 
of 2.2 versus 2.4 A. 
3. Results and discussion 
We were able to efficiently overexpress 
pfENR as a fusion protein with the maltose-
binding protein (MBP) using the pMALc2x 
expression vector. The reSUlting MBP-ENR 
fusion protein was readily purified through 
affinity chromatography (Fig. la, lane 2). 
However, endoproteolytic digestion of pure 
~9kDa 
-- }-- Overdigestion 
~OkDa 
-
14kDa 
-
(a) (b) 
figure 1 
~a) SOS-PAGE of pfENR purification. SigmaMarker wide-range molecular-weight markers are shown in lane 1. Pure MBP-ENR fusion protein produced by the pMALc2x 
r eCtor (lane 2) and factor Xa-digested fusion protein (lane 3) are shown. Lane 4 shows pfENR produced by in vivo cleavage using the pMALcHT vector. (b) Schematic 
a~preSentation of the pMALcHT vector. Amino acids in the linker region between the maltose-binding protein (MBP) and pfENR (ENR) are shown using single-letter 
breViations. The seven-residue TEV protease recognition site is boxed and a gap indicates the protease cleavage site. 
'-----------------------------------------------------------------------------------------
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Figure 2 
A representative 10 oscillation image of data 
collected from a crystal of pfENR complexed with 
NAD+ and triclosan on a Quantum Q4 CCD detector 
on station 14.1 at the SRS Daresbury Laboratory. The 
resolution at the edge of the image corresponds to a 
resolution of 2.2 A.. 
MBP-ENR with factor Xa protease yielded 
overdigestion products under conditions 
that did not completely digest all of the 
MBP-ENR fusion protein (Fig. la, lane 3). 
Better results were obtained using in vivo 
cleavage of the fusion protein by the tobacco 
etch virus (TEV) protease. The linker region 
of the pMALc2x vector was modified to 
contain a TEV protease cut site followed 
by a six-histidine tag, generating the 
pMALcHT expression vector (Fig. Ib). This 
vector was cotransformed into Escherichia 
coli along with a plasmid encoding the TEV 
protease (pKM586) and a plasmid encoding 
three rare tRNAs (pRIL). A long low-
temperature induction period during the 
expression of the MBP-ENR fusion protein 
also served to expose the fusion protein to 
digestion by constitutively expressed TEV 
protease. The resulting pfENR digestion 
product could then be purified via a histidine 
tag exposed by cleavage. Since pfENR is a 
multimer (see below), uncut MBP-ENR will 
tend to copurify with cut pfENR. We were 
able to remove trace amounts of uncut 
MBP-ENR by using a subtractive amylose 
column. 
The data collected at the Daresbury 
Synchrotron Radiation Source (SRS) were 
processed and scaled using the DENZO/ 
SCALEPACK package (Otwinowski & 
Minor, 1997). Analysis of the diffraction 
data using the autoindexing routine in the 
program DENZO showed that the crystals 
belong to the primitive monoclinic system, 
Table 1 
Data collection and processing for pfENR crystals. 
Values in parentheses refer to data in the highest 
resolution shell. 
Space group 
Wavelength used (A.) 
Resolution range (A.) 
Unique reflections 
Multiplicity 
Completeness ('Yo) 
Ila(I) > 3 ('Yo) 
Rm.,.et ('Yo) 
n, 
0.9600 
0-2.18 (2.26-2.18) 
77321 (7521) 
3.1 (3.0) 
97.2 (94.7) 
72.6 (49.6) 
0.095 (0.395) 
t Rm"ge = L.klII, - 1m I/L.kl I" where I, and 1m are the 
observed intensity and mean intensity of related reflections, 
respectively. 
with unit-cell parameters a = 88.18, b = 82.37, 
c = 94.82 A, ot = y = 90, f3 = 90.77°. Reflec-
tions were observed along the OkO axis (b*) 
only where they satisfied the condition k = 2n, 
indicating that the crystals belonged to space 
group n 1. Significant reflections were 
observed to the edge of the image-plate 
detector (Fig. 2) and a good-quality data set 
was collected to 2.2 A. Data-collection and 
processing statistics can be found in Table 1. 
Gel-filtration studies indicate that pfENR is 
a tetramer in solution like the enzymes from 
E. coli and B. napus (Baldock et al., 1998; 
Rafferty et al., 1995); consideration of the 
possible values of VM suggest that the 
asymmetric unit contains a complete 
tetramer with a VM of 2.2 A3 Da-l, which is 
within the range observed for protein crys-
tals (Matthews, 1974). 
A preliminary attempt to solve the struc-
ture using molecular replacement with the 
AMoRe program (Navaza, 1994) as imple-
mented within the CCP4 package (Colla-
borative Computational Project, Number 4, 
1994) has been carried out using the co-
ordinates of B. napus ENR (PDB code 
Id70) as a search model A promising solu-
tion was obtained and ultimately it is hoped 
that refinement of the structure to high 
resolution may provide insights into the 
details of inhibitor binding and allow us to 
see any important interactions with the 
additional loop present in the pfENR. 
This work was supported by the Wellcome 
Trust and the BBRSC. The Krebs Institute is 
a designated BBRSC Biomolecular Science 
Centre and a member of the North of 
England Structural Biology Centre. This 
work was also supported by. the 
USAMRMC (US Army Medical Research 
and Materiel Command). Preliminary 
sequence data were obtained from the 
Plasmodium Genome Database, http:// 
PlasmoDB.org, which is a collaborative 
effort supported by the Burroughs We Il-
come Fund. JBR is the Royal Society Olga 
Kennard Fellow and RML is the Jules and 
Dorris Stein RPB Professor at the Univer-
sity of Chicago, USA. 
References 
Baldock, C, Rafferty, 1. B., Sedelnikova, S. E., 
Baker, P. 1., Stuitje, A. R, Slabas, A. R., 
Hawkes, T. R & Rice, D. W. (1996). Science, 
274, 2107-2110. 
Baldock, C, Rafferty, 1. B., Stuitje, A. R., Slabas, 
A. R & Rice, D. W. (1998). J. Mol. BioI. 284, 
1529-1546. 
Breman, J. G. (2001). Am. J. Trop. Med. Hyg. 64, 
1-11. 
Collaborative Computational Project, Number 4 
(1994). Acta Cryst. D50, 760-763. 
Kapoor, M., Dar, M. J., Surolia, A. & Surolia, No 
(2001). Biochem. Biophys. Res. Commun. 289, 
832-837. 
Kapust, R B. & Waugh, D. S. (2000). Protein Expf. 
Puri! 19,312-318. . 
Levy, C W., Baldock, C, Wallace, A. J., Sedelnl-
kova, S., Viner, R C, Clough, J. M., Stuitje, 
A. R., Slabas, A. R, Rice, D. W. & Rafferty, 1. B. 
(2001). J. Mol. BioI. 309,171-180. i 
Levy, C W., Roujeinikova, A., Sedelnikova, S., 
Baker, P. J., Stuitje, A. R, Slabas, A. R, Rice, 
D. W. & Rafferty, J. B. (1999). Nature (London), 
398, 383-384. 
Magnuson, K., Jackowski, S., Rock, C. O. &. 
Cronan, J. E. Jr (1993). Microbiol. Rev. 57, 52Z~ 
542. 
Matthews, B. W. (1974). J. Mol. BioI. 82, 513-5Z6. 
Navaza, J. (1994). Acta Cryst. A50, 157-163. 
Otwinowski, Z. & Minor, W. (1997). Methods 
Enzyrnol. 276, 307-326. . 
Perozzo, R, Kuo, M., Sidhu, A. S., ValiyaveeUI, 
J. T., Bittman, R, Jacobs, W. R Jr, Fidock, D.!:.' 
& Sacchettini, J. C. (2002). J. BioI. Chern. 21" 
13106-13114. 
. Qiu, X., Janson, C A., Court, R I., Smyth, M. G)., 
Payne, D. J. & Abdel-Meguid, S. S. (1999, 
Protein Sci. 8, 2529-2532. 
Rafferty, J. B., Simon, J. W., Baldock, c" 
Artymiuk, P. J., Baker, P. J., Stuitje, A. R:i' 
Slabas, A. R & Rice, D. W. (1995). Structure, ' 
927-938. 
Smith, S. (1994). FASEB J. 8, 1248-59. 1 
Surolia, N. & Surolia, A. (2001). Nature Med. ' 
167-173.. G., 
Waller, R. E, Keeling, P. J., Donald, R. !'I 
Striepen, B., Handman, E., Lang-Unnasch, ; 
Cowman, A. E, Besra, G. S., Roos, D. S. . 
McFadden, G. I. (1998). Proc. Natl Acad. Set. 
. USA, 95, 12352-12357. . 
Waters, N. c., Kopydlowski; K. M., GusZCzyns\(~' 
T., Wei, L., Sellers, P., Ferlan, J. T., Lee, P. J., L~ 
Z., Woodard, C L., Shallom, S., Gardner, .~. i 
& Prigge, S. T. (2002). Mol. Biochern. PartS1tO ' 
U3,85-94. 
-------------------------------------------------------------------------------------------~ 1248 Muench et al. • P. fa/Ciparum enoyl reductase Acta Cryst. (2003). D59, 1246-1Z48 
Appendix III 
Delivery of antimicrobials into parasites 
Samuel, B. D., Hearn, B., Mack, D., Wender, P., Rothbard, J., Kirisits, M. 
J., Mui, E., Wernimont, S., Roberts, C. W., Muench, S. P., Rice, D. W., 
Prigge, S. T., Law, A. B. & McLeod, R. 
Proc Natl Acad Sci USA. (2003) 100, 14281-14286. 
132 
Delivery of antimicrobials into parasites 
B. U. Samuel*t, B. Hearnt*, D. MackH , P. Wender*§ll, J. Rothbard*§, M. J. Kirisits*, E. Mui*, S. Wernimont*, 
C. W. Robertsll, S. P. Muench**, D. W. Rice**, S. T. Priggett, A. B. Lawtt, and R. McLeod*ll 
*Department of Visual Sciences, University of Chicago, 5841 South Maryland, AMB S-208, Chicago, Il60637; *Department of Chemistry, Stanford University, 
Stanford, CA 94305; sCell Gate Inc., 552 Del Rey Avenue, Sunnyvale, CA 94086; IIDepartment of Immunology, University of Strathclyde, G4 ONR Glasgow, 
Scotland; **Department of Molecular Biology, Sheffield University, Firth Court, Western Bank, Sheffield S10 2TN, United Kingdom; and ttMalaria Research 
Institute, The Johns Hopkins University School of Public Health, Baltimore, MD 21205 
COntributed by P. Wender, September 25, 2003 
To eliminate apicomplexan parasites, inhibitory compounds must 
cross host cell, parasitophorous vacuole, and parasite membranes 
and cyst walls, making delivery challenging. Here, we show that 
Short oligomers of arginine enter Toxoplasma gondii tachyzoites 
and encysted bradyzoites. Triclosan, which inhibits enoyl-ACP 
reductase (ENR), conjugated to arginine oligomers enters extracel-
lUlar tachyzoites, host cells, tachyzoites inside parasitophorous 
vacuoles within host cells, extracellular bradyzoites, and brady-
ZOites within cysts. We identify, clone, and sequence T. gondii enr 
and produce and characterize enzymatically active, recombinant 
ENR. This enzyme has the requisite amino acids to bind triclosan. 
Triclosan released after conjugation to octaarginine via a readily 
hYdrolyzable ester linkage inhibits ENR activity, tachyzoites in 
Vitro, and tachyzoites in mice. Delivery of an inhibitor to a micro-
organism via conjugation to octaarginine provides an approach to 
transporting antimicrobials and other small molecules to seques-
tered parasites, a model system to characterize transport across 
Illultiple membrane barriers and structures, a widely applicable 
paradigm for treatment of active and encysted apicomplexan and 
other infections, and a generic proof of principle for a mechanism 
of Illedicine delivery. 
T he vast majority of interesting small molecules will never be 
used for therapeutics because they cannot traverse biologic 
barriers to reach their targets. A special challenge for the 
development of antimicrobials effective against apicomplexan 
parasites is delivery. Effective agents have to gain entry to host 
cells, cross the parasitophorous vacuole, and enter parasites and 
t~eir specialized organelles. This is potentially more difficult 
With Toxoplasma gondii bradyzoites, which reside in cysts com-
POsed partly of host and partly of parasite constituents. The 
stUdies described herein were performed to determine whether 
Short oligomers of arginine (Fig. 1A) could provide a solution to 
these challenges. Arginine oligomers linked to immunomodula-
tory and antitumor compounds can actively transport such 
~Ompounds across a variety of epithelial barriers, including skin, 
ung, and eye (1-4). Oligoarginine-medicine conjugates have 
b(een administered safely to experimental animals and humans 
ref. 1 and unpublished data) . 
. Better approaches for treating apicomplexan parasite infec-
~ons (e.g., toxoplasmosis and malaria) are needed. For example, 
. gondii bradyzoites infect 30-50% of people throughout the 
WOrld, but no currently used medicines eradicate this slowly 
~rowing, encysted, latent parasite that causes chronic, lifelong 
~fections in brain and eye with recrudescence causing severe 
Illness (5). Available antimicrobial agents to eliminate rapidly 
&rOWing T. gondii tachyzoites, which cause tissue destruction 
during active infection, are limited by toxicity and allergy (5). 
~noyl-ACP reductase (ENR) is a key enzyme active in fatty 
a~ld synthesis (6). Bacterial and apicomplexan fatty acid synthe-
SIS OCcurs by the type II pathway (6-10) (Fig. 5, which is 
~Ublished as supporting information on the PNAS web site) and 
epends on monofunctional polypeptides, including ENR. In 
Contrast, mammalian fatty acid synthesis occurs by the type I 
Pathway in which the key enzymes are present on a polyfunc-
"'vvw.pnas.org/cgi/doi/10.1073/pnas.2436169100 
tional single polypeptide (6-10). In apicomplexans, type II fatty 
acid synthesis enzymes are in a plastid organelle (6, 8). 
Some monofunctional type II enzymes had been identified in 
Plasmodia and T. gondii (6-10), but T. gondii ENR (TgENR) had 
not been identified. The antimicrobial agent 5-chloro-2-[2,4-
dichlorophenoxy]phenol (triclosan) had been found to inhibit 
bacterial ENRs (11). We (6) and Surolia and Surolia (9) had 
found that ILM concentrations of triclosan dissolved in DMSO 
inhibit replication of apicomplexan parasites, presumably by 
binding to, and inhibiting, apicomplexan ENR. Triclosan was 
active only when solubilized in DMSO (6, 9). Structures of 
triclosan, oligomers, and conjugates of oligoarginines are shown 
in Fig. 1 (see also Fig. 5). 
Materials and Methods 
Short Arginine Oligomers, Conjugates, and Controls. Peptides were 
synthesized by using solid-phase techniques and commercially 
available fluorenylmethoxycarbonyl amino acids, resins, and 
reagents with an Applied Biosystems 433 peptide synthesizer. 
Fastmoc cycles were used with O-(7-azabenzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HATU). 
Peptides and conjugates were cleaved from resin by using 95% 
trifluoroacetic acid and 5% triisopropylsiIane for 24 h. Pep tides 
were subsequently fIltered from resin, precipitated with diethyl 
ether, purified by using HPLC reverse-phase columns, and 
characterized by using 1 H NMR and electrospray MS. 
For synthesis of triclosan-Orn(FITC)-Arg,,-CONHz, 4 and 5, 
triclosan was reacted with a-bromo acetic acid to provide the 
desired a-substituted acetic acid product. Attachment of the 
resin-bound carrier was accomplished by reaction of this acetic 
acid product with the appropriate oligomer of L-argi-
nine(2,2,4,6, 7-pentamethyldihydrobenzofuran-5-sulfonyl, Pbf) 
containing an N-terminal L-ornithine(methyltrityl). After cleav-
age of the side-chain methyltrityl protecting group with 1% 
trifluoroacetic acid in dichloromethane, the conjugates were 
labeled with FITC in the presence of diisopropylethylamine 
(DIPEA). The conjugates were then deprotected and cleaved 
from the resin by using the previously described protocol. For the 
synthesis of triclosan-Orn(tetramethylrhodamine isothiocya-
nate )-Args-CONHz, ent-6, tetramethylrhodamine isothiocya~ 
nate was reacted in the solution phase with triclosan-D-Orn-D-
Args-CONHz in the presence of DIPEA. Triclosan was reacted 
with glutaric anhydride (GA) in the presence of DIPEA to 
provide the desired glutaric acid product, i.e., triclosan-GA-
Arg,,-CONH2. 7 and 8. Attachment of the carrier was accom-
plished by the solution-phase reaction with the appropriate 
oligomer of D- or L-arginine. For the synthesis of triclosan-acetic 
Abbreviations: ENR, enoyl-ACP reductase; TgENR, Toxoplasma goOO;1 ENR; Pbf, 2.2.4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl. 
Data deposition: The sequence reported in this paper has been deposited In the GenBank 
database (accession no. AY372520). 
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Fig. 1. Schematic representations of oligomers and conjugates, uptake of short oligomers of arginine and lysine by T. gondiitachyzoites, encysted bradyzoites, 
and effect of azide on uptake of arginine triclosan conjugates by parasites. (A) Structures of short oligomers of arginine and conjugates used in these studies. 
Releasable conjugates use readily hydrolyzable ester linkages for the attachment of triclosan to the oligoarginine carrier (structures 7 and 8). Nonreleasable 
triclosan conjugates use nonhydrolyzable ether bonds for the attachment oftriclosan (structures 4, 5,6, and 9). Control compounds 10 and 11 are the hydrolysis 
products of releasable conjugates 7 and 8, respectively. Ent designates the dextro isomer. Synthetic details are in Materials and Methods. (B) Comparative flow 
cytometryto measure labeling of T. gondiitachyzoites incubated w ith FITC..:onjugated polyamino acid compounds. Numbers in parentheses indicate percentage 
of Positive cells. (Inset) Fluorescence and differential interference contrast (Ole) microscopy assays of uptake of r7 FITC, compound 1, by T. gondiitachyzoites. 
(C) Fluorescence images showing uptake of FITC..:onjugated polyamino acid compounds by T. gondiitissue cysts. (Scale bar = 10 Mm.) (D-F) Fluorescein and DIC 
microscopy images showing inhibition of uptake of arginine triclosan conjugates by azide in T. gondii. (D) Tachyzoites. (E) Excysted bradyzoites. (F) Uptake of 
r8 triclosan (compound 7) and less inhibition in isolated brain cysts. The arginine carrier was conjugated to fluorophore and triclosan in a nonreleasable manner 
(4 and ent-6). (Scale bar = 10 I'm.) 
acid-Argx-CONH2, 9, the previously described a-substituted 
acetic acid product was attached to the carrier by reaction with 
the resin-bound octa-L-arginine(Pbf). The conjugate was subse-
qUently cleaved from the resin, and the Pbf sulfonamides were 
removed. For the synthesis of GA-Argn-CONH2, 10 and 11, the 
resin-bound oligomer of L-arginine(Pbf) was reacted with GA in 
the presence of DlPEA, followed by cleavage of the resin and Pbf 
deprotection. 
The half-life of conjugate 7 decomposition in PBS was deter-
Illined by using HPLC to monitor the change in the ratio of 
Conjugate-to-internal standards (benzoic acid) over time. 
1. gond;; Parasites. Tachyzoites of the RH strain were maintained 
and used in experiments as described (12, 13). GFP-, plastid-
labeled RH strain parasites were kindly provided by B. Streipen 
and D. Roos (University of Pennsylvania, Philadelphia). Pro-
duction and isolation of T. gondii cysts were as described (14). 
StUdies on the Uptake of Short Arginine and Lysine Oligomers into T. 
gondii. Live cells incubated with conjugates were examined by 
uSing a Zeiss Axiovert inverted fluorescence microscope or Zeiss 
Axioplan equipped with cooled charge-coupled device camera. 
For flow cytometry, parasites and cells were incubated in 
PBS/2% FCS containing 12.5 ILM of each oligomer at ISoC for 
10 min, washed in cold PBS three times, resuspended in PBS, and 
then analyzed by flow cytometry with a FACScan and CELL 
QUEsT software. Before analysis, intracellular parasites were 
eXposed to 12.5 ILM conjugate for 10 or 30 min. 
treatment with Azide. Parasites were preincubated for 30 min with 
0.5% azide (tachywites, bradyzoites) or 0.5-2% azide (cysts), 
aU in 2% FCS/PBS buffer, before the addition of 12.5 ILM 
COnjugate. 
~Ioning and Sequencing of TgENR. A cDNA library was screened to 
l(dentify and characterize the TgENR gene as described (15, 16) 
~ee Supporting Text, which is published as supporting informa-
hOn on the PNAS web site). 
14282 I www.pnas.org/ cgi / doV10.1073/ pnas.2436169100 
Expression and Purification of Recombinant TgENR. A construct of 
TgENR containing residues 103-417 (and lacking the putative 
signal and transit peptides) was designed for in vivo cleavage by 
tobacco etch virus (TEY) protease. Amplified DNA encoding 
residues 103-417 of TgENR was ligated into a modified version 
of the pMALc2x vector (pMALcHT) in which the linker region 
was altered to contain nucIeotides encoding a TEY protease 
cleavage site followed by a six-histidine tag (17). The resulting 
ligation product, pSTPS, was transformed into BL21 Star (DE3) 
cells (Invitrogen). These cells were cotransformed with the pRIL 
plasmid from BI21-CodonPlus (DE3) cells (Stratagene) and a 
plasmid (pKM5S6) encoding the TEY protease (IS). Cells were 
grown, harvested, and lysed as described (17). TgENR was 
purified by using metal chelate and anion exchange chromatog-
raphy (see Fig. 38). 
Effect of r8-Triclosan on Recombinant TgENR. The activity ofTgEN R 
was assayed by using crotonyl-CoA as a substrate and monitoring 
the consumption of the NADH cofactor. Inhibition by rS-
triclosan over a 24-h period was measured by incubating TgENR 
at 37°C with different concentrations of rS-triclosan. Aliquots 
were removed at 0, 12, and 24 h and assayed for TgENR activity. 
Briefly, 10 ILl of 1 mM NADH and 10 ILl of 1 mM crotonyl-CoA 
were added to SO ILl of incubated TgENR/rS-triclosan, and the 
reaction was followed for 120 s in a Beckman DU-640 spectro-
photometer. Final concentration of TgENR was 11.6 nM, and 
the final concentrations of r8-tricIosan were 2 ILM, 0.4 ILM, SO 
nM, 16 nM, 3.2 nM, 640 pM, and 12S pM. TgENR was inhibited 
by rS-triclosan with an ICso value > 1ILM at 0 h, an ICso value = 
40 nM ± 10 nM at 12 h, and an ICso value < 16 nM at 24 h (see 
Fig. 3C). The ICso value at 24 h is an upper limit because 
inhibition cannot be properly measured near the concentration 
of TgENR used in these assays (11.6 nM). 
Assays to Assess Inhibition of T. gondi; Tachyzoite Growth and Effect 
of Antimicrobial Agents on Host Cells in Vitro. These studies were 
performed as described (12, 13). 
Effect of r8-Triclosan on Tachyzoites in Vivo. One thousand RH 
strain parasites were inoculated lop. into five female SW mice 
Samuel et a/. 
(each = 25 g and between 2 and 4 months of age). Lypholized 
releasable r8-triclosan or triclosan were resuspended in Dulbec-
co's PBS. Forty milligrams per kilogram of r8-triclosan or 
Control PBS was inoculated i.p. each day. On the fourth day, 1.5 
ml of PBS (pH 7.4) was inoculated. All available peritoneal fluid 
plus PBS was withdrawn on the fourth day. Total numbers 
of parasites and concentrations of parasites were quantitated 
microscopically. 
Analysis of Data and Statistics. Statistical analysis was with Stu-
dent's t test, XZ analyses, one-way ANOV A, or Tukey's test. 
Detailed Methods. See Supporting Text for more details on ma-
terials and methods used. 
Results and Discussion 
Initially, uptake of f1uoresceinated hepta-o-arginine (r7, com-
POund 1, Fig. lA) and control compounds penta-o-arginine (r5, 
cOmpound 2, Fig. lA) and hepta-L-Iysine (K7, compound 3, Fig. 
lA) into extracellular and intracellular tachyzoites, and extra-
cellular and encysted bradyzoites, was studied by using decon-
volution fluorescence microscopy and flow cytometry (Fig. 1 
B-F). R designates levo isomer, r designates dextro isomer, and 
the number after r indicates the number of arginines in the 
cOmpound. Short arginine oligomers were found to cross all 
m~mbranes and to enter each life cycle stage and compartment 
(Fig. 1 B-F). Deconvolution fluorescence microscopy revealed 
that r7 facilitated uptake of fluoresceinated compounds into 
tachyzoites (Fig. lB Inset). Flow cytometric analysis (Fig. lB) 
demonstrated that uptake of r7 was greater than that of r5 or K7 
(seven arginines » five arginines or seven lysines). This finding 
W~s consistent with earlier studies demonstrating that longer 
ol~gomers of arginines (seven or eight) entered certain eukary-
ftt~ cells better than shorter oligomers (one to four). Deconvo-
utton microscopy demonstrated that short arginine oligomers 
Could cross cyst walls and enter encysted bradyzoites (Fig. Ie 
~nd Movie 1, which is published as supporting information on the 
NAS web site). Uptake of short arginine oligomers into 
tachyzoites and bradyzoites was very rapid (seconds), and in 
bradyzoites, the f1uoresceinated compound moved from the 
cytoplasm to the nucleus over the first day (data not shown). 
Floresceinated, nonreleasable triclosan R8, conjugate 4, then 
Was studied by microscopic analyses. The conjugated triclosan 
Was taken up by extracellular tachyzoites and bradyzoites within 
cYsts = 10 s after addition (Fig. 1 D-F). Treatment with azide 
blocked uptake of short arginine oligomers linked to triclosan by 
tachyzoites (Fig. ID) and bradyzoites (Fig. IE) but did not 
COmpletely inhibit uptake into encysted bradyzoites under the 
Conditions studied (Fig. IF). Thus, uptake into tachyzoites and b~adyzoites is a facilitated process. Uptake of f1uoresceinated 
tnclosan R8 (conjugate 4) into tachyzoites was substantially 
~reater (one and a half logs) than triclosan R4 (conjugate 5), 
~t~r incubation for 10 s, 1 min, and 10 min. Uptake of triclosan 
b 8 mcreased over time (data not shown). As uptake into isolated 
radyzoites was blocked by azide, the inability of azide to 
Completely abrogate uptake by encysted bradyzoites is surprising 
a~d suggested that more than a single mechanism of uptake 
might be involved in uptake across the cyst wall. 
Fluorescein-tagged conjugate 4 and its enantiomer both en-
tered host fibroblasts. T. gondii is an obligate intracellular 
karasite and resides inside a specialized vacuolar compartment 
nown as the parasitophorous vacuole delimited by the parasi-
tOphorous vacuole membrane. To determine whether the carrier 
Conjugated to triclosan can enter this specialized compartment, 
tachyzoites within a vacuole in human fibroblasts were studied. l(ntr~cellular tachyzoites took up fluoresceinated r8-triclosan 
Conjugate ent-4) within minutes (Fig. 24). This finding was also 
COnfirmed by flow cytometric analysis (Fig. 2B). 
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Fig. 2. Intracellular and extracellular tachyzoites take up triclosan conju· 
gated to rS. (A) Fluorescence images of live intracellular tachyzoites after 10 
or 30 min of exposure to r8-triclosan conjugate (nonreleasable conjugate 4). 
Parasite nuclei (arrows) and host cell nuclei (HN) were stained with Hoechst. 
FITC signal is seen in host celf cytoplasm (HQ and nuclei (HN), and in parasites 
residing in parasitophorous vacuole (v) , (Scale bar = 10 J.Lm.) (8) Uptake of 
tric/osan rS conjugate (nonreleasable conjugate 4) by extracellular and intra-
celfulartachyzoites. Flow cytometric analysis showing representative dot blots 
of RH strain (pink) and transgenic paraSites expressing the GFP (ACP·GFP, 
extracellular, red; intracellular, green) exposed to rS-tric/osan conjugated to 
rhodamine (ent-6) for 10 min. Intracellular parasites were exposed to the 
carrier and then released from the host cells before analyses. 
Previously, the only apicomplexan ENR identified was that of 
Plasmodium falciparum. We (17) and others (19) have cloned, 
sequenced, and solved the structure of P. falciparum ENR. It was 
of interest to compare P. falciparum ENR and TgENR for the 
present study, particularly with reference to their triclosan 
binding sites. Portions of TgENR were identified in a database, 
full-length cDNA clones were isolated and sequenced, deduced 
amino acid sequences were determined, and enzymatically active 
recombinant protein was produced (Fig. 3). Analysis of the 
deduced amino acid sequence revealed that key amino acid 
residues are conserved between T. gondii (Fig. 3A, GenBank 
accession no. A Y372520), P. falciparum, Brassica napus, and 
bacterial ENRs and that 11 amino acid residues involved in 
triclosan binding are also conserved (Fig. 3A). This result 
suggests that triclosan is likely to have a similar mode of 
inhibition in T. gondii as in other species. In keeping with a 
plastid localization of this enzyme in other apicomplexans, a 
bi-partite transit sequence consisting of a cleavable von Heijne 
secretory signal (the first 27 aa) followed by a chloroplast-like 
targeting sequence (amino acid numbers 28-66) were identified. 
Alignment with the genomic DNA sequence in the database 
indicated that there are four introns. In analyzing the amino acid 
sequence of P. falciparum ENR, several amino acid insertions 
were found. B. napus ENR had inserts corresponding to two of 
those from P. falciparum ENR. The sequence of TgENR has 
multiple amino acid sequences that coincide with those inserts 
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Fig. 3. TgENR: Deduced amino acid sequence and structure, purification of recombinant protein, and kinetics of enzyme activity in the presence ofr8 releasable 
COnjugate. (A) Multiple structure-based sequence alignment showing deduced amino acid sequence of TgENR and enoyl reductases of Escherichia coli, 
Helicobacter pylori, Bacillus subtilis, P. falciparum, and B. napus. This sequence was confirmed by isolation and sequencing offive separate clones from an RH 
irain T. gondii library kindly provided by J. Ajioka (Cambridge University, Cambridge, U.K.) . The secondary structures and sequence numbers of the E. coli and 
. . napus enzymes are shown above and below the alignment, respectively. The residues that are completely conserved are in reverse type, and those involved 
In triclosan binding are indicated bye. The residues in red are conserved between B. napus ENR, P. falciparum ENR, and TgENR. Red arrows indicate /3-sheets, 
and blue-green cylinders indicate a-helices. (B) SDS/ PAGE ofTgENR purification. SigmaMarker (Sigma) wide-range molecular weight markers are shown in lane 
1. Lanes 2- 6 show fractions eluted from the HiTrap Q Fast Flow column containing pure TgENR. (e) Time course ofTgENR inhibition by releasable r8-triclosan 
~onjugate (Tr8), compound 7. Inhibition curves were measured at 0 h (_), 12 h (At.), and 24 h (e) of incubation at 37"C. The three open symbols to the right show 
9ENR activity at these time points with no added inhibitor. Enzyme activity is expressed as turnovers per TgENR molecule per s, and inhibitor concentration is 
~~pressed as the log of the Tr8 concentration in molar units. ICso values calculated by nonlinear regression analysis are displayed graphically as dashed vertical 
.Ines for the three inhibition curves, showing an increase of inhibitory activity with time. A black vertical dashed line marks the concentration of TgENR used 
In these assays and thus represents a value below which inhibition cannot be properly measured in these assays. Error bars show the variation between triplicate 
1l1easurements at each point. When not visible, the variation is smaller than the symbol. . 
14284 I www.pnas.org/ cgijdoij l0.l073/ pnas.2436169100 Samuel et al. 
A Controls TAl non- TAlnt_uble 
releasable 
~...,. 
E i~ 
. " c= 
'68 11 ~ *~ 
0 
~? 120,000 
rt ~c:+-Ie 90,000 i l 60,000 ~l 
~~ 30,000 
0 
«'« • .., ~ «'« • .., ~~~~~ Uf! ... ... ... a.. Concentration (J,lM) 0000 
B C 
t 
~ (OJ 
li~:kL i,," 100 
50 
C T TrS 
Fig. 4. In vitro and in vivo effects of octaarginine triclosan conjugates on T. 
90 ndii growth and subcellular distribution of rhodamine-conjugated octa-
arginine triclosan. (A) RS conjugated to triclosan, either as a nonreleasable or 
releasable compound, had little or no toxic effect on replication of host cells 
~s measured by [3Hlthymidine uptake. Only releasable RS triclosan conjugate 
ad an inhibitory effect on parasite growth, as measured by [3Hluracil incor-
Poration. Controls included T. gondii-infected host cells in medium (e) or 
treated with pyrimethamine (0.1 /Lg / ml) and sulfadiazine (25 IL9/ml) (P I S), 
Which inhibit parasite growth. (8) Srief exposures of T. gondii to releasable 
r&'triclosan (TrS) but not triclosan m in Dulbecco's PBS had a small inhibitory 
effect on T. gondii. Two hours after infection of host cells with tachyzoites, 
Cultures were incubated with T or TrB (12.5 I'M) either in PBS or growth 
Illedium (Iscove's modified Dulbecco's medium-FCS). For the PBS-exposed 
C~ltures (not controls), Tor TrS PBS then were replaced at varying intervals 
With Iscove's modified Dulbecco's medium-FCS, which was present for the 
~emainder ofthe 3.S-day culture period. Parasite growth also was determined 
y [3Hluracil uptake atthe end of 3.5 days of culture in growth medium (data 
~Ot shown). Brief exposures to TrS partially inhibited parasite growth and the 
,S'day exposure (or a 48-h exposure, data not shown) inhibited parasite 
~r0':'1:h almost completely. Unconjugated triclosan had no effect. The pho-
bOmlcrographs (Giemsa stain) onthe rightshowthe "protective" effectofTrB, 
Ut not T, in PBS on the infected host cell monolayer. The large empty areas 
represent host cell destruction by intracellular parasite growth, which is 
~~hibited by rS-conjugated triclosan and not by tne triclosan in PBS. (C) 
~bcellular distribution of rS-triciosan conjugate in tachyzoites was deter-
Illi ned by deconvolution microscopy using nonreleasable rS-triciosan conju-
;~ted to rhodamine, and transgenic parasites expressing the GFP targeted to 
e parasite plastid organelle. Fluorescence and differential interference 
COntrast (Ole) images showing rhodamine signal surrounds the GFP Signal, 
Partly overlapping it. (Inset) Higher magnification ofthe boxed area showing 
Salll uel et al. 
present in both P. fa.lciparum and B. napus ENRs. P. falciparum 
ENR also contained a third polar insert that had no counterpart 
in other species. Analysis of the TgENR sequence indicates only 
partial conservation of this larger malarial insert. The func-
tion(s) and origins of these inserts are unknown. 
The predicted ENR structure suggested a strategy whereby 
octaarginine could be conjugated to triclosan both in a releas-
able manner, exposing a key part of the inhibitor essential in the 
binding of triclosan to ENR only upon its release, and in a 
nonreleasable manner, preventing access to the critical site 
where a hydroxyl in triclosan binds apicomplexan ENR (Figs. 1 
and 5). Triclosan's insolubility in aqueous media, unless pre-
pared with DMSO or ethanol, limits its clinical use, but provided 
us with an opportunity to compare efficacy against T. gondii 
of triclosan alone and triclosan delivered by conjugation to 
octaarginine. 
We then studied effects of triclosan conjugated to short 
oligomers of arginine on activity of recombinant ENR (Fig. 3 B 
and C) and on intracellular T. gondii (Fig. 4A and B). For these 
studies, a releasable conjugate of triclosan, compound 7, was 
synthesized. Attachment of triclosan to octaarginine was 
achieved by readily hydrolyzable ester bonds so that the triclosan 
cargo could be released to bind to TgENR and thus to inhibit the 
parasite. 
Inhibition of enzyme activity paralleled kinetics of release of 
the conjugated triclosan (Fig. 3). Releasable triclosan octaargi-
nine (conjugates 7 and 8) were effective in inhibiting T. gondii 
tachyzoites (Fig. 4), as was triclosan but only when dissolved in 
DMSO (data not shown). Neither nonreleasable triclosan R8 
(conjugate 9) nor octaarginine alone was active, indicating the 
specificity of triclosan (Fig. 4). 
As the nonreleasable triclosan R8 (conjugate 9) was without 
effect, triclosan must be released from R8 to be active (Fig. 1). 
It is not sufficient just to make triclosan soluble, and R8 
(compound 10) and R4 (compound 11) had no effect on T. gondii 
alone. 
A kinetic analysis of the pharmacologic effect of the conjugate 
(TI!2 = 12 h) revealed that some activity could be detected after 
short exposure: For example, after a brief (10 min to 2 h) 
exposure there was a modest effect of r8-triclosan (conjugate 
ent-7) in PBS, but not triclosan in PBS, when uptake of rH]uracil 
by Toxoplasma tachyzoites was measured in the last 18 h of 3.5 
days of culture (data not shown). Two hours was substantially 
less than the time required for 50% dissociation of r8-triclosan 
(conjugate ent-7) (half-life of dissociation in PBS = 12 h). 
Exposure throughout the first 48 h was essential, however, for 
full efficacy (i.e., 140) of r8-triclosan (compound ent-7) in 
medium and serum (Fig. 4B). This finding is consonant with the 
"delayed death phenotype" seen for antimicrobial agents, such 
as clindamycin and azithromycin, believed to effect plastid-
associated processes. 
To be active against the parasite, tricJosan must be targeted to, 
and released in the vicinity of, or within, the plastid where 
enzymes of apicomplexan fatty acid synthesis are targeted and 
active (6-10). Because short oligomers of arginine alone and 
linked to triclosan rapidly entered the parasite cytoplasm and 
nucleus, we wanted to determine whether short oligomers of 
arginine linked to triclosan also were in close proximity to or 
entered the plastid, as the delayed death phenotype of tric10san 
suggested that they were likely to act on a pfastid associated 
process. Also, analysis of TgENR suggested that the plastid was 
a likely site of action of this inhibitor of ENR. To determine 
rhodamine signal partly overlapping plastid. (Scale bar = 10 I'm.) (0) In vivo 
administration of releasable rS-triciosan, ant-7, but not triclosan in PBS, 
reduces numbers of i.p, tachyzoites 5 days after challenge (P = 0.006) . 
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",,:h~ther short oligomers of arginine delivered triclosan to the 
Vl~lllity of the plastid, a rhodamine-conjugated r8 linked to 
tnclosan (ent-6) was synthesized to facilitate co localization 
studies of r8 conjugate, and a parasite in which the plastid was 
labeled with GFP was examined. These studies showed a dense 
ring of rhodamine signal at the perimeter of the plastid that 
~olocalized with the outer portion of the plastid with a much less 
Intense signal in the center of the plastid (Fig. 4C). 
As triclosan conjugate , was effective in vitro, studies were 
P~rformed to determine the effect of this triclosan conjugate in 
VIVO. For these studies, we developed a model in which 
tachyzoites of the RH strain were inoculated i.p. into mice. Mice 
were treated i.p. with r8-triclosan (conjugate ent-,) or triclosan 
(SUspended in PBS) or PBS daily for 4 days beginning on the day 
they were infected. The numbers of parasites present in the 
peritoneal cavity were determined on the fifth day, after the 4 
days of treatment. To develop and test this assay, initially, 
sulfadiazine was given to mice in their drinking water in the 4 
d~ys after infection. Sulfadiazine (data not shown) and r8-
tnclosan (conjugate ent-,), but not triclosan in PBS, reduced 
Subsequent parasite burden (P < 0.(06) (Fig. 4D). 
Our studies described herein demonstrate that short oligomers 
of arginine can transport inhibitory compounds into an apicom-
plexan parasite, including extracellular T. gondii tachyzoites and 
bradyzoites, intracellular tachyzoites, and encysted bradyzoites. 
The peptide carrier can deliver to and release lead inhibitory 
C?mpounds inside tachyzoites that are multiplying within para-
sltophorous vacuoles, to their cytoplasm and subcellular or-
ganelles such as the apicomplexan nucleus and the perimeter of 
t~e plastid, where they are efficacious. Furthermore, octaargi-
nIne can deliver compounds into bradyzoites in cysts and 
t~chyzoites in vivo. Oligoarginine antimicrobial conjugates pro-
Vl?e a way to eliminate T. gondii tachyzoites and deliver anti-
nl1crobial agents to intracellular T. gondii tachyzoites and bra-
dyzoites within cysts. 
It is noteworthy that after crossing the host cell external 
lllembrane, octaarginine can cross each of the obstacles the 
jarasite has specified to create sequestered, protected, intracel-
ular or intracyst niches. Most notably, the carrier with its 
antimicrobial cargo crosses the walls of the cysts that contain 
un~eatable bradyzoite forms of the parasite. No currently used 
antImicrobial compound previously has been shown to cross the 
cyst wall. 
We selected, designed, and developed a method of delivery as 
~ g~neric proof of principle, showing the ability of a carrier to 
ehv~r small molecules to microbes that are sequestered by 
lllUltIple membranes and structures. This proof of principle is 
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based on discoveries reported herein of a promising enzyme 
target for antimicrobials (TgENR), production and purification 
of recombinant TgENR, demonstration and characterization of 
TgENR activity, and kinetics of its inhibition by triclosan that 
parallels kinetics of the release of triclosan from the octaarginine 
carrier. Deductions concerning the structure of this promising 
enzyme target are then used to design an approach for testing 
efficacy and toxicity of releasable octaarginine inhibitor conju-
gates (Fig. 4). Identification and characterization of this enzyme 
in T. goMii provides useful information for further development 
of unique classes of antimicrobial agents effective against api-
complexans, It was not obvious or certain a priori that T. gondii 
would have this enzyme as certain organisms, e.g., the pneumo-
coccus, that use type II fatty acid synthesis do not have an ENR. 
As a proof of concept, our observations show the potential for 
delivery, with efficacy and without toxicity, of an inhibitor of 
ENR by a releasable carrier in vitro and in vivo (Figs. 3 and 4). 
We demonstrate a mechanism of medi(;ine delivery to an 
important pathogen target enzyme. Octaarginine delivers a 
"prodrug" processed by the organism to an enzyme that is 
essential for pathogen survival. A number of inhibitors of ENR 
described so far are inherently poorly soluble in part because 
they reflect the lipophilic nature of the enzyme substrate. One 
clear advantage of the delivery system is that the specific 
solubilizing agent attaches a strongly hydrophilic functionality to 
the drug, which gives rise to freely soluble compounds, 
As short oligomers of arginine are being optimized for use in 
delivery across skin, eye, and blood-brain barrier, results de-
scribed herein provide potential for significantly improving 
treatment of apicomplexan, and perhaps other, infections. Fu-
ture characterization of the mechanisms whereby the parasite 
cyst wall and multiple host and parasite membranes (of pro-
karyotic and eUkaryotic lineage) are traversed by short arginine 
oligomers to deliver its antimicrobial agent cargo will be of 
considerable interest. 
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Appendix IV 
Crystallization and preliminary X-ray crystallographic studies on the 
class II cholesterol oxidase from Burkholderia cepacia containing bound 
flavin. 
Aunpad, R., Muench, S. P., Baker, P. J., Sedelnikova, S., Panbangred, 
W., Doukyu, N., Aono, R. & Rice, D. W. 
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Crystallization and preliminary X-ray 
crystallographic studies on the class II cholesterol 
oxidase from Burkholderia cepacia containing 
bound flavin 
Burkholderia cepacia cholesterol oxidase (ChoS) is a 58.7 kDa 
molecular-weight fiavoenzyme which has been categorized as a 
3tl-hydroxysteroid oxidase converting the 3tl-hydroxyl group of a 
range of hydroxysteroids to the corresponding ketone. Analysis of 
enzymes with this activity has shown that two classes of cholesterol 
oxidase can be defined. Enzymes belonging to class I contain non-
covalently bound FAD, whereas the class II enzymes contain FAD 
covalently bound to an active-site histidine. Despite cataiysing the 
same chemical reaction, the class I and class II enzymes show no 
sequence similarity and have a different molecular architecture. 
Crystals of a recombinant class II enzyme from B. cepacia have been 
grown by the hanging-drop vapour-diffusion method using poly-
ethylene glycol as a precipitating agent. The crystals belong to space 
group P3121, with unit-cell parameters a = b = 119.6, c = 101.1 A, and 
have one subunit in the asymmetric unit. These crystals diffract to at 
least 2.0 A resolution at the Daresbury SRS and are suitable for a full 
structure determination. Ultimately, analysis of the structure of 
B. cepacia ChoS may allow the characteristics and structural features 
which contribute to its suitability as a diagnostic reagent for tl1e 
detection of cholesterol and unresolved mechanistic features of the 
class II enzymes to be understood. 
Received 16 April 2002 
Accepted 23 September 2002 
1. Introduction 
Cholesterol oxidase (3tl-hydroxysteroid 
oxidase; EC 1.1.3.6), a key enzyme in 
cholesterol metabolism, is an FAD-dependent 
enzyme which catalyses the oxidation of 
3tl-hydroxyl groups of steroids to the corre-
sponding ketone. This enzyme has an impor-
tant application in clinical assay kits for the 
determination of serum levels of cholesterol in 
a coupled system with cholesterol esterase and 
peroxidase (Allain et al., 1974). Biochemical 
studies of cholesterol oxidase from Brevi-
bacterium sterolicllm have suggested that two 
classes of enzyme can be distinguished 
(Croteau & Vrielink, 1996). The class 1 
enzymes have been shown to contain non-
covalently bound FAD. In contrast, the class II 
enzymes contain FAD covalently linked to an 
active-site histidine via the C8a atom of the 
flavin isoalloxazine ring. Despite catalysing the 
same chemical reaction, these two classes of 
enzyme show no significant sequence simi-
larity. 
Cholesterol oxidase (ChoS) from Burkhol-
deria cepacia oxidizes various 3tl-hydro-
xysteroids with the activity for cholesterol 
being greatest (Doukyu & Aono, 1998). This 
ellzyme is a particularly attractive target for 
the development of a cholesterol assay because 
the Michaelis constant of the BlIrkholderia sp. 
ChoS enzyme is lower than that of other 
commercially available oxidases. Biochemical 
studies have shown that a further favourable 
feature of the Burkholderia sp. ChoS is the 
finding that in the organic solvents used in the 
clinical assay the enzyme is both stable and 
shows an oxidation rate enhanced by more 
than threefold (Doukyu & Aono, 1998). 
Analysis of the sequence of the cholesterol 
oxidase from B. cepacia showed no similarity 
to the class I enzymes. Rather, this enzyme 
shows 46% sequence identity to the class II 
cholesterol oxidase from Br. sterolicum, indi-
cating that the B. cepacia enzyme is a class II 
cholesterol oxidase containing covalently 
bound FAD. 
The structures of representative class I 
enzymes containing non-covalently bound 
FAD have been determined for the enzymes 
from both Br. sterolicum (V rielink et aL, 1991) 
and Streptomyces sp. (Yue et al., 1999). More 
recently, the structure of the Br. sterolicum 
class II cholesterol oxidase containing cova-
lently bound FAD from has been solved to 
1.7 A resolution and has shown that the fold of 
this enzyme is unrelated to that of tl1e class I 
enzyme (Coulombe et al., 2001). Analysis of 
tl1e class II BT. steTolicum ChoS has shown that 
the jl.ctive site consists of a cavity sealed off 
from the exterior of the protein. Moreover, a 
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novel feature suggested for this enzyme 
from the structure is the observation that a 
water-filled hydrophobic channel extending 
to the flavin moiety may act as the entry 
point for oxygen to the catalytic site during 
the oxidative half-reaction. Control of access 
by oxygen to this cavity is suggested to 
involve concerted movements of key argi-
nine, glutamate and isoleucine residues 
which were observed to occupy multiple 
conformations in the structure (Coulombe et 
af., 2001). In order to contribute to a full 
understanding of the mechanism of enzymes 
belonging to this class and, in particular, to 
the nature of the conformational changes 
which control gating to molecular oxygen, 
we have initiated crystallographic studies on 
Burkholderia sp. ChoS. Furthermore, the 
structure might also provide important 
insights into the molecular features of 
B. cepacia cholesterol oxidase that make it 
stable in the presence of organic solvents 
and therefore suitable as a diagnostic 
reagent for cholesterol. In this paper, we 
report the crystallization and preliminary 
X-ray analysis of ChoS. 
2. Materials and methods 
The overexpression and initial purification 
of the B. cepacia ChoS were initially carried 
out as previously described (Doukyu & 
Aono, 1998). However, to further purify the 
protein before crystallization trials, an 
additional step of preparative gel-filtration 
chromatography was carried out using a 
Superdex 200 HiLoad 16/60 column (Phar-
macia) equilibrated with 10 roM PBS buffer 
pH 8.0. After this step. the enzyme was 
concentrated to 10 mg ml-1 (estimated by 
the Bradford assay; Bradford, 1976) in 
10 roM Tris-HO pH 8.5. The protein sample 
Was then centrifuged at 25 OOOg for 10 min to 
clarify the solution before initiating any 
crystal trials. 
Preliminary crystallization experiments 
were carried out at 290 K with the Hampton 
Crystal Screens I and II and the PEG ion 
SCreen using the hanging-drop vapour-
diffusion technique, mixing 2 Jll of protein 
Solution and an equivalent volume of reser-
voir solution. Promising trials were refined 
to give optimum conditions, the best of 
Which were based on a reservoir solution 
consisting 28% PEG 400, 0.1 M Na HEPES 
pH 7.5 and 0.2 M calcium chloride. 
Under these conditions, crystals with the 
morphology of square plates of dimensions 
Acta Cryst. (2002).058,2182-2183 
Table 1 
Data-collection statistics for the 2.0 A ChoS data set. 
Values in parentheses indicate values for the highest 
resolution shell 
Resolution (A) 
No. of unique reflections 
Completeness (%) 
R~,."(%) 
lIu(I) > 3 (%) 
Multiplicity (%) 
1S-2.0 (2.1S-2.0) 
45559 
8K9 (91) 
0.059 (0.348) 
82.6 (58.7) 
4.48 (4.30) 
up to 0.2 x 0.25 x 0.2 mm were obtained 
after two weeks. Preliminary X-ray analysis 
of the crystals, flash-frozen using the reser-
voir buffer as a cryoprotectant, showed that 
they diffracted well to high resolution. 
Subsequently, a complete data set was 
collected to 2.0 A resolution at 100 K, using 
1° rotation frames and X-rays with a wave-
length of 0.978 A on an ADSC Quantum 4 
detector at station PX 14.2 at the Daresbury 
SRS. The data were processed using the 
DENZOISCALEPACK package (Otwi-
nowski & Minor, 1997). 
3. Results and discussion 
Autoindexing and scaling of the data using 
DENZOISCALEPACK and analysis of the 
pattern of systematic absences is consistent 
with a primitive trigonal crystal system, 
identifying the space group as P3121 (or its 
enantiomorph P3221), with unit-cell para-
meters a = b = 119.6, c = lOLl A. Significant 
reflections were observed to the edge of the 
image-plate detector and a high-quality data 
set was collected to this resolution (Table 1). 
Considerations of possible values of V M 
suggest that the asymmetric unit could either 
contain a monomer with a V M of 
3.5 A? Da-1 or a dimer with a VM of 
1.75 A3 Da-l, both of which lie within the 
range observed by Matthews (1977), with 
the former being more probable. Gel-
filtration studies on ChoS strongly suggest 
that this enzyme is a monomer in PBS buffer 
solution, consistent with this conclusion. 
In order to provide a completely inde-
pendent solution to the structure, we initially 
carried out a heavy-atom screen which 
yielded a number of very promising deriva-
tives based on either mercury, gold or 
gadolinium. Using these derivatives a pre-
liminary map at 2.4 A resolution was calcu-
lated and showed a clear molecular 
boundary. Whilst this work was in progress, 
the coordinates for the class 1I ChoS from 
e!ectronic reprint 
crystallization papers 
Br. sterilocum were deposited in the Protein 
Data Bank (Berman et aL, 2000) (PDB code 
1i19). A preliminary attempt to solve the 
structure by molecular replacement gave a 
solution in space group P3121 corresponding 
to a monomer in the asymmetric unit, which 
made acceptable packing interactions in the 
cell. Given the quality of the derivatives and 
in order to examine the conformation of key 
residues at the active site in a manner in 
which any bias is minimized. we have chosen 
to proceed with the structure determination 
using an isomorphous replacement 
approach. Ultimately, it is hoped that a 
complete solution of this structure will lead 
to a better understanding of the enzymes 
belonging to the cholesterol oxidase family 
. and so help in the design of more efficient 
clinical tools for the assay of cholesterol. 
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